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2 Chapter 1  
1 Introduction 
 
1.1 G-protein-coupled receptors: structure and function 
 
The G-protein-coupled receptors (GPCR), also called seven-transmembrane domain recep-
tors (7TMR), are shapeshifting signalling proteins involved in responses to hormones and 
neurotransmitters, such as neuropeptide Y and histamine. 7TMRs are encoded by approx. 
800 sequences (including olphactory GPCRs; Bjarnadóttir et al., 2006), which account for 
only 3% of the human genome (26,383 genes in total; Venter et al., 2001). Nevertheless, 
GPCRs comprise a significant part of the druggable human genome, representing 30% of the 
marketed small-molecule drug targets (Hopkins and Groom, 2002). A well known and widely 
accepted pharmacological paradigm for this class of receptors states that an elementary unit, 
required for signal transduction, involves a sole receptor molecule, interacting via its unique 
binding site with a single pharmacophoric moiety (Lazareno, 2001). However, this classical 
model will probably require revision, as a series of experimental data indicate that oligo- or 
dimerization of the receptors is a quite abundant phenomenon (Ferré et al., 2009). Also the 
examination of other lively discussed postulates for GPCR pharmacology, including alloster-
ism and functional selectivity, might be advantageous for both, research and clinics. 
 
1.1.1 3D Structures 
 
Class A GPCRs (also referred to as rhodopsin-like family) includes inter alia neuropeptide Y 
Y1 (NPY Y1R) as well as histamine H2 and H4 receptors (H2R and H4R) as representative 
peptidergic and aminergic GPCRs, respectively. Apart from the typical seven transmembrane 
domains surrounding a pocket with the recognition site for the endogenous ligand (Fig. 
1.1.1), this class of receptors reveals other common features, such as a disulfide bridge be-
tween the second (ECL2) and the third extracellular loop (ECL3), a series of highly con-
served amino acids (e.g. the DRY motif in the second intracellular loop, ICL2) or a palmitoy-
lated cysteine at the C-terminus (Gether, 2000). The first known 3D models for class A 
GPCRs were established by means of high-resolution electron crystallography for bacterial 
and bovine rhodopsins (Kimura et al., 1997; Palczewski et al., 2000). However, the current 
information on the spatial arrangement of the domains and the shape of the binding pocket is 
mainly based on the crystal structures of the human β2-adrenergic receptor (β2AR,) recently 
described by Kobilka and colleagues (Rasmussen et al., 2007; Rosenbaum et al., 2007). 
Using these templates, homology models of the H2R and H4R have been derived in our re-
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search group (Kraus et al., 2009; Seifert et al., 2011). Whereas the experiments with rhodop-
sin, an archetypal GPCR, demonstrated the formation of receptor dimers (Fotiadis et al., 
2006), the aforementioned studies on the β2AR revealed rather monomeric state of the re-
ceptors. The last finding contradicted the results from earlier studies using BRET and immu-
noprecipitation (Kroeger et al., 2004). Additionally, both the transmembrane core of the 
GPCR (containing the orthosteric ligand-binding site) and the cytoplasmic domains (involved 
in G-protein coupling) were found to be highly conserved. By contrast, the structural diversity 
of the extracellular domains of GPCRs offers an opportunity for the discovery of subtype-
selective drugs. Moreover, the conformational coupling between the extracellular domains 
and the orthosteric recognition site, shown by means of NMR spectroscopy, suggests that 
ligands binding to the extracellular domains might function as allosteric modulators (Bokoch 
et al., 2010).  
 
 
Fig. 1.1.1. A prototype class A GPCR (7TMR). (A) Sche-
matic diagram showing three extracellular loops (ECLs), 
seven transmembrane domains (TMs) and three intra-
cellular loops (ICLs). (B) Helical wheel diagrams of the 
receptor as seen from the extracellular side. The helices 
are positioned in a counterclockwise manner (adopted 
from Gether, 2000). Amino acids, presumed to form the 
contact points for the binding of small-molecule ligands, 
are located in a binding crevice between TMs. By con-
trast, the predicted contact points for peptide agonists 
are found in the extracellular domains on top of the he-
lices. 
 
 
  
A 
B 
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1.1.2 Models of ligand-receptor interaction for GPCRs 
 
1.1.2.1 GPCR dimers and bivalent ligands 
The phenomenon of dimerization among numerous types of GPCRs has been investigated 
during the last three decades, significantly contributing to the understanding of intermolecular 
interactions in cellular signal transduction pathways. For the investigation of GPCR dimers 
different approaches have been used, such as functional complementation, resonance en-
ergy transfer techniques and immunoprecipitation (Gomes et al., 2001; Kroeger et al., 2004; 
Milligan and Bouvier, 2005). The dimerizing receptor protomers might be of the same or dif-
ferent type (Table 1.1.1, cf. Ferré et al., 2009). For example, the functional H2R homooli-
gomers have been found in the transfected insect Sf9 (Sporodoptera frugiperda 
cell/baculovirus expression system) and mammalian COS-7 cells (Fukushima, 1997). 
Table 1.1.1. Proposed nomenclature for the oligomeric interactions of GPCRs (cf. Ferré et al., 2009). 
Classification Definition Examples 
Hetero(di)meric 
receptor 
the minimal functional unit is composed 
of two or more different subunits that are 
not functional on their own 
GABAB receptor: subunits 
GABAB1 and GABAB2  
(Marshall et al., 1999) 
Homo(di)meric  
receptor 
the minimal functional unit is composed 
of two or more identical subunits that 
are not functional on their own 
- 
Receptor 
homo(di)mer 
composed of two or more identical func-
tional receptor units with biochemical 
properties that are different from those of 
its individual components 
H2 recetor 
(Fukushima, 1997) 
NPY Y1 recetor 
(Dinger et al., 2003) 
Receptor  
hetero(di)mer 
composed of two or more different func-
tional receptor units with biochemical 
properties that are different from those of 
its individual components 
μ and δ opioid receptors 
(Daniels et al., 2005) 
 
In addition to that, bivalent ligands, composed of two pharmacophoric moieties joined with a 
linker, have been reported for some GPCRs (5-HT1B receptors: Perez et al., 1998; opioid δ 
and κ receptors: Bhushan et al., 2004; gonadotropin releasing hormone receptor: Bonger et 
al., 2008; serotonin 5-HT4 receptor: Lezoualc’h et al., 2009; other receptors reviewed in: 
Shonberg et al., 2011). Provided that twin compounds, are capable of addressing two bind-
ing sites simultaneously, such bivalent ligands may be valuable tools to investigate whether 
GPCR dimers are involved in the activation or inhibition of receptor-mediated signal trans-
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duction. However, it is still unclear, if binding of bivalent ligands involves bridging of receptor 
dimers or rather orthosteric/allosteric interaction with a single receptor protein or if these 
compounds simply bind with high affinity only to a single (orthosteric) receptor binding site 
(Fig. 1.1.2). 
 
 
Fig. 1.1.2. Possible binding modes of bivalent ligands: (A) bridging of a GPCR dimer, (B) dualsteric 
(simultaneous binding to ortho- and allosteric binding sites at the same GPCR), (C) univalent (adopted 
from Bonger et al., 2007 with modifications). 
 
It is worth mentioning that in the case of GPCRs “twin compounds”, supporting the existence 
of receptor dimers, have only been reported by the group of Portoghese for opioid receptors 
(μ and δ receptors in mice, Daniels et al., 2005). In order to address both binding pockets of 
a receptor dimer, the distance between the two pharmacophore moieties in a bivalent com-
pound should be equal to 20–21 carbon atoms (Bhushan et al., 2004). Additionally, the as-
sumed binding mode of a radioactively labelled bivalent ligand should also result in a halved 
maximal binding (Bmax) in saturation binding experiments, compared to its monovalent coun-
terpart. Moreover, the binding of one pharmacophore to the first receptor could strengthen 
the interaction of the other pharmacophore with the second receptor molecule (positive co-
operativity). In the latter case, the affinity of bivalent compounds should increase and the 
slope (Hill coefficient) of saturation and displacement curves should be greater than unity 
(chapter 4; cf. Repke and Liebmann, 1987). 
 
1.1.2.2 Allosteric interactions 
 
Bivalent ligands, possessing two pharmacophores, may also bind to two distinct non-
interconverting sites on the same receptor molecule, resulting in dualsteric (bitopic, orthos-
teric/allosteric) ligands, as shown for the M2 muscarinic acetylcholine receptors (Valant et al., 
2008). The cooperative interaction between orthosteric (usually occupied by the natural 
ligand) and allosteric binding sites is reciprocal (conformational linkage). The modulatory 
effect of allosteric agents on affinity or/and intrinsic activity of natural orthosteric ligands can 
be positive, neutral or negative. Occupation of an allosteric site does not exclude simultane-
ous interaction of the orthoster with its receptors. Allosterically acting compounds should not 
block receptors, as do competitive antagonists, and therefore, might lead to new therapeutic 
A B C
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applications of the former. Moreover, allosteric binding site, being less structurally conserved 
as the orthosteric one, could be an excellent target for drug design due to its improved selec-
tivity profile (May et al., 2007). 
The bitopic binding mode of bivalent compounds can lead to the flattening of saturation and 
displacement curves. When the Hill coefficient is smaller than unity, negative cooperativity 
may be assumed (the binding to one binding site weakens the interaction with the second 
binding site). However, this fact may have other reasons than cooperative interaction, e.g. a 
heterogenic population of the ligand binding sites (Repke and Liebmann, 1987). Allosteric 
properties of test compounds can be verified using radioligand binding methodology concern-
ing kinetic studies. Simultaneous occupation of ortho- and allosteric binding sites should lead 
to the formation of a ternary orthoster-receptor-alloster complex with altered dissociation 
and/or association of an orthosteric radioligand (chapter 5; cf. Kostenis and Mohr, 1996).  
 
1.1.2.3 Ternary complex model 
 
The Hill slopes of ligand binding curves approximating unity are consistent with a competitive 
ligand-receptor interaction and reflect the presence of homogenic population of ligand bind-
ing sites (Repke and Liebmann, 1987). As mentioned above, flattened displacement curves, 
which are sometimes detected for agonists, may suggest the existence of two binding sites 
with different affinities for a tested agonist, when using an antagonist radioligand (Fig. 1.1.3). 
To explain this phenomenon, a ternary complex model has been proposed. According to this 
model, agonists are believed to bind with a higher affinity to receptors coupled to nucleotide-
free G proteins than to unbound receptors, resulting in ternary agonist-receptor-G-protein 
complexes. 
 
 
Fig. 1.1.3. Effect of standard H2R 
ligands: histamine (HIS), cimetidine 
(CIM) and famotidine (FAM) on the 
binding of 0.3 nM [125I]iodoamino-
potentidine ([125I]APT) to mem-
branes prepared from CHO-rH2 
cells. The flat competition curve of 
histamine (nH of 0.43) was right-
shifted and steepened (nH of 0.80) 
in presence of 100 µM Gpp(NH)p 
(adopted from Traiffort et al., 1992 
with modifications). 
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Guanine nucleotides (Fig. 1.1.4) such as GTP, being substrates for G proteins, are known to 
disrupt these complexes (Maguire et al., 1976). Disappearance of a high-affinity binding site 
and a concomitant decrease in agonist affinity can be observed as a rightward shift and 
steepening of the binding curve after addition of exogenous GTP (Lazareno, 2001). The 
same effect can be observed in intact cells, where the high intracellular concentration of GTP 
leads to dissociation of the ternary complex, allowing agonists to bind only to the low-affinity 
binding site, as it can be deduced from steep binding curves (Kenakin, 2006). Contrary to 
that, antagonists, which do not change the affinity of receptors to G proteins, are insensitive 
towards guanine nucleotides. For example, a lacking GTP shift was previously demonstrated 
for N-methylscopolamine, an antagonist of muscarinic receptors in membranes of the rabbit 
myocardium (Ehlert et al., 1985).  
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Fig. 1.1.4. Guanine nucleotides: GTP and its non-hydrolyzable analogues. 
 
If the number of G proteins significantly exceeds the amount of receptors, agonists would 
bind mostly to the high-affinity binding site, resulting in left-shifted binding curves with slopes 
of 1 (Fig. 1.1.5). However, if binding to receptors takes place in the absence of G protein, 
rightward-shifted and steep curves would be expected, like in the presence of GTP. Finally, 
by similar receptor-to-G-protein stoichiometry, formation of the ternary complexes can lead to 
a depletion of free G proteins (Kenakin, 2006). In thist case, two binding sites occur and a flat 
binding curve will be detected.  
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Fig. 1.1.5. Impact of the G-
protein-to-receptor (G/R) stoi-
chiometry on the binding of a 
radioligand agonist. The binding 
curves were simulated for the 
indicated G/R ratios expressed 
as % (adopted from Kenakin, 
1997 with modifications). 
 
 
The ratio of high- and low-affinity values in the absence of guanine nucleotides may be used 
for the prediction of agonist efficacy. Moreover, the estimation of agonist efficacy should also 
be possible from the GTP shift, defined as the ratio of the IC50 values in the presence and 
absence of GTP (Lazareno, 2001). Provided that an agonist binds to a receptor according to 
the ternary complex model, the shape of its binding curve reflects both, the proportion of the 
high-affinity binding site, and the ratio of affinity constants of the two binding sites. However, 
it seems , easier to identify and interpret such results from a single IC50 value and a slope, 
when the logistic rather than biphasic curve is used to fit the binding data (cf. section 4.3.2; 
Lazareno, 2001). 
 
1.1.2.4 Extended ternary complex model 
 
Basal activity in the absence of agonists has been already reported for a number of receptor 
types, for example on Sf9 membranes expressing hH2R-GsαS and gpH2R-GsαS fusion proteins 
(Preuss et al., 2007). Constitutive activity could be reduced by ligands, known so far as an-
tagonists in other test systems. Such unusual findings can be explained only, when it is as-
sumed that a significant proportion of receptors is precoupled to G proteins (already in the 
absence of agonists). Then, such ligands, called inverse agonists, bind much stronger to free 
receptors than to receptor-G-protein complexes, reducing the affinity of receptors to the 
G proteins (Fig. 1.1.6). These assumptions are part of the extended ternary complex model.  
According to this model, receptors can isomerize between ground and active states (Laza-
reno, 2001). Only receptors in the active state are able to form effective ternary complexes. 
Agonists, possessing higher affinity towards the active conformation of a receptor, induce 
isomerization of receptors to the active form. This, in turn, increases the affinity of receptors 
to G proteins and triggers a response of a typical biological system. However, in case of sys-
tems with constitutive activity, the equilibrium is already shifted to the active form of receptor. 
Therefore, inverse agonists, which have higher affinity to the ground state of the receptor, 
diminish the prevalence of the active form and reduce basal activity. Both, the simple and the 
extended ternary complex model, are equivalent in terms of equilibrium binding. The simple 
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model is usually sufficient to fit ligand binding data. However, its extended version allows the 
interpretation of results from systems with genetically modified receptors (Lazareno, 2001). 
 
 
 
Fig. 1.1.6. Concentration-response curves of 
different ligands in a system with constitutive 
activity as predicted by the extended ternary 
complex model. 
 
 
 
 
 
 
1.1.3 Signal transduction pathways of GPCRs 
 
1.1.3.1 Mechanisms of receptor activation, endocytosis and resensitization 
 
According to the ternary complex model, binding of an agonist to its GPCR leads to the acti-
vation of a trimeric G protein (composed of α, β and γ subunits). As a result, GDP (bound to 
the Gα subunit) is exchanged for GTP. The Gα subunit dissociates subsequently from the βγ 
heterodimer, activating or inhibiting appropriate effector proteins. An intracellular signal is 
mediated by second messengers until the Gα-bound GTP is hydrolyzed to GDP. For exam-
ple, coupling of the receptor to the Gs protein raises the enzymatic activity of adenyl cyclase 
(AC), which leads to an increase in the intracellular concentration of cAMP. The cAMP-
dependent signalling pathway was described previously for the β2AR and H2R. The biological 
effect can be measured at a point more or less distal from the activated receptor, enabling 
the pharmacological characterization of an agonist (Schneider and Seifert, 2010). 
However, the initial stimulus also releases regulatory mechanisms, which silence the signal 
in order to keep a delicate cellular balance. Otherwise, the cell would be exposed to a per-
manent triggering and its homeostasis would be at risk. Therefore, an intracellular receptor 
domain is phosphorylated by GRK (G-protein-coupled receptor kinase). The phosphorylation 
of the GPCR increases the affinity of cytosolic β-arrestins to the receptor (β-arrestin recruit-
ment) and leads to uncoupling of the G-protein α subunit. This, in turn, results in a reduced 
response to the next agonist exposure. The desensitization is accompanied by the interac-
tion of β-arrestin with β2-adaptin (subunit of the AP-2 heterotetrameric adaptor complex) and 
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the subsequent internalization of the receptor into clathrin-coated pits (Fig. 1.1.7; cf. Fergu-
son, 2001).  
 
Fig. 1.1.7. Desensitization and internalization of the phosphorylated (P) receptors upon agonist (hor-
mone, H) stimulation involve interactions with numerous proteins: GRKs (GPCR kinases), β-arrestins 
(βArr), adaptins (subunits of the AP-2 heterotetrameric adaptor complex) and clathrins (adopted from 
Ferguson, 2001 with modifications). 
 
Subsequently, the internalized agonist-receptor complexes dissociate due to the low pH in 
endosomes, which, in turn, leads to the release of β-arrestins. Then, in the absence of 
β-arrestins, receptors can be dephosphorylated and rapidly recycled to the cell membrane 
(resensitization). However, after long exposure to an agonist, receptors may undergo the 
lysosomal degradation pathway also referred to as down-regulation (Gurevich and Gurevich, 
2006). 
 
1.1.3.2 β-Arrestin-mediated signalling (inclusive biased agonism) 
 
In the classical model of GPCR activation, signalling is exclusively mediated by G proteins. 
Contrary to that, the current model predicts signal transduction by both G proteins and 
β-arrestins. This means that β-arrestins are recognized not only as the regulators of receptor 
desensitization and internalization, but (together with G proteins) also as true adaptor pro-
teins of the heptahelical receptors. β-arrestin-mediated signalling involves multiple mediators: 
G-protein-coupled receptor kinase (GRK), mitogen-activated protein kinase (MAPK), phos-
phoinositide 3-kinase (PI3K), etc. The regulation of the kinases may be accompanied by the 
transactivation of the epidermal growth factor receptor (EGFR), by the control of chemotaxis 
and apoptotic/anti-apoptotic signaling, as well as by the regulation of mRNA translation and 
protein synthesis (DeWire et al., 2008; Luttrell and Gesty-Palmer, 2010; Rajagopal et al., 
2010). 
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In a balanced system, after binding of an agonist, the signal is transduced equally by G pro-
teins and β-arrestins (Fig. 1.1.8). However, in systems with biased agonism (functional selec-
tivity) the signalling proceeds through one pathway only (β-arrestin- or G-protein-biased sys-
tems). Furthermore, bias may also result from the properties of the used ligands (Violin and 
Lefkowitz, 2007), as in case of the recently discovered first H4R biased ligand (JNJ7777120, 
an antagonist with respect to G-protein activation, induced β-arrestin recruitment indepen-
dently of G proteins; Rosethorne and Charlton, 2011; Seifert et al., 2011). Such biased sig-
nalling presumes the existence of different ligand-induced conformations of GPCRs. Namely, 
in the presence of biased ligands, distinct prevailing receptor conformations are assumed to 
be stabilized, triggering the coupling of receptors to different protein effectors (Kenakin and 
Miller, 2010).  
 
Fig. 1.1.8. Current model of receptor activation. Signaling is mediated by both G proteins and 
β-arrestins. Additionally, the latter regulate desensitization and internalization of heptahelical recep-
tors. 
 
It is widely accepted that conformational changes in proteins are crucial for the signal trans-
duction. They may result either from non-covalent interactions (ligand binding, association of 
receptors, G-protein coupling) or from covalent modifications (phosphorylation by kinases). 
Given that each agonist induces/stabilizes a unique receptor conformation, the binding of a 
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small-molecule ligand at the specific recognition site may affect the shape of other receptor 
domains due to conformational linkage (allosteric regulation). For example, lateral transloca-
tions of helices along the plane of the membrane might result in modified interactions with 
other membranal proteins (receptor dimerization; chapter 4). Changes induced in the ex-
tracellular domains and at the orthosteric binding site can alter the binding affinity towards 
other ligands (allosterism; cf. chapter 5). Finally, movements of the intracellular loops may 
imply variable coupling to adaptor proteins like G proteins and β-arrestins. This “vectorial 
nature” of the allosteric interactions of 7TMRs is depicted in Fig. 1.1.9 (cf. Kenakin and Miller, 
2010). 
 
 
 
 
Fig. 1.1.9. Allosteric interactions of 
7TMRs have “vectorial” nature. The 
existence of ligand-specific receptor 
conformations may help to explain 
such complex phenomena as alloster-
ism, receptor dimerization and func-
tional selectivity (adopted from Ke-
nakin and Miller, 2010 with modifica-
tions). 
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1.2 Neuropeptide Y and histamine receptors: signalling and 
pharmacology 
 
1.2.1 Neuropeptide Y receptors 
 
Neuropeptide Y is a peptide neurotransmitter involved in numerous behavioral and 
physiological processes such as the regulation of food intake, energy balance, emotional 
behavior or stress response. Together with peptide YY (PYY) and pancreatic polypeptide 
(PP), they comprise the family of pancreatic polypeptides. In humans, the effects of 
these peptides are mediated via four receptor subtypes designated Y1, Y2, Y4 and Y5, 
which belong to the rhodopsin-like (class A) GPCRs. All these receptors possess similar 
signalling patterns. Upon agonist challenge, they couple to the pertussis toxin-sensitive 
Gi/o proteins, reduce subsequently the intracellular level of cAMP and increase the intra-
cellular Ca2+ concentration (Michel et al., 1998; Merten and Beck-Sickinger, 2006; 
MacNeil, 2007). 
 
1.2.1.1 Dimerization of NPY receptors 
 
FRET-based studies performed previously by Beck-Sickinger and coworkers suggested 
that NPY receptors can oligomerize. The human Y1R, hY2R and hY5R, C-terminally 
tagged with fluorescent proteins (GFP, DsRed, ECFP and EYFP), were found to bind the 
natural ligand and to remain functional, as shown by the saturation and competition ex-
periments with [3H]propionyl-NPY and by the inhibition of adenylyl cyclase (Dinger et al., 
2003). Additionally, the results of the BRET-based studies on the rhesus Y4R supported 
the agonist-induced dissociation of homodimers (Berglund et al., 2003). 
In contrast to these earlier findings, the application of the bivalent ligand approach to Y1R 
antagonists, pioneered at our department, did not support the hypothesis of receptor 
dimerization (Keller et al., 2009). 
 
1.2.1.2 Pharmacological tools for the NPY Y1 receptor 
 
Stimulation of NPY Y1 receptors by the natural agonist changes the intracellular concen-
trations of second messengers, which can be measured either in the cAMP assays or in 
the ratiometric calcium assays with fura-2 (cf. subsection 3.2.6). Additionally, agonist-
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stimulated internalization may be visualized by confocal microscopy, as shown previous-
ly for the NPY Y
1 
receptor tagged with the green fluorescent protein (Gicquiaux et al., 
2002). In order to obtain pharmacological tools for flow cytometry and confocal micro-
scopy, the ε-amino group of Lys4 of pNPY has been coupled to different dyes, resulting 
in far-red fluorescent Y1R agonists with significantly reduced autofluorescence (Fig. 
1.2.1; Schneider, 2005; Schneider et al., 2006). 
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Fig. 1.2.1. Structures of selected Y1R agonists: porcine NPY and its far-red fluorescent deriva-
tives. Dy-635-pNPY and Cy-5-pNPY were obtained by coupling of the ε-amino ogroup of Lys4 of 
pNPY (shown in red) to the appropriate fluorescent dye by an amide bond (Schneider et al., 
2006). 
 
 
However, the peptidic agonists have some drawbacks, as they may undergo both, pro-
teolytic cleavage and adsorption (Ziemek, 2006). Moreover, long periods of incubation 
may implicate receptor internalization, making it difficult to interpret the binding data. 
Therefore, in order to avoid these limitations, small-molecule ligands have been devel-
oped for the Y1R. The first non-peptidic Y1R antagonist described in the literature was 
the arpromidine-type H2R agonist BU-E-76, also referred to as HE 90481, with a pA2 
value of 4.43 in HEL cells (Buschauer, 1989; Michel and Motulsky, 1990). Significant 
increase in affinity and selectivity towards the NPY Y1 receptor was reported for BIBP-
3226 (Fig. 1.1.2) with Ki of 7 nM (Rudolf et al., 1994). Noteworthy, BIBP-3226 shows 
structural similarity to the C-terminus of NPY, as it mimics the last two amino acid resi-
dues (Arg35 and Tyr36 shown in Fig. 1.2.1 in cyan).  
Numerous analogs of this compound have been developed in our laboratory (Aiglstorfer 
et al., 1998; Brennauer et al., 2004) resulting in the synthesis and characterization of the 
first non-peptide fluorescent NPY Y1 receptor ligands (Schneider and Keller et al., 2007; 
Keller, 2008, Keller et al., 2011) and the first selective Y1R radioligand (Fig. 1.2.2). 
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In previous studies, the tritium-labelled NG-propionylargininamide UR-MK114, structurally 
derived from the antagonist BIBP-3226, revealed excellent one-digit nanomolar affinity 
(Kd values: 2.9 ± 0.4 nM on MCF-7 cells; 1.2 ± 0.1 nM on SK-N-MC cells), achieving 
saturation of the receptors already at a concentration of approx. 4 nM (Keller, 2008; Kel-
ler et al., 2008).  
 
H
N(R)
N
H
NH
NH2N
O
X
O
OH
R3 =
O
Z N
H
H
N
O
N S
N CH3
H3C
O
TFA
n
R2 =
H
O
R1 =
3H
H
H
3H
 
 
Fig. 1.2.2. The selective Y1R antagonist 
BIBP-3226 and its derivatives: the radio-
ligand [3H]UR-MK114 (Keller et al., 2008) 
and the far-red fluorescent ligands UR-
MK115 and UR-MK131 (cf. Keller, 2008; 
Keller et al., 2011). 
 
 
 
1.2.2 Histamine receptors 
 
Histamine (2-(1H-imidazol-4-yl)ethanamine) is an important neurotransmitter and auta-
coid that exerts its function via four known receptor subtypes (H1–4R), belonging to the 
aminergic class A GPCRs (de Esch et al., 2005). The signal transduction pathways as 
well as the physiological role of histamine receptors are summarized in Table 1.2.1. 
More than 100 years of histamine research (discovery of histamine in 1910 by Barger 
and Dale) have resulted in the development of drugs, successfully applied in the therapy 
of allergy (H1R) and gastric ulcer (H2R). The recent discovery of new histamine receptor 
subtypes intensified the development of novel agents for the potential treatment of cogni-
tive (H3R) and inflammatory (H4R) diseases (Hill et al., 1997; Tiligada et al., 2009). These 
receptors are also subjects of great interest in our department and appropriate pharma-
cological methods and tools, including selective radioligands and fluorescent ligands, 
have been already in our hands (Igel et al., 2009; Erdmann, 2010). 
 
Compound X Z n 
BIBP-3226 H - 0 
[3H]UR-MK114 R1 - 0 
UR-MK115 R2 R3 1
UR-MK131 - R3 2
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Table 1.2.1. Comparison of pharmacological profiles of the histamine receptor subtypes (cf. Hill et 
al., 1997; Tiligada et al., 2009). 
 Signaling Distribution Physiological role 
H1R 
Gq/11, PLC (↑),  
Ca2+ (↑) 
ubiquitous, blood ves-
sels, ileum, lung, brain 
contraction of smooth 
mucles 
H2R Gs, cAMP (↑) ubiquitous, stomach, heart, brain, monocytes 
gastric acid secretion, 
increase in heart rate 
H3R 
Gi/o, cAMP (↓),  
Ca2+ (↑), MAPK (↑) 
central nervous system, 
presynaptic autoreceptor 
memory processing, 
sleep, feeding behavior 
H4R 
Gi/o, cAMP (↓),  
Ca2+ (↑), MAPK (↑) 
hematopoietic cells,  
neurons 
chemotaxis, control of 
pain and cell cycle 
 
1.2.2.1 Pharmalogical tools for the histamine H2 and H4 receptors 
 
The histamine H2 receptor (H2R) mediates numerous histamine-induced effects pre-
dominantly via coupling to Gs protein (cAMP-dependent signalling). The H2R antagonists 
have been widely used for the treatment of peptic ulcer and gastroesophageal reflux 
disease, whereas the H2R agonists are exclusively pharmacological tools (Fig. 1.2.3). 
NG-Acylated hetarylpropylguanidines, developed in our research group, represent a new 
class of H2R agonists with improved pharmacokinetic properties compared to the corre-
sponding guanidines due to substantially reduced basicity (Ghorai et al., 2008; Kraus et 
al., 2009). Very recently, a tremendous increase in potency was achieved by applying 
the bivalent ligand approach to acylguanidine-type H2R agonists (Fig. 1.2.4; Kraus, 2007; 
Birnkammer et al., 2010). 
In order to develop binding assays for flow cytometry and confocal microscopy, a series 
of green fluorescent ligands with the high affinity towards the H2R (pA2 up to 8.0 at the 
guinea-pig atrium) were previously developed in our research group (Li et al., 2003). 
A new generation of pharmacological tools for the H2R comprises far-red fluorescent 
ligands, which can be detected with 650 nm long-pass filters, as the autofluorescence of 
cells is marginal in this region of spectrum. These novel squaramide derivatives, synthe-
tized by Dr. Daniela Erdmann, are labeled with the fluorescent dyes S-0536 (UR-DE54 
and UR-DE56) or Dy-675 (UR-DE74), which have excitation maxima at approx. 670 nm, 
or with the pyrylium dye Py-5 (cf. UR-DE108) resulting in pyridinium fluorophores, which 
can be excited with the 488 nm line of an argon laser. Additionally, the new H2R tritiated 
ligand [3H]UR-DE257 has been recently developed for equilibrium and kinetic binding 
studies (Fig. 1.2.5, Erdmann, 2010). 
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Fig. 1.2.3. Selected H2R agonists and antagonists (cf. Buschauer, 1989; Xie et al., 2006). 
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Fig. 1.2.4. Novel NG-acylated monovalent (1–3) and bivalent (4–14) H2R ligands. 
18 Chapter 1  
O
N
N
H NH
OO
(CH2)n X Z
TFA
N
N
N N SO3
ON
N SO3
N
H
O
3H
H
3H
H
H
R2 =
R4 =
R3 =
R1 =
22
  
 
Fig. 1.2.5. Pharmacological tools for 
the H2R (cf. Erdmann, 2010). 
 
 
 
 
 
 
The discovery and cloning of the human histamine H4 receptor in 2000 (Oda et al., 2000) 
led to the revision of selectivity data of the ligands for other histamine receptor subtypes. 
For example, thioperamide (known so far as a H3R ligand with pKi of 7.2) showed high 
affinity towards the H4R (pKi of 7.4), being an inverse agonist (Fig. 1.2.6; cf. de Esch et 
al., 2005; Tiligada et al., 2009). It should be noted that the H2R bivalent compounds of 
the imidazole series revealed one-digit nanomolar potency at the human H4R (Kraus, 
2007). The imidazolylpropylguanidine moiety turned out to be a privileged structure with 
respect to histamine receptors. Additionally, the H4R antagonist JNJ7777120 (pKi of 8.4) 
was reported to induce the recruitment of β-arrestins in a G-protein-independent manner, 
suggesting functional selectivity at this receptor (Rosethorne and Charlton, 2011; Seifert 
et al., 2011). 
Due to much higher affinity at the H4R than at the H2R, the natural ligand is routinely 
used as radioligand at the H4R (cf. Kd value of [3H]HIS: 11 ± 1 nM at the hH4R expressed 
in SK-N-MC cells, Lim et al., 2005; 9.8 ± 0.9 nM at Sf9 membranes expressing the hH4R 
+ Giα2 + Gβ1γ2 + GAIP, Schnell et al., 2011). Very recently, tritium-labelled N1-[3-(1H-
imidazol-4-yl)propyl]-N2-propionylguanidine ([3H]UR-PI294) has been developed in our 
laboratory by Dr. Patrick Igel as a high-affinity H3R and H4R radioligand (Fig. 1.2.6; cf. 
Compound X Z n 
UR-DE54 NHCO R1 4 
UR-DE56 NHCO R1 6 
UR-DE74 NHCO R2 4 
UR-DE108 - R3 4
[3H]UR-DE257 - R4 6
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Igel et al., 2009). In this context it is indispensable to mention that so far the only pub-
lished results of kinetic studies on H4R radioligands refer to [3H]UR-PI294 (cf. chapter 5). 
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Fig. 1.2.6. Selected H4R ligands (cf. Igel et al., 2009; Tiligada et al., 2009). 
 
1.2.2.2 Selected testing systems for the histamine H2 and H4 receptors 
 
The isolated guinea-pig right atrium is used in our institute (cooperation with Prof. Dr. 
Sigurd Elz, University of Regensburg) as a classical pharmacological test system for 
characterization of H2R ligands (H2R agonists induce a positive chronotropic response, 
Fig. 1.2.7 A). Nowadays, various readout systems using genetically engineered cells are 
standard, enabling the investigation of substance libraries at the human receptors of in-
terest, at corresponding species orthologs and receptor mutants, e.g. cAMP and 
[3H]cAMP accumulation assays, CRE (cAMP response element) gene transcription as-
says (Monczor et al., 2006; Baker, 2008). In our laboratory, for instance, functional stu-
dies can be performed in GTPase assays at insect Sf9 (Sporodoptera frugiperda) mem-
branes, expressing recombinant human (h) or guinea-pig (gp) H2Rs (Schneider and Sei-
fert, 2010). Additionally, the Sf9 cell/baculovirus system enables modifications of the 
receptor of interest including fusions with other proteins, for instance the expression of 
H2Rs fused with the GsαS protein (the short splice variant of the α subunit of Gs protein). 
The use of receptor-Gα fusion proteins provides a constant 1:1 coupling stoichiometry 
and stronger signals than in case of coexpressed receptors and G proteins (Seifert and 
Wieland, 2005). The H4R can be fused, in turn, to GAIP (also referred to as the regulator 
of G-protein signaling RGS19) for more efficient signalling and can be coexpressed with 
the Giα2 and Gβ1γ2 subunits (Schneider and Seifert, 2009). 
The access of ligands to the receptor of interest may strongly depend on the test system. 
For example, an exceptional latency period had been observed in experiments on the 
guinea-pig right atrium, where the positive inotropic effects of bivalent H2R agonists at 
low concentrations (< 10 nM) reached a plateau not before 2.5 to 3 hours of incubation 
(Prof. Dr. Sigurd Elz, personal communication). These problems, resulting most probably 
from slow distribution of these ligands in the isolated organ, should be overcome at the 
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Sf9 membranes, due to simplicity of the system. A recent study by Saito et al. showed 
that Sf9 membrane preparations contain vesicles (Saito et al., 2006). Moreover, scan-
ning electron microscopy revealed that there were many pores formed in the Sf9 cell 
membranes 5 days after infection with baculoviruses. The imaging of membrane sus-
pensions, prepared according to previously described procedures (Wenzel-Seifert et al., 
2001), confirmed that the investigated samples were composed of small, predominantly 
agregated vesicles (Fig. 1.2.7 B–G). Staining of the Sf9 membranes was performed with 
the fluorescent dye Cell Mask Deep Red (Invitrogen), Sudan Black (indication of lipids) 
and methylene blue according to Loeffler (indication of proteins). However, little is known 
about both, the orientation of the plasma membrane vesicles (inside-out or right-side-out) 
and the existence of the pores, as (according to the standard protocol) the membranes 
are harvested and prepared 48 hours after virus infection. Nevertheless, more detailed 
characterization of the morphology of the Sf9 membrane vesicles might be helpful for the 
elucidation of complex binding behavior of some ligands (e.g. slow dissociation of the 
radioligand [3H]UR-DE257 as shown in Fig. 5.3.4; cf. Erdmann, 2010). 
 
   
Fig. 1.2.7. Testing systems for H2R ligands: (A) spontaneously beating guinea-pig right atrium; 
(B–G) Sf9 membranes, expressing gpH2R-GsαS fusion proteins. The membranes were prepared 
as previously described (Wenzel-Seifert et al., 2001) and stained with: (B) Cell Mask Deep Red 
(microscope settings: Plan Apochromat 63x/1.4 Oil, HeNe 633, HFT UV/488/543/633, NFT 545, 
LP 650); (C–E) Sudan Black; (F–G) Loeffler’s methylene blue. Images B–G were acquired with a 
Carl Zeiss Axiovert 200M inverted microscope coupled to a Zeiss LSM510 scanning device and 
an Axiocam digital camera. 
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Experiments conducted on intact cells should provide closer similarity to physiological 
conditions than those performed on membranes, due to the higher complexity of the for-
mer. For example, high intracellular concentration of GTP in intact cells implicates that 
only the low-affinity binding site can be observed for agonists in radioligand binding stud-
ies, as it can be deduced from steep binding curves. By contrast, flat curves (resulting 
from the formation of the ternary complex) can be found for agonists in assays con-
ducted with broken-cell preparations (Lazareno, 2001; Kenakin, 2006). Moreover, using 
the living cells allows for the investigations of agonist-induced receptor internalization. As 
reported previously, the endogenous hH2R undergoes a rapid homologous desensitiza-
tion upon the HIS stimulation both on the monocytic U-937 (Smit et al., 1994) and the 
gastric carcinoma MKN-45 (Arima et al., 1993) cell lines. Previous studies of guanidine-
type H2R agonists showed that human neutrophils are a valuable model for functional 
investigations on endogenously expressed H2R, in particular by measuring superoxide 
(O2–) formation (Burde et al., 1990). The additional expression of the hH4R on the U-937 
cells was recently the matter of a controversial discussion (Cao et al., 2001; Damaj et al., 
2007). 
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1.3 Fluorescence- and radioactivity-based methods: selected 
aspects 
 
Ligand binding studies and functional assays are indispensable to characterize receptor 
agonists and antagonists and are important methods to investigate the mechanisms of 
ligand-receptor interactions. Information on ligand affinities is often decisive for the de-
velopment of new drug candidates and the optimization of lead structures. At the same 
time, binding experiments allow for the pharmacological characterization of drug targets 
(e.g. new receptor subtypes). The commonly approved strategies involve radioactive or 
fluorescent labelling of known ligands to obtain pharmacological tools, which are used for 
the investigation of novel chemical entities. Additionally, detailed analysis of both kinetic 
(time-course) and equilibrium binding data may provide a deeper insight into the as-
sumed ligand binding mode, which in case of bivalent compounds may imply “bridging” 
of receptor dimers, the ternary complex model, allosteric interactions or multiple ligand-
specific receptor conformations (Kenakin, 2006; Xie et al. 2006; Valant et al., 2008, 
Shonberg et al., 2011). 
On the other hand, current progress in protein labelling techniques facilitates the elucida-
tion of protein-protein interactions as well as the subcellular localization of the labelled 
structures. For example, fluorescent tagging of the GPCRs allows for the visualization of 
receptor dimerization and agonist-induced internalization (Milligan and Bouvier, 2005; 
Osawa et al., 2005). 
 
1.3.1 Requirements for ligand binding at equilibrium 
 
In order to obtain information on binding parameters (Kd, Bmax, Fig. 1.3.1), the system to-
be-investigated has to attain equilibrium at the time point of the measurement. 
 
 
Fig. 1.3.1. Saturation binding experiments at equilibrium allow measurements of both ligand affini-
ty (Kd) and the number of receptors (Bmax): (A) a saturation binding curve; (B) a Scatchard plot. 
A B
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For ligand binding at equilibrium, it is assumed that there is no ligand depletion. This 
requirement is fulfilled when the experimental settings are adjusted to ensure that the 
bound ligand fraction does not exceed 15% of the total amount of ligand (Lazareno, 
2001). Another important assumption consists in a sufficiently long incubation period. 
A premature termination of incubation (pre-equilibrium) may lead to artefacts (Hulme, 
1992). 
According to the law of mass action (Motulsky and Christopoulos, 2004), binding of a 
ligand A to its receptor R is described by the following reaction, where k1 (kon) and k2 (koff) 
are association and dissociation rate constants, respectively (Eq. 1.3.1):  
A+R AR
k1
k2  
(Eq. 1.3.1)
]AR[k]R[]A[k
dt
d([AR])
21   (Eq. 1.3.2)
 0
dt
d([AR])
21 k]AR[k]R[]A[ 
 
(Eq. 1.3.3)
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(Eq. 1.3.4)
The rate of forward binding is proportional to the concentrations of both the free ligand 
and the receptor, whereas the dissociation rate is proportional only to the concentration 
of the AR complex. Equilibrium is reached (steady state), when two reaction rates be-
come equal (Eq. 1.3.2–3). Then the ratio of k2 to k1 defines the equilibrium dissociation 
constant Kd (Eq. 1.3.4). 
The observed rate constant of radioligand association kobs depends on the used ligand 
concentration [A], the equilibrium dissociation constant Kd and the dissociation rate con-
stant k2, as expressed by the Eq. 1.3.5–6 (cf. Lazareno, 2001): 
  21obs k]A[kk      .constA   if   (Eq. 1.3.5)



  1
K
]A[kk
K
kk
d
2obs
d
2
1
 
(Eq. 1.3.6)
A general rule defines the time needed for equilibration as a 5-fold half-life of the radio-
ligand dissociation, if the used ligand concentration [A] is much less than Kd (Hulme, 
1992). When higher concentrations are used, the equilibration becomes even faster (Eq. 
1.3.5–6; cf. Lazareno, 2001): 
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  2obsd kk    KA   if   (Eq. 1.3.7)
 
d
2obsd K
]A[kk     KA   if   (Eq. 1.3.8)
 
1.3.2 Fluorescent proteins in confocal microscopy 
 
Confocal laser scanning microscopy (CLSM) allows for real time visualization and even 
subcellular localization of fluorescently stained structures, due to significantly improved 
image resolution in comparison to the usual fluorescence microscopy. This methodology 
has been successfully applied also for the investigation of GPCRs in living cells, involv-
ing the parallel acquisition of multi-labelled specimen and colocalization studies, as well 
as imaging of receptor internalization and intracellular recycling (Leterrier et al., 2004). 
The discovery of the green fluorescent protein (GFP) and development of its numerous 
spectral variants (Fig. 1.3.2) by O. Shimomura, M. Chalfie and R. Y. Tsien revolutionized 
the studies on protein-protein interactions and was awarded with the Nobel Prize in 
Chemistry in 2008 (http://nobelprize.org/nobel_prizes/chemistry/laureates/2008/). The 
GFP-like proteins are very advantageous, due to quick chromophore formation, mostly 
enabling undisturbed folding and function of the tagged protein (Ormö et al., 1996; 
Miyawaki et al., 2003; Shaner et al., 2005). Additionally, after successful transfection of 
the cells, no further chemical modifications are necessary (contrary to the BRET and 
FlAsH techniques; Hoffmann et al., 2005; Milligan and Bouvier, 2005). Fig. 1.3.3 shows 
examples how fluorescent proteins have been applied to investigate the GPCR-mediated 
signal transduction. 
 
 
 
Fig. 1.3.2. The enhanced cyan fluorescent protein (ECFP). 
The ECFP model was generated with the KiNG Viewer 
program (from the RCSB Protein Data Bank). 
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Fig. 1.3.3. Selected applications of fluorescent proteins for the investigation of GPCR signalling: 
(A) redistribution (translocation) of GPCRs or β-arrestins, (B) conformational change of receptors, 
(C) proximity assays (recruitment of β-arrestins) upon agonist stimulation (adopted from Vilardaga 
et al., 2003; Rajagopal et al., 2010 with modifications). 
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2 Scope and Objectives 
Membranal proteins as members of the family of G-protein-coupled receptors (GPCR) 
comprise a significant part of the druggable human genome. A well known and widely 
accepted pharmacological paradigm for this receptor class states that an elementary unit 
required for signal transduction in the cell involves a sole receptor molecule, interacting 
via its unique binding site with a single pharmacophoric moiety (Lazareno, 2001). How-
ever, in the last three decades, a plethora of experimental data (for example Förster 
resonance energy transfer (FRET) at fluorescently labelled receptors) supported the hy-
pothesis of dimerization of the GPCRs, including neuropeptide Y (NPY YxR) and hista-
mine (HxR) receptors (Fukushima et al., 1997; Kroeger et al., 2004; Ferré et al., 2009). 
Moreover, bivalent GPCR ligands, which might be capable of simultaneously binding to 
the orthosteric recognition sites of dimerizing protomers, have been reported (Bhushan 
et al., 2004; Shonberg et al., 2011). Thus, in addition to labelled receptors, ligand-based 
approaches might contribute to gain deeper insight into GPCR dimerisation. Additionally, 
targeting of GPCR dimers, although requiring the revision of the classical pharmacology, 
could be advantageous not only for understanding (patho)physiological processes, but 
also with respect to pharmacotherapy. 
The aim of the present work was to explore the applicability of both approaches to the 
investigation of histamine and neuropeptide Y (NPY) receptor subtypes as examples of 
aminergic and peptidergic GPCRs. The aforementioned FRET measurements, enabling 
the non-radioactive investigation of receptor dimerization in living cells, involve tagging of 
receptors to fluorescent proteins, which constitute a donor and an acceptor of a FRET 
pair. At the beginning of this project it was known that the transiently expressed human 
NPY Y1R, C-terminally tagged with enhanced cyan or yellow fluorescent proteins (ECFP 
and EYFP), were still able to bind the natural ligand and transduce the signal into the cell 
(Dinger et al., 2003).Beyond that, doctoral projects pursued in parallel at our department, 
were aiming at the synthesis of bivalent ligands for the Y1R (Keller et al., 2009) and the 
histamine H2R and H4R, i. e. ligands fulfilling the structural requirements for binding to 
putative GPCR dimers were already available or are subject of ongoing work. For exam-
ple, the application of the bivalent ligand approach to acylguanidine-type H2R agonists 
resulted in the most potent agents known so far (up to 4000-fold more potent than hista-
mine), both on the isolated guinea-pig right atrium and in steady-state GTPase assays 
on H2R-Gss fusion proteins expressed in Sf9 cells. Surprisingly, the maximum of potency 
was obtained for compounds with relatively short octamethylene spacers (Kraus, 2007; 
Birnkammer et al., 2010), theoretically insufficient to bridge the receptor dimers 
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(Bhushan et al., 2004). As the reason for this tremendous gain in potency compared to 
monovalent analogues was unclear, this class of compounds was selected for more de-
tailed analyses of the binding mode. The existence of an accessory (allosteric ?) binding 
site on the same receptor molecule should be taken into account. It is noteworthy that 
allosterically acting ligands have been reported for a few GPCR types (α2A-
adrenoreceptors, Leppik et al., 1998; muscarinic receptors, Valant et al., 2008), but only 
studies on the opioid receptors revealed advantages of compounds, which address re-
ceptor dimers (Daniels et al., 2005). 
Exploring the applicability of stably expressed fluorescently labelled NPY Y1 receptors for 
prospective FRET-based investigations of receptor dimerization by means of confocal 
microscopy (van Rheenen et al., 2004), was one subject of this work. As a first step, a 
cell line, stably expressing either Y1R-ECFP or Y1R-EYFP fusion proteins, should be 
established. The correct membranal localization of both, the receptor and the fluorescent 
protein, had to be examined by using a selective Y1R radioligand (Keller et al., 2008) and 
fluorescent ligands (Schneider et al., 2006; Schneider, Keller et al., 2007). If possible, a 
functional assay should be performed with the ratiometric calcium-chelating dye fura-2 
(Kracht, 2001). 
The second part of this doctoral project focused on the detailed analysis of H2R binding 
in order to learn more about the differences between mono- and bivalent acylguanidines 
compared to the natural ligand. Radioligand competition binding studies with selected 
ligands should be performed at Sf9 cell membranes expressing the human or guinea pig 
H2R alone, or as fusion proteins with GsS (Erdmann, 2010). Due to the recently revealed 
one-digit nanomolar affinity of these compounds at the human H4R (Kraus, 2007), analo-
gous experiments could be performed using this receptor as well (Igel et al., 2009). As 
the Hill coefficients of both, saturation and competition curves, might be good indicators 
of cooperativity and ligand–receptor stoichiometry, binding isotherms of the mono- and 
bivalent ligands had to be carefully analyzed (Hill and Scatchard plots; Kenakin, 2006). 
In addition, the investigation of the sensitivity of ligand binding to guanine nucleotides 
and the screening of various cell lines for the expression of H2R and H4R were consid-
ered suitable for this project. 
The assumed binding mode of bivalent acylganidines may imply, apart from receptor 
dimerization, the ternary complex model, allosteric interactions or functional selectivity. 
Simultaneous occupation of both, ortho- and allosteric binding sites, should lead to an 
altered dissociation of an orthosteric radioligand. Hence, potential allosterism could be 
verified by measuring radioligand off-rate at Sf9 cell membranes, expressing H2Rs and 
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H4Rs in the presence of different ligands, by analogy to the procedure described previ-
ously for muscarinic receptors (Kostenis and Mohr, 1996). 
To further elucidate the intracellular fate of H2Rs after exposure to the bivalent ligands, 
H2R endocytosis (involving β-arrestins) had to be investigated in parallel with radioligand 
binding studies. It was planned to express the human H2R, tagged with red fluorescent 
protein in CHO cells, in order to visualize agonist-induced receptor internalization by 
means of confocal microscopy (Osawa et al., 2005; Shcherbo et al., 2009). In combina-
tion with the results from the GTPase assays (receptor-dependent G-protein activation), 
previously obtained in our research group, this new approach was considered to be help-
ful to get a hint to functional selectivity at the human H2R (Rajagopal et al., 2010). 
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3 Stable expression of neuropeptide Y Y1 receptors 
tagged with fluorescent proteins for the FRET-based 
investigation of receptor dimerization 
 
3.1 Introduction 
 
Fluorescence-based techniques, especially fluorescence resonance energy transfer 
(FRET), have been used for the investigation of dimerization among numerous types of 
GPCRs, including NPY Y1 receptors (Dinger et al., 2003; Kroeger et al., 2004; Hébert et 
al., 2006; Ferré et al., 2009). The hypothesis that receptor dimers can participate in traf-
ficking, signal transduction and recycling (Smith and Milligan, 2010) has been gaining 
ever broader recognition for the last three decades, as an extremely challenging concept 
for both the molecular pharmacology and the drug design. The aforementioned FRET 
measurements require tagging of receptors to fluorescent proteins which constitute a 
donor and an acceptor of a FRET pair. When donor (ECFP) and acceptor (EYFP) mole-
cules are in spatial proximity (most probably due to the interaction between two recep-
tors; Fig. 3.1.1 A), the measurement of a FRET signal should be possible, enabling the 
non-radioactive investigation of receptor dimerization in living cells (Milligan and Bouvier, 
2005). Moreover, transiently expressed NPY Y1 receptors C-terminally tagged with en-
hanced cyan or yellow fluorescent proteins (ECFP and EYFP) have been previously re-
ported to be able to bind the natural ligand and to remain functional (Dinger et al., 2003). 
However, there is a very serious limitation of this method, namely that FRET signals 
come not exclusively from the cell membrane, but can also arise in cellular compart-
ments (Maurel et al., 2008) due to intracellular fluorophore interaction. 
 
3.1.1 RET-based assays for the investigation of receptor dimerization 
 
3.1.1.1 FRET between GPCRs tagged with fluorescent proteins 
 
As mentioned in subsection 1.3.2, tagging with fluorescent proteins is a very attractive 
method for the detection of protein trafficking in living cells, as these fluorophores are 
genetically encoded and no additional chemical modification of the cells is needed. 
ECFP and EYFP are suited for the investigation of direct protein-protein interactions, 
involving FRET measurements, due to spectral overlap (Fig. 3.1.1 B). The experimental 
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setup requires an external source of light, proper for the excitation of the donor. In the 
absence of acceptor molecules, the excited donor fluoresces in the region of spectrum 
which is typical for the ECFP emission. However, when donor and acceptor molecules 
are in close spatial proximity (Förster radius, usually less than 10 nm), the energy of the 
ECFP can be transduced in a non-radiative manner onto the EYFP. As a result, the ex-
cited acceptor molecules emit the light of the wavelength, characteristic for EYFP emis-
sion (Milligan and Bouvier, 2005). Fluorescence signals can be detected by means of 
fluorimetry or confocal microscopy and converted into FRET signals. Other combinations 
of fluorophores for FRET are also possible (Pfleger and Eidne, 2005), including green or 
yellow fluorescing donors (e.g. GFP or fluorescein isothiocyanate FITC) and red fluo-
rescing acceptors (e.g. RFP/DsRed or rhodamine derivatives like Texas Red). 
  
Fig. 3.1.1. ECFP and EYFP as a donor-acceptor FRET pair in receptor dimerization studies: (A) 
FRET signal resulting from receptor dimerization (adopted from Pfleger and Eidne, 2005 with 
modifications), (B) the excitation and emission spectra of ECFP and EYFP – the overlapping part 
of the ECFP emission and the EYFP excitation is shown in green (adopted from 
http://www.semrock.com/fret.aspx with modifications). 
 
3.1.1.2 BRET-based experiments 
 
Another method for investigation of GPCR dimerization, utilizing fluorescent proteins as 
acceptors, is bioluminescence resonance energy transfer (BRET). In contrast to FRET, 
an external light source is not required in this technique, because the excitation is pro-
vided by photochemical reactions catalyzed by Renilla luciferase-coupled donors. Thus, 
BRET is characterized by a relatively simple experimental setup and the lack of photob-
leaching, which is a common problem for FRET. As a consequence of the negligible au-
tofluorescence, BRET measurements provide a higher signal-to-noise ratio than those 
based on FRET (Milligan, 2004), but the addition of a substrate for the photochemical 
reaction is mandatory. 
A B
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3.2 Materials and methods 
 
3.2.1 Materials 
 
The hY1R-pECFP-N1 and hY1R-pEYFP-N1 plasmids (Dinger et al., 2003) were kind gifts 
from Prof. Dr. Annette G. Beck-Sickinger (University of Leipzig, Germany), whereas the 
pECFP-Mito, pQCXIP/ECFP-Mem and pEYFP-N1 plasmids were from Dr. Dietmar 
Gross (University of Regensburg). 
RNase A (100 µg/mL), Mass Ruler DNA Ladder mix, EcoRI (10 U/μL), NotI (10 U/μL), 
6x Loading Dye, 10x “O” (orange) buffer and 10x Tango buffer were purchased from MBI 
Fermentas (St. Leon-Rot, Germany) and 10x BSA (0.1%) solution was from Amersham 
Pharmacia Biotech (Piscataway, NJ, USA). Gel chambers of the PerfectBlue Mini S gel 
system and agarose were from Peqlab (Erlangen, Germany). Ethidium bromide solution 
was obtained from Janssen Chimica (Beerse, Belgium). Tris·HCl was from Serva (Hei-
delberg, Germany), whereas tris base was from USB (Cleveland, OH, USA). NaOH, 
KAc, glacial acetic acid and EDTA (obtained as Titriplex III) were from Merck (Darmstadt, 
Germany). Phenol-chloroform-isoamylalcohol (25:24:1) was from Carl Roth (Karlsruhe, 
Germany). Ethanol was from Mallinckrodt Baker (Griesheim, Germany). SDS and kana-
mycin was from Sigma-Aldrich (Steinheim, Germany). QIAquick Gel Extraction and 
QIAGEN Plasmid Maxi kits were from QIAGEN (Hilden, Germany). 
CHO cells were from the DSMZ (Deutsche Sammlung für Mikroorganismen und Zellkul-
turen, Braunschweig, Germany), whereas A-431, MCF-7, U-118 MG and U-373 MG cells 
were purchased from the ATCC (American Type Culture Collection; Manassas, VA, 
USA). MCF-7-Y1 cells (a MCF-7 subclone with higher Y1 receptor expression) were re-
cently established in our laboratory (Keller, 2008; Memminger, 2009). FuGENE 6 and 
HD transfection reagents were from Roche Diagnostics (Mannheim, Germany), whereas 
Lipofectamine 2000 was from Invitrogen (Karlsruhe, Germany). Ham’s nutrient mixture 
F12, Eagle's minimum essential medium (EMEM), Dulbecco´s minimum essential me-
dium (DMEM) and stabilized penicillin−streptomycin−neomycin solution were purchased 
from Sigma-Aldrich. Fetal calf serum (FCS) and geneticin (G418) were from Biochrom 
(Berlin, Germany). Trypsin-EDTA (10x) was from PAA Laboratories (Pasching, Austria). 
The NPY Y1R selective ligands: BIBP 3226, the fluorescent ligands UR-MK115 and UR-
MK131 as well as the radioligand Nω-([2,3-3H]propionyl)-BIBP 3226 ([3H]UR-MK114; 
1.9 TBq/mmol) were synthesized by Dr. Max Keller as described previously (Fig. 1.2.2; 
Keller, 2008; Keller et al., 2008). The fluorescent ligands Dy-635-pNPY and Cy5-pNPY 
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were synthesized by Dr. Erich Schneider (Fig. 1.2.1; Schneider, 2005; Schneider et al., 
2006). The pNPY was kindly provided by Prof. Dr. Chiara Cabrele (Ruhruniversität Bo-
chum). HEPES was from Serva (Heidelberg, Germany). NaCl, KCl, CaCl2·2H2O, 
KH2PO4, MgCl2·6H2O, MgSO4·7H2O, NaHCO3, urea, glacial acetic acid and 1 N NaOH 
were from Merck. BSA, bacitracin and Triton-X-100 were from Sigma (Deisenhofen, 
Germany). The 8-well Lab-Tek chambers were from Nunc (Wiesbaden, Germany). Lei-
bovitz's L-15 medium without phenol red and fura-2/AM were from Invitrogen. Lyso-
Tracker Green DND-26 was purchased from Invitrogen (Molecular Probes; Eugene, OR, 
USA) and DRAQ5 was from Biostatus Limited (Leicestershire, UK). Microscopic images 
were taken with a Carl Zeiss Axiovert 200M LSM510 confocal laser-scanning micro-
scope (Oberkochen, Germany). 
 
3.2.2 Transformation of bacteria and preparation of plasmids 
 
3.2.2.1 Transformation of bacteria 
 
The transformation of competent E. coli bacteria (TOP10 strain) was conducted as in 
subsection 6.2.3 with minor modifications. Briefly, 25 ng (10 µL) of either the hY1R-
pECFP-N1 or hY1R-pEYFP-N1 plasmid (Fig. 3.2.1) were added to 100 µL of bacterial 
suspension and incubated with SOC medium at 37 °C for 1 hour under shaking at 
150 rpm. The transformed bacteria were plated on an agar plate containing kanamycin 
(30 μg/mL) for selection, as both vectors enclose a kanamycin/neomycin resistance 
gene. Subsequently, the agar plates were incubated overnight at 37 °C. 
 
3.2.2.2 Mini-Prep 
 
For each plasmid used for transfection, one colony was picked from the bacteria grown 
on the selective agar plate to inoculate 5 mL of LB medium, containing 30 μg/mL kana-
mycin. After overnight incubation at 37 °C under shaking at 250 rpm, the suspensions 
were centrifuged for 1 min at 13,000 rpm. To purify the DNA samples, small-scale alka-
line lysis (Mini-Prep) was performed in parallel (3 x 1.5 mL of each bacterial suspension) 
as described before by Dr. Nathalie Pop (Pop, 2010). DNA concentration was measured 
by UV spectroscopy: the concentration of aqueous solution of double-stranded DNA in 
µg/mL was calculated from absorbance at 260 nm A260 and dilution factor F, according to 
Eq. 3.2.1. 
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gc 260DNA 

      (Eq. 3.2.1) 
 
The purity was considered sufficient if the ratio of absorbances measured at 260 nm and 
280 nm A260/A280 was higher than 1.5. The purified plasmids were stored at -20 °C until 
use for transformation. 
 
Fig. 3.2.1. Map of the unique restriction sites for enzymatic digest of the hY1R-pEYFP-N1 plasmid 
(as generated by the pDRAW32 programm). The hY1R-pECFP-N1 plasmid contains the se-
quence of ECFP instead of EYFP. 
 
3.2.2.3 Restriction analysis and agarose gel electrophoresis 
 
Double digestion of both plasmids was performed in a final volume of 15 μL under follow-
ing conditions: 1 μL of either the hY1R-pECFP-N1 or hY1R-pEYFP-N1 plasmid was 
added to 10.5 µL of Millipore water. The mixture was supplied with 1.5 μL of 10x “O” (or-
ange) buffer, 1 μL of EcoRI (10 U/μL) and 1 µL of NotI (10 U/μL). The samples were 
mixed, shortly centrifuged and incubated for 1 hour at 37 °C. Thereafter, 3 µL of 6x load-
ing dye were added and the samples were mixed. 
Agarose gel electrophoresis was performed as described in subsection 6.2.2.2. Briefly, 
18 μL of each DNA sample as well as 10 μL of ready-to-use MassRuler DNA Ladder Mix 
(for reference) were pipetted to separate pockets of the 1.5% agarose gel. The voltage 
(90 V) was supplied and the gel was running for approx. 50 min. The separated DNA 
bands were visualized by transillumination at 254 nm while using the Quantity One soft-
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ware (Gel Doc 2000; Bio-Rad Laboratories, Munich, Germany). The illumination of the 
analytic gel revealed the expected lengths (cf. Fig. 3.2.1) of the digested EcoRI-hY1R-
ECFP(EYFP)-NotI fragment (1900 bp) as shown in Fig. 3.2.2. 
 
 
 
Fig. 3.2.2. The digested Mini-Prep product (P) contained 
EcoRI-hY1R-ECFP-NotI fragment (1900 bp) and the rest 
of the vector (4000 bp). The MassRuler DNA Ladder Mix 
was used as a DNA marker (M). 
 
 
 
 
Additionally, the fragments of the purified plasmids encoding the hY1R, ECFP and EYFP 
were inspected by sequencing, performed by Entelechon (Regensburg, Germany), using 
the following primers: 
 
 for hY1R-pECFP: 
 pEGFP-N1-fwd (forward: annealing upstream of the hY1R gene), 
 pEGFP-N1-rwd (reverse: annealing at the beginning of the ECFP gene), 
 pECFP-C1-rev (reverse: annealing downstream of the ECFP gene); 
 for hY1R-pEYFP: 
 pECFP-N1-fwd (forward: annealing upstream of the hY1R gene), 
 pECFP-N1-rwd (reverse: annealing at the beginning of the EYFP gene), 
 pECFP-C1-rev (reverse: annealing downstream of the EYFP gene). 
 
In both plasmids, the sequences of the hY1R and the fluorescent protein were identically 
equal to those from Prof. Dr. A. Beck-Sickinger (University of Leipzig, Germany). 
 
3.2.3 Cell culture and transfection 
 
3.2.3.1 Cell culture 
 
To prepare 1 L of trypsin, 100 mL of 10-fold trypsin-EDTA solution were diluted in 
900 mL PBS, sterile filtered and stored at -20 °C in 50-mL or 100-mL aliquots. 
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Cells were maintained in the culture media listed in Table 3.2.1 at 37 °C in the humidified 
atmosphere containing 5% CO2. Every 4–7 days, cells were trypsinized and passaged 
(1:10) to a fresh 25-cm2 culture flask. 
 
Table 3.2.1. Cell culture conditions. 
Cell line Cell culture conditions 
A-431 EMEM + 5% FCS (Guiswé, 2000) 
A-431 hY1R-EYFP EMEM + 5% FCS + 400 or 750 μg/mL G418 
CHO-K1 Ham’s F12 + 10% FCS 
U-118 MG DMEM + 5% FCS (Müller, 2007) 
U-118 hY1R-ECFP DMEM + 5% FCS + 400 μg/mL G418 
U-373 MG EMEM + 5% FCS (Müller, 2007) 
U-373 hY1R-ECFP EMEM + 5% FCS + 400 or 750 μg/mL G418 
U-373 hY1R-EYFP EMEM + 5% FCS + 400 or 750 μg/mL G418 
 
3.2.3.2 Stable transfection 
 
Two days prior to transfection, the glioblastoma/astrocytoma U-373 MG cells were 
seeded in a 24-well plate. The confluent cells were transfected with the mammalian ex-
pression vectors hY1R-pECFP-N1 or hY1R-pEYFP-N1 using the FuGENE 6, the 
FuGENE HD or the Lipofectamine 2000 transfection reagent in different reagent-to-
plasmid DNA ratios according to manufacturer’s instructions. Lipofectamine revealed to 
be not suitable for transfection as it was toxic. The obtained stable transfectant clones of 
U-373 cells were selected as described in subsection 6.2.5, using 400 or 750 µg/mL 
G418, and subsequently tested in fluorimetric calcium assays as well as in radioligand 
and flow cytometric binding studies. Also the glioblastoma/astrocytoma U-118 MG and 
the skin epidermoid carcinoma A-431 cells were used for the transfection with the hY1R-
pECFP-N1 or hY1R-pEYFP-N1 plasmid, respectively. The resulting transfectant clones 
were tested in preliminary radioligand binding studies (not shown) and illuminated by 
means of CLSM, but they were not suitable for further cultivation (A-431 cells were resis-
tant to trypsin, whereas U-118 MG cells did not grow in monolayers). 
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3.2.3.3 Transient transfection 
 
CHO-K1 and U-373 MG cells were transfected with the localization vector pECFP-Mito 
and/or the retroviral expression vector pQCXIP/ECFP-Mem (Gross, 2006) as positive 
controls for mitochondrial and membranal expression of ECFP, respectively. U-373 MG 
cells were transfected with pEYFP-N1 plasmid for the cytosolic expression of EYFP 
(control for microscope settings). Two days prior to transfection, the cells were seeded in 
8-well Lab-Tek chambers (approx. 65,000 cells per well) and cultivated without antibiot-
ics. Transfection was performed with 1 µL of FuGENE 6 and 250 ng of the appropriate 
plasmid per well. The cells were imaged (CLSM) on the next day. 
 
3.2.4 Radioligand binding on intact cells 
 
Binding buffer was prepared as described before (cf. buffer I, Kracht, 2001) by dissolving 
2.38 g of HEPES (10 mM), 8.77 g of NaCl (150 mM), 373 mg of KCl (5 mM), 368 mg of 
CaCl2·2H2O (2.5 mM CaCl2), 163 mg of KH2PO4 (1.2 mM), 296 mg of MgSO4·7H2O 
(1.2 mM MgSO4) and 2.1 g of NaHCO3 (25 mM) in 1 L of Millipore water. After pH was 
adjusted to 7.4, using 1 N NaOH, the solution was sterile filtered and stored at 4 °C until 
use. For the preparation of 500 mL of lysis solution (Keller, 2008), 240.2 g of urea (8 M), 
85.8 mL of acetic acid (3 M) and 6 mL of Triton-X-100 (1% m/m) were dissolved in Milli-
pore water. 
Radioligand binding assays were performed in triplicate according to the protocol used in 
our research group (Aiglstorfer et al., 1998; Keller et al., 2009) with minor modifications. 
Two days prior to the binding assay, cells were seeded in 24-well plates. On the day of 
experiment, confluent cells were carefully washed (2 x 300 µL) with binding buffer and 
covered with 200 µL of binding buffer containing 1% BSA and 0.01% (m/v) bacitracin 
(added in order to prevent the peptide ligand pNPY from adsorption and protease-
mediated degradation, respectively). Then 25 µL of binding buffer (for total binding) or 
25 µL of pNPY (1.8 µM final, for unspecific binding) were added to each well. After 3 min 
of preincubation, the samples were completed by addition of 25 μL of Nω-([2,3-
3H]propionyl)-BIBP 3226 ([3H]UR-MK114) to yield a final concentration of 6 nM and incu-
bated for 12 min at room temperature (20–23 ºC). The binding buffer was removed by 
aspiration and the cells were gently washed (2 x 500 µL) with ice-cold binding buffer 
(approx. 20 s). Finally, 200 µL of lysis solution were added to each well and the plates 
were incubated for at least 30 min under gentle shaking. The lysates were transferred 
into scintillation vials (filled with 3 mL of scintillator). The wells were washed with 100 µL 
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of lysis solution and the lysates were transferred into the vials. Samples were measured 
for 5 min in a LS 6500 Liquid Scintillation Counter from Beckman Coulter (Krefeld, Ger-
many). The hY1R number/cell was calculated by using the specific radioactivity of radioli-
gand (cf. Eq. 4.2.2). 
 
3.2.5 Flow cytometric binding and cell sorting 
 
3.2.5.1 Binding assays 
 
Binding buffer for flow cytometry was prepared as described before (Sheikh and Wil-
liams, 1990; cf. buffer II, Kracht, 2001; Ziemek, 2006) by dissolving 5.95 g of HEPES 
(25 mM), 368 mg of CaCl2·2H2O (2.5 mM CaCl2) and 203 mg of MgCl2·6H2O (1 mM 
MgCl2) in 1 L of Millipore water. After pH was adjusted to 7.4 using 1 N NaOH, the solu-
tion was sterile filtered and stored at 4 °C until use. 
Flow cytometric binding assays were performed as described previously by Dr. Ralf Zie-
mek (Ziemek, 2006) with minor modifications. Briefly, 4–6 days prior to the experiment, 
the stably transfected cells were seeded in 1–3 fresh 175-cm2 culture flasks in medium 
without antibiotics. On the day of the experiment, the cells were trypsinized and centri-
fuged for 5 min at 1000 rpm (300 g) with a Minifuge RF from Heraeus Sepatech (Oste-
rode, Germany). The pelleted cells were washed with binding buffer and centrifuged 
again. Subsequently, the cells were resuspended in fresh binding buffer containing 
1% BSA and 0.01% (m/v) bacitracin (cf. subsection 3.2.4) to obtain the required density 
of 1 million cells per mL. For unspecific binding, 5 µL of the porcine NPY (800 nM final) 
or BIBP 3226 solution (1 µM or 10 µM final) were pipetted to siliconized 1.5-mL reaction 
vessels, whereas 5 µL of the appropriate solvent were used for total binding. Thereafter, 
490 µL of the cell suspension were added and incubated for 2 hours with 5 µL of Dy-635-
pNPY (8 nM final) under gentle shaking (light protected). Samples were measured in a 
FACSCalibur flow cytometer from Becton Dickinson (Heidelberg, Germany). The ac-
quired data (fluorescence from Fl-4 channel) were processed with WinMDI2.9 software 
(Phoenix, AZ, USA). 
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3.2.5.2 Cell sorting (FACS) 
 
The U-373 hY1R-ECFP cells were sorted by Dr. Louay Jouma (Institute of Immunology, 
University Regensburg) using a BD FACSAria cell sorter, equipped with a 407 nm violet 
laser and 450/40 nm BP filter (Pacific blue filter sets, cf. the excitation and emission 
spectra of ECFP in Fig. 3.1.1 B). Four days prior to sorting, the wild-type and the trans-
fected U-373 cells (in presence of G418) were seeded in a 75-cm2 and a 25-cm2 culture 
flask, respectively. On the day of the experiment, the cells were trypsinized, centrifuged 
at 300 g for 7 min (at 4 °C) and suspended in PBS (phosphate buffered saline) with 
2% FCS to obtain the density of 2–3 million cells per mL. A FSC/SSC gate was set for 
the wild-type U-373 MG cells, and the U-373 hY1R-ECFP cells were sorted into 1 mL of 
FCS (100%) according to the fluorescence signal of ECFP. The sorted cells (15,000 
events) were put on ice, centrifuged and suspended in culture medium with 5% FCS and 
400 µg/mL G418. Finally, the cells were seeded in one well of a 96-well plate. 
The U-373 hY1R-EYFP cells were sorted with a Becton Dickinson FACSCalibur flow cy-
tometer according to the manufacturer’s instructions, using the FACSComp software. 
Briefly, 5 days prior to sorting, the cells were seeded in a 75-cm2 culture flask in pres-
ence of G418. Additionally, 5 L of PBS were prepared and sterile filtered. One day before 
sorting, four 50-mL tubes were filled with sterile 4% BSA and stored at 4 °C. On the day 
of the sorting, 4% BSA was replaced with EMEM containing 25% FCS (5 mL in each 
tube). The flow cytometer was sterilized with 70% ethanol and washed with sterile PBS. 
The freshly trypsinized cells were centrifuged for 5 min at 1000 rpm (300 g) and sus-
pended in sterile PBS to obtain the density of 1 million cells per mL (17 million cells). The 
cells were sorted in the ‘single cell’ mode (approx. 120,000 events) into the prepared 
50-mL tubes with EMEM and 25% FCS, using fluorescence from Fl-1 channel (488 nm 
argon laser, 530/30 BP filter; cf. the excitation and emission spectra of EYFP in Fig. 
3.1.1 B). The wild-type U-373 cells were used to set up a FSC/SSC gate. After success-
ful sorting, the tubes with the hY1R-EYFP cells were put on ice and centrifuged at 300 g 
for 10 min. The resulting cell pellets were suspended in culture medium with 20% FCS 
and seeded in a 12.5-cm2 flask. After reaching confluence, the cells were passaged into 
a 25-cm2 culture flask. To prevent contaminations, a mixture of penicillin (100 U/mL), 
streptomycin (100 µg/mL) and neomycin (200 µg/mL) was added to culture medium for 
approx. 3 weeks after sorting (Lindl, 2000).  
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3.2.6 Fluorescence-based ratiometric calcium assays 
 
The stably transfected cells were loaded with fura-2/AM as described by Dr. Erich 
Schneider (Schneider, 2005). Samples were excited alternately at 340 and 380 nm and 
fluorescence was detected at 510 nm using a LS 50 B Luminescence Spectrometer from 
Perkin Elmer (Überlingen, Germany). Fluorescence intensity ratios R were counted as 
F340/F380 and the intracellular Ca2+ concentration was calculated according to the 
Grynkiewicz equation (Eq. 3.2.2; Grynkiewicz et al., 1985): 
     SFBRR RRKCa max mind2      (Eq. 3.2.2) 
where Kd (dissociation constant of fura-2-Ca2+ complex; 224 nM) is the concentration of 
calcium at which 50% of fura-2 molecules bind calcium ions and R, Rmin as well as Rmax 
are ratios measured at different Ca2+ concentrations (at a Ca2+ concentration to be de-
termined, in absence of Ca2+ and in presence of a saturating Ca2+ concentration, respec-
tively). The SFB value, determined while calibration, is the ratio of fluorescence intensi-
ties of calcium-free and calcium-bound fura-2 at 380 nm. 
 
3.2.7 Confocal microscopy experiments 
 
3.2.7.1 Preparation of specimens 
 
Cells were seeded in 8-well Lab-Tek chambers 2 days before imaging (Gross, 2006) and 
cultivated without antibiotics at 37 °C in the humidified atmosphere with 5% CO2 (cf. sub-
section 6.2.6.1). For experiments with MCF-7-Y1 cells, 1 nM estrogen (1:000 dilution of 
1 µM solution in ethanol) was added to culture medium (Keller, 2008; Memminger, 
2009). Shortly before imaging, culture medium was carefully changed to Leibowitz’s L-15 
medium. For better orientation, the cell nuclei were stained with the red nuclear dye 
DRAQ5 at a final concentration of 5 μM (1:1000 dilutions in L-15). The nuclei were visible 
already 5 min after staining; no washing was required. Appropriate controls (unstained 
cells) were performed to exclude the possibility of cross-talk and bleed-through between 
fluorophores. For binding studies with fluorescent Y1R ligands, cells were covered with 
240 µL of L-15 medium. Than 80 µL of either BIBP 3226 (for unspecific binding, final 
5 µM) or Millipore water (for total binding) were used. Finally, the samples were com-
pleted by addition of 80 µL of a 5-fold concentrated solution of an appropriate fluorescent 
ligand in L-15 medium and incubated at room temperature (20 °C) in the dark. Non-
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peptide fluorescent Y1R antagonists were solved in 100% DMSO and stored at -80 °C 
(1 or 2 mM stock solutions; cf. Keller, 2008). Therefore, for microscopic binding studies, 
5-fold concentrated solutions of those ligands in L-15 were prepared freshly from 10 µM 
auxiliary solutions in 20% DMSO. Specimens were investigated with a Carl Zeiss Axio-
vert 200M LSM510 microscope. 
 
3.2.7.2 Microscope settings 
 
For imaging of ECFP, the excitation line of an argon ion laser (Ar) of 458 nm (transmis-
sion >86%), a 458 nm main dichroic beam splitter (HauptFarbTeiler, HFT) and a 475 nm 
long-pass (LP) or a 475–525 nm band-pass (BP) filter were used. If not otherwise stated, 
EYFP was detected with FITC filter sets: a 488 nm excitation line of an Ar laser (trans-
mission of 3-12%), a 488 nm HFT, a 515 nm secondary dichroic beam splitter (Neben-
FarbTeiler, NFT) and a 505–550 nm BP filter (cf. the excitation and emission spectra of 
ECFP and EYFP in Fig. 3.1.1 B). For the fluorescent proteins in combination with the red 
nuclear counterstain DRAQ5, a helium ion laser of 543 nm (transmission of 37%), a 
458/543 nm HFT, a 545 nm NFT and a 650 nm LP filter were additionally used, using the 
multi-track facility of the CLSM (with switching of Ar and HeNe lasers after each frame). 
Fluorescence of the fluorescent ligand UR-MK115 was detected using the 488 nm exci-
tation line of an Ar laser (5% transmission), a 488 nm HFT, a 515 nm or a 545 nm NFT 
and a 650 LP filter, whereas for binding studies with the non-peptide UR-MK131 and the 
peptide Cy5-pNPY fluorescent ligands a 633 nm excitation line of HeNe laser 
(14% transmission), a UV/488/543/633 nm HFT and a 650 nm LP filter were used (multi-
track acquisition mode). 
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3.3 Results and discussion 
 
The FRET-based investigations of receptor dimerization require comparable expression 
levels of the receptors fluorescently labelled with donor (e.g. ECFP) and acceptor (e.g. 
EYFP) molecules simultaneously in the same cell (Dinger et al., 2003; Carrillo et al., 
2004). However, in order to prove proper expression and functionality of the fusion pro-
teins, the U-373 MG (HTB-17) glioblastoma/astrocytoma cells were transfected exclu-
sively with either the hY1R-pECFP-N1 or the hY1R-pEYFP-N1 plasmid (single labelling, 
controls). To quantify the expression level of the hY1R tagged with either ECFP or EYFP, 
stably transfected U-373 cells were investigated with a selective hY1R radioligand (Keller 
et al., 2008) and fluorescent ligands by means of flow cytometry (Schneider, Keller et al., 
2007). As the wild-type U-373 MG cells utilize calcium ions as a second messenger 
(Kracht, 2001), it was also possible to perform a functional assay, using the calcium-
chelating dye fura-2 (Schneider, 2005). Finally, confocal microscopy imaging (CLSM) 
enabled the detection of the subcellular localization of the hY1R-ECFP and the hY1R-
EYFP fusion proteins in the transfected U-373 and in other cell lines (A-431, U-118 and 
CHO). 
 
3.3.1 Stable expression of the functionally active NPY Y1R tagged with ECFP 
and EYFP 
 
3.3.1.1 Radioligand binding 
 
The quantification of hY1R binding sites on the cells expressing the fusion proteins was 
performed with a selective neuropeptide Y Y1 receptor radioligand synthesized in our 
research group by Dr. Max Keller (Keller, 2008). In previous studies, the tritium-labeled 
NG-propionylargininamide UR-MK114, structurally derived from the selective NPY Y1 
receptor antagonist BIBP 3226 (Aiglstorfer et al., 1998), revealed excellent one-digit 
nanomolar affinity (Kd values: 2.9 ± 0.4 nM on MCF-7 cells; 1.2 ± 0.1 nM on SK-N-MC 
cells), achieving saturation of the receptors already at a concentration of approx. 4 nM 
(Keller et al., 2008). Therefore, a radioligand concentration of 6 nM was chosen for the 
estimation of hY1R expression to saturate the binding sites. Significant specific binding of 
the radioligand was found in both the transfected U-373 hY1R-ECFP and U-373 hY1R-
EYFP cells. The measured values of bound radioactivity per cell were converted into 
receptor number per cell, using the specific activity of the radioligand (cf. Eq. 4.2.2). 
Among the cells expressing hY1R-ECFP fusion proteins, the highest receptor density 
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was obtained for the transfectant clones 1 and 4, corresponding to 35,000 and 90,000 
receptors per cell, respectively (Table 3.3.1 and Fig. 3.3.1). Similarly, radioligand binding 
confirmed the presence of Y1R binding sites on the U-373 hY1R-EYFP cells, with the 
highest density of 30,000 and 40,000 receptors per cell for the clones 7 and 10, respec-
tively (Table 3.3.2 and Fig. 3.3.2). 
 
Table 3.3.1. Different U-373 hY1R-ECFP cell clones and conditions for their stable selection. The 
transfectant clones were used for binding experiments as shown in Fig. 3.3.1. 
U-373 hY1R-ECFP 
transfectant clone 
Transfectant 
reagent 
FuGENE:DNA 
ratio [µL:µg] 
Concentration 
of G418 [µg/mL] 
1 FuGENE 6 6:2 750 
2 FuGENE 6 8:2 750 
3 FuGENE HD 8:2 400 
4 FuGENE 6 10:2 400 
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Fig. 3.3.1. Binding of 6 nM [3H]UR-MK114 on wild-type (WT) and transfected U-373 cells express-
ing hY1R-ECFP (different transfectant clones 1–4, see Table 3.3.1). Data are mean values ± SEM 
of an experiment performed in 3–6 replicates for each clone. 
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Table 3.3.2. Different U-373 hY1R-EYFP cell clones and conditions for their stable selection. The 
transfectant clones were used for binding experiments shown in Fig. 3.3.2. 
U-373 hY1R-EYFP 
transfectant clone 
Transfectant 
reagent 
FuGENE:DNA 
ratio [µL:µg] 
Concentration 
of G418 [µg/mL] 
5 FuGENE HD 6:4 750 
6 FuGENE HD 8:4 750 
7 FuGENE 6 6:4 750 
8 FuGENE 6 8:4 750 
9 FuGENE 6 8:4 400 
10 FuGENE 6 6:4 400 
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Fig. 3.3.2. Binding of 6 nM [3H]UR-MK114 on wild-type (WT) and transfected U-373 cells express-
ing hY1R-EYFP (different transfectant clones 5–10, see Table 3.3.2). Data are mean values ± 
SEM of an experiment performed for each clone in triplicate (wild-type cells) or sextuplicate 
(clones 5–10). 
 
Table 3.3.3 and Fig 3.3.3 show the expression levels of the hY1R-ECFP and hY1R-EYFP 
fusion proteins for the best transfectant clones. After sorting of the U-373 hY1R-EYFP 
cells according to the fluorescence signal of EYFP (as described under 3.2.5), the num-
ber of the radioligand binding sites increased. This result correlated with the data from 
flow cytometric binding assays (cf. Fig. 3.3.6). 
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Table 3.3.3. Estimation of hY1R number per cell for the best transfectant clones (calculated ac-
cording to Eq. 4.2.2, using the binding data from Fig. 3.3.3). 
 
 U-373 cell clone (n=6) Cells/well Receptors/well 
A hY1R-ECFP  192,000 90,000 
B1 hY1R-EYFP before FACS 287,000 30,000 
B2 hY1R-EYFP after FACS 189,000 70,000 
WT A B1 B2
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Fig. 3.3.3. Binding of 6 nM [3H]UR-MK114 to wild-type (WT) and transfected U-373 cells: hY1R-
ECFP, clone 4 (A); hY1R-EYFP, clone 7 (B1 – before and B2 – after sorting). These cells revealed 
high specific binding, allowing the estimation of receptor number, as shown in Table 3.3.3. 
 
High specific binding of [3H]UR-MK114 confirmed the presence of hY1R binding sites on 
the surface of the stably transfected U-373 cells. This is in accordance with previous 
studies (Keller et al., 2008). As reported earlier by Prof. Dr. A. Beck-Sickinger and col-
leagues, the transiently transfected BHK or CHO cells expressed functionally active 
hY1R-ECFP and hY1R-EYFP fusion proteins, as shown by binding of [3H]propionyl-NPY 
and inhibition of adenylyl cyclase (Dinger et al., 2003). 
 
3.3.1.2 Flow cytometry 
 
Like in the radioligand binding assay, the U-373 hY1R-ECFP cells showed significant 
specific binding of a fluorescent pNPY derivative, Dy-635-pNPY (Fig. 3.3.4 A). However, 
in case of the U-373 cells expressing the hY1R-EYFP, no specific binding of the fluores-
cent ligand could be measured (data not shown). 
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Fig. 3.3.4. Binding of 8 nM Dy-635-pNPY on wild-type (WT) and transfected U-373 cells express-
ing hY1R-ECFP (different transfectant clones 1–4). (A) Data are mean values ± SEM of an expe-
riment performed for each cell clone in 2–6 replicates. Unspecific binding was determined in the 
presence of 800 nM pNPY. (B) Only the events from the selected blue gate (on the shown 
FSC/SSC dot plot) were used for counting the binding data (about 10-20% of all acquired events). 
 
Therefore, the cells were sorted in a FACSCalibur flow cytometer according to the fluo-
rescence signal of EYFP from the Fl-1 channel (488 nm excitation line of an argon laser; 
530 ± 15 nm band pass filter), as depicted in Fig. 3.3.5 (cf. Materials and methods, sub-
section 3.2.5.2). After sorting, the difference between total and unspecific binding was 
measurable but still not as pronounced as for the U-373 hY1R-ECFP cells, indicating the 
lower hY1 receptor density (Fig. 3.3.6). Nevertheless, the concentrations of unlabelled 
pNPY and BIBP 3226, needed for the displacement of Dy-635-pNPY, were much higher 
than those determined at native hY1Rs in HEL cells (cf. Ki of pNPY: 1.3 ± 0.2 nM; Kd of 
BIBP 3226: 2.7 ± 0.5 nM; Schneider, 2005; Schneider et al., 2006). 
 
     
Fig. 3.3.5. Forward scatter light (FSC, depending on the size of particles) plotted against fluores-
cence signal of EYFP from Fl-1 channel: (A) U-373 MG cells, (B) U-373 hY1R-EYFP cells. Only 
the U-373 hY1R-EYFP cells in the right upper quadrant were sorted in a FACSCalibur flow cyto-
meter. 
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Fig. 3.3.6. Flow cytometric binding assays on wild-type (WT) and stably transfected U-373 cells, 
expressing either the hY1R-ECFP (A) or the hY1R-EYFP (B) – the latter after sorting (see text). 
The data (total and unspecific binding of 8 nM Dy-635-pNPY) are mean values ± SEM of an expe-
riment performed for each cell clone in 2–6 replicates. Unspecific binding was measured in the 
presence of 1 µM (A) or 10 µM (B) of BIBP 3226. 
 
3.3.1.3 Ratiometric calcium assays 
 
The U-373 MG cells utilize Ca2+ ions as a second messenger (Kracht, 2001). Therefore it 
was possible to perform a functional assay with the ratiometric Ca2+-chelating dye fura-2 
(cf. subsection 3.2.6). In the cells stably expressing hY1R-ECFP or hY1R-EYFP fusion 
proteins a minor mobilization of intracellular Ca2+ was observed in response to 100 nM 
NPY (Fig. 3.3.7 A), while there was no effect of 100 nM NPY on the wild-type U-373 MG 
cells (data not shown). This indicated the presence of functionally active hY1Rs at the 
transfected cells, but the number of receptors was rather low. As shown in Fig. 3.3.7 B 
for the hY1R-EYFP, the response to NPY was blocked when the cells were preincubated 
with BIBP 3226. As positive control, the U-373 hY1R-ECFP were stimulated with 30 µM 
histamine, as the histamine H1 receptor is constitutively expressed by the U-373 MG 
cells (Kracht, 2001). As expected, the effect of histamine was suppressed when the cells 
were preincubated for 15 min with the H1R antagonist mepyramine (Fig. 3.3.7 A). 
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Fig. 3.3.7. Fluorimetric calcium assays in U-373 hY1R-ECFP (A) and U-373 hY1R-EYFP cells (B). 
Both fusion proteins hY1R-ECFP and hY1R-EYFP transduced the signal (addition of NPY indi-
cated by a green arrow) into cells that led to intracellular Ca2+ mobilization. The intracellular cal-
cium concentration was counted from fluorescence intensities ratios according to the Grynkiewicz 
equation (cf. Eq. 3.2.2). For reference, 30 µM histamine (in the presence or absence of 30 nM 
mepyramine) was used, as wild-type U-373 MG cells express the histamine H1 receptor (panel A). 
 
The stably transfected U-373 MG cells expressed functional hY1R-ECFP or hY1R-
EYFP fusion proteins, as revealed in binding studies with the specific Y1R radioli-
gand UR-MK114 (Fig. 3.3.1 and 3.3.2) and the fluorescent agonist Dy-635-pNPY 
(Fig. 3.3.4 and 3.3.6) as well as in ratiometric calcium assays with fura-2 (Fig. 3.3.7 
A and B). The sorting of the U-373 hY1R-EYFP cells increased the mean number of 
binding sites, as confirmed in radioligand (Table 3.3.3) and flow cytometric binding 
studies (cf. Fig. 3.3.6). 
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3.3.2 Confocal microscopy imaging of fluorescently labelled NPY Y1Rs 
 
3.3.2.1 Subcellular localization of the hY1R-ECFP 
 
In order to obtain positive controls of membranally expressed ECFP (ECFP-Mem), both 
CHO and U-373 MG cells were transiently transfected with the retroviral expression vec-
tor pQCXIP/ECFP-Mem, as described in subsection 3.2.3.3. For the visualization of nuc-
lei in confocal microscopy, specimens were stained with DRAQ5 (cf. Gross, 2006) and 
prepared as stated in subsection 3.2.7.1. Both CHO and U-373 cells expressed the 
ECFP-Mem in the cell membrane as well as in the intracellular compartments 
(Fig. 3.3.8). However, most probably due to the low transfection efficiency, there was no 
expression of the ECFP-Mem in many cells. As expected, there was no cross-talk (spec-
tral interference) between the ECFP and the DRAQ5 channels (negative control: cells 
with the stained cell nuclei, but without ECFP-Mem in Fig. 3.3.8). 
 
   
Fig. 3.3.8. Expression of ECFP-Mem in transiently transfected CHO (A) and U-373 MG cells (B) 
found in the cell membrane (indicated by arrows) as well as in the intracellular compartments. 
Plan-Apochromat 63x/1.4 oil; ECFP (cyan): Ar 458, HFT 458, LP 475; nuclear dye DRAQ5 (ma-
genta): HeNe 543, HFT 458/543, LP 650. 
 
Confocal imaging demonstrated that only approx. 5% of the transfected U-373 
hY1R-ECFP cells expressed the fluorescently tagged Y1 receptors. Moreover, the 
fluorescence signal of ECFP was very weak (Fig. 3.3.9 A) and did not exclusively 
arise in the cell membrane, but – for the most part – in the intracellular compart-
ments (Fig. 3.3.9 B). Therefore, although there was no detectable cross-talk with the 
filter settings for EYFP (Fig. 3.3.9 C), the found distribution pattern of hY1R-ECFP 
fusion proteins disqualifies their usage as donors in the prospective FRET-based in-
vestigations of receptor dimerization in the cell membranes. 
 
A B
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Fig. 3.3.9. Expression of hY1R-ECFP fusion proteins by U-373 MG 
cells: (A) clone 4 (Ar 458, HFT 458, LP 475) and (B) clone 1 (Ar 458, 
HFT 458, BP 475–525). (C) There was no detectable cross-talk with 
the EYFP channel (the same specimen as in B; EYFP: Ar 488, HFT 
488, BP 505-550; DRAQ5: HeNe 543, HFT 458/543, LP 650). Plan-
Apochromat 63x/1.4 oil. (D) The schematic drawing represents the 
hY1R-ECFP in the cell membrane. 
 
Also the glioblastoma/astrocytoma U-118 MG cells were stably transfected with the 
hY1R-pECFP-N1 plasmid, as described in subsection 3.2.3.2. However, due to the rela-
tively high autofluorescence and the lacking emission signal in the cell membrane 
(Fig. 3.3.10), no further experiments were performed with these cells. 
 
 
 
Fig. 3.3.10. The U-118 MG cells stably transfected with the 
hY1R-pECFP-N1 plasmid. Plan-Apochromat 63x/1.4 oil, 
Ar 458, HFT 458, LP 475. 
 
 
 
3.3.2.2 Subcellular localization of the hY1R-EYFP 
 
The U-373 MG cells transiently transfected with pEYFP-N1 plasmid (for the cytosolic 
expression of EYFP) revealed a strong fluorescence signal in the EYFP channel and 
were used as positive control (Fig. 3.3.11 A). The detected EYFP fluorescence of the 
stably transfected U-373 hY1R-EYFP cells was much lower than that of the control cells 
(Fig. 3.3.11 B and 3.3.12). Thus, increased laser transmission was required (6% instead 
of 2%) to detect the fluorescence signal of the fusion protein. 
 
hY1R 
A    ECFP channel B    ECFP channel C    EYFP channel 
D 
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Fig. 3.3.11. Filter settings for EYFP emission: (A) U-373 cells expressing cytosolic EYFP; (B) no 
detection of the EYFP signal in the U-373 hY1-EYFP cells (with the same settings as in panel A). 
Plan-Apochromat 63x/1.4 oil; EYFP (pale green): Ar 488 (2%), HFT 488, BP 505-550; DRAQ5 
(magenta): HeNe 543 (37%), HFT 458/543, LP650). 
 
Similarly to U-373 hY1R-ECFP cells, extremely high heterogeneity of the U-373 MG 
cells expressing hY1R-EYFP fusion proteins was found, concerning both the amount 
and the localization of the EYFP-tagged Y1 receptors (Fig. 3.3.12 A–C). Although 
sorting of the cells increased the mean number of binding sites (cf. Table 3.3.3 and 
Fig. 3.3.6), the expression pattern of the hY1R-EYFP was not improved. Cells, which 
either did not fluoresce or with improper intracellular localization of the fusion pro-
teins were still present (Fig. 3.3.12 D) 
 
   
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.12. The U-373 MG cells express-
ing hY1R-EYFP (clone 7) constituted 
a very heterogenous population (A–C). 
The same cell clone after sorting (D). 
Plan-Apochromat 63x/1.4 oil; EYFP 
channel: Ar 488 (6%), HFT 488, BP 505-
550; nuclear dye DRAQ5: HeNe 543 
(37%), HFT 458/543, NFT 545, LP 650. 
The schematic drawing (E) represents the 
hY1R-EYFP in the cell membrane. 
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hY1R 
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Additionally, epidermoid skin carcinoma A-431 cells were stably transfected with the 
hY1R-pEYFP-N1 plasmid (subsection 3.2.3.2). Nevertheless, the fluorescence signal 
of these transfected cells was similar to the autofluorescence of the wild-type cells 
(Fig. 3.3.13 A), excluding the A-431 cell line from further studies. At the same time, 
confocal imaging of the transiently transfected CHO cells revealed a similar hY1R-
EYFP expression pattern to that in U-373 MG cells – EYFP fluorescence was found 
in both the cell membrane and intracellular compartments (Fig. 3.3.13 B). 
 
   
Fig. 3.3.13. Other cell lines transfected with the hY1R-pEYFP-N1 plasmid: (A) stably transfected 
A-431 cells (C-Apochromat 40x/1.2 W corr, Ar 514 (2%), HFT 458/514 nm, BP 530-600); (B) tran-
siently transfected CHO cells (Plan-Apochromat 63x/1.4 oil, Ar 488 (4%), HFT 488, NFT 490, BP 
505-550). 
 
Limitations of the fluorescent protein-based RET techniques. Despite the fact that 
the tagging of receptors with GFP-like proteins is a very useful method, it has also some 
drawbacks. Typically, FRET- or BRET-based proximity assays for the identification of 
GPCR dimerization are performed on systems with overexpressed receptors, although 
the efficiency of resonance energy transfer depends strongly on the expression level of 
the interacting partners (Table 3.3.4; cf. James et al., 2006). 
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Table 3.3.4. The expected BRET efficiency (BRETeff) in systems coexpressing BRET partners 
(donors D and acceptors A) in case of random or dimeric interactions between A and D (cf. 
James et al., 2006). The variable parameters are the total expression level of acceptor and donor 
molecules (A+D) as well as the acceptor-to-donor ratio (A/D). 
Expected BRET effi-
ciency depending on the 
expression of D and A 
The nature of interactions between BRET partners 
Random interactions Oligomeric interactions 
constant A+D;  
increasing A/D  
(above threshold) 
constant 
(the same distance 
between D and A) 
increasing hyperbolic 
(depending on stoichiometry; self-
associating D decreases BRETeff) 
increasing A+D; 
constant A/D 
pseudo-linear 
falling to 0  
at low A+D 
expression level dependent,  
but not falling to 0 at low A+D 
in case of non-constitutive dimers 
(independent of expression level
in case of constitutive dimers) 
 
The second major disadvantage of the usage of GFP-like proteins for FRET is the fluo-
rescent signal occurring in the intracellular compartments, where the FP-tagged receptor 
proteins are synthesized and post-translationally modified prior to being transported to 
the cell membrane (Fig. 3.3.14, cf. Dinger et al., 2003). According to Pin and colleagues, 
in such a case, FRET signals do not refer exclusively to the protein-protein interaction at 
the cell surface, disabling the unequivocal confirmation or rejection of receptor oligomeri-
zation in the cell membrane (Maurel et al., 2008). Therefore, it is crucial to prove the 
subcellular localization of fluorescent proteins and confirm the membranal expression of 
the FP-tagged GPCRs, using selective radioactive tracers or fluorescent ligands by 
means of flow cytometry and confocal microscopy. 
 
Fig. 3.3.14. The confocal images of the BHK cells cotrans-
fected with hY1R-GFP and hY1R-DSRed fusion proteins: (A) 
in the GFP channel and (B) in the DSRed channel (adopted 
from Dinger et al., 2003 with modifications). The arrows indi-
cate the fluorescently tagged Y1 receptors in the intracellular 
compartments. 
 
3.3.2.3 Alternative methods for labelling of receptor dimers 
 
In order to avoid the artefacts due to intracellular aggregation of FP-tagged receptors, 
alternative FRET-based techniques have been developed for the investigation of the 
quaternary structure of GPCRs at the surface of living cells. These included the applica-
tion either of well-established fluorescently labelled antibodies or of small-sized geneti-
cally encoded tags for receptor labelling (e.g. snap or tetracysteine tags). The latter 
62 Chapter 3 
might be very advantageous as biosynthesis, folding and trafficking of the tagged recep-
tors remain almost unchanged (Maurel et al., 2008). Furthermore, the low-molecular-
weight tags should allow virtually undisturbed protein-protein interactions of the tagged 
GPCRs, including their putative dimerization. 
Receptor proteins might be tagged with a tetracysteine sequence, which enables label-
ling with a fluorescein derivative containing two arsen-(III) substituents (fluorescein ar-
senical hairpin binder = FlAsH). The membrane-permeant FlAsH, being non-fluorescent 
in a free form, reveals high fluorescence, when bound to a specific amino acid sequence 
at the C-terminus of a receptor (Hoffmann et al., 2005). Such FlAsH-labelled receptors 
can function as FRET partners (acceptors) for receptors tagged with CFP (donors). 
However, the main drawbacks of this method are a certain level of unspecific binding of 
FlAsH to other proteins in the cell membrane as well as toxicity. 
Another labeling method utilizes so called “snap tags”, which are genetically fused to 
receptors (N-terminally) and encode O6-guanine nucleotide alkyltransferase. The en-
zyme reacts with fluorescently labelled benzyl guanine (BG), catalyzing covalent label-
ling of receptors with fluorophores carried by the benzyl group of BG. By using non-
permeant fluorescent BG derivatives, only snap-tagged receptors on the cell surface 
should be labelled, as shown in Fig. 3.3.15 B (cf. Maurel et al., 2008). 
 
Fig. 3.3.15. The confocal images of the 
GABAB1-receptors fused to snap tags 
and GFP (green, FRET donor), ex-
pressed alone (A). The same receptors 
coexpressed with GABAB2 receptors and 
labelled with the BG-d2 fluorescent dye 
(orange) as FRET acceptor (B). Note-
worthy, only the cell-surface receptors 
were labelled with the d2 (adopted from 
Maurel et al., 2008, with modifications). 
 
 
3.3.2.4 Binding studies with the fluorescent Y1R ligands 
 
In order to examine the prevalence of human Y1 receptor binding sites on the stably 
transfected U-373 MG cells expressing hY1R-ECFP and hY1R-EYFP fusion proteins, the 
samples were incubated with a specific Y1R fluorescent ligand, UR-MK131, synthesized 
in our research group by Dr. Max Keller (Keller, 2008, Keller et al., 2011).  
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The fluorescent Y1R ligand UR-MK131 was bound to the membranes of the U-373 
cells stably expressing hY1R-ECFP fusion proteins (Fig. 3.3.16 A). This interaction 
could be blocked in the presence of the unlabelled Y1R antagonist BIBP 3226 (Fig. 
3.3.16 D). A strong colocalized signal (overlapping fluorescence of ECFP and UR-
MK131) detected for total binding (Fig. 3.3.16 C) disappeared in the presence of ex-
cessive BIBP 3226 (Fig. 3.3.16 F), confirming the expression of Y1R binding sites on 
the cell surface. Similar results were obtained for the U-373 cells stably expressing 
the hY1R-EYFP fusion proteins (Fig. 3.3.17 A and C). 
 
     
     
Fig. 3.3.16. Binding of 70 nM UR-MK131 to the hY1R-ECFP cells after 25 min of incubation: (A) 
total and (D) unspecific binding (after 1 min of preincubation with 10 µM BIBP 3226). Additionally, 
the images with the corresponding ECFP signals (B and E) and the colocalized pictures (C and F) 
are shown. Plan-Apochromat 63x/1.4 oil; EYFP channel: Ar 458 (86%), HFT 458, BP 475-525; 
UR-MK131 channel: HeNe 543 (38%), HFT 458/543, NFT 545, LP 650. 
 
      
Fig. 3.3.17. Binding of 70 nM UR-MK131 to the hY1R-EYFP cells (shown are cell protrusions) 
after 15 min of incubation: (A) total and (C) unspecific binding (after 5 min of preincubation with 
5 µM BIBP 3226). The images B and D show the corresponding fluorescence of EYFP. Plan-
Apochromat 63x/1.4 oil; EYFP channel: Ar 488 (12%), HFT 488, BP 505-550; UR-MK131 chan-
nel: HeNe 633 (14%), HFT UV/488/543/633, LP 650. 
A total binding B EYFP channel C unsp. binding D EYFP channel 
A   total binding B   ECFP channel C    colocalized 
D   unsp. binding E   ECFP channel F    colocalized 
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Binding studies on the U-373 hY1R-EYFP cells were also performed with another far-red 
fluorescent ligand, UR-MK115 (Keller, 2008), which can be excited at 488 nm. Unexpec-
tedly, confocal imaging of the cells treated with this fluorescent ligand (incubation period: 
8–50 min) revealed the far-red emission signal arising in the perinuclear region instead 
of the cell membrane (Fig. 3.3.18 A and B). Moreover, the binding of UR-MK115 could 
not be displaced by an excess of the Y1R antagonist (Fig. 3.3.18 C).  
   
Fig. 3.3.18. Binding of 70 nM UR-MK115 to the U-373 hY1R-EYFP cells: (A) total binding after 
35 min of incubation (far-red channel: Ar 488 (5%) HFT 488, LP 650); (B) total binding after 8 min 
of incubation (EYFP channel: Ar 488 (9%), HFT 488, BP 505-550; far-red channel as in panel A); 
(C) unspecific binding after 28 min of incubation in the presence of 5 µM BIBP 3226 (1 min of pre-
incubation; filter settings as in panel B). Plan-Apochromat 63x/1.4 oil. 
 
Any spectral interference with the EYFP should be excluded, as no far-red fluorescence 
could be detected for the untreated hY1R-EYFP cells (Fig. 3.3.19 B). Interestingly, stain-
ing of the wild-type U-373 cells with UR-MK115 revealed filamentous structures similar to 
the mitochondria (Fig. 3.3.20). To reject or confirm this hypothesis, further experiments 
were performed with the U-373 cells transiently transfected with the localization vector 
pECFP-Mito (cf. subsection 3.2.3.3) for mitochondrial expression of the ECFP 
(Fig. 3.3.21). The comparison of the confocal images allowed the definite identification of 
the structures labelled by UR-MK115 as the mitochondria. 
  
Fig. 3.3.19. The untreated U-373 hY1R-EYFP cells in the EYFP (A) and the far-red (B) channels. 
No signal could be detected in the far-red channel, excluding the possibility of cross-talk with the 
fluorescent ligand UR-MK115. Plan-Apochromat 63x/1.4 oil; EYFP channel: Ar 488 (9%), HFT 
488, BP 505-550; far-red channel for UR-MK115: Ar 488 (5%), HFT 488, LP650. 
A    total binding B    total binding C    unsp. binding 
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Fig. 3.3.20. Binding of 70 nM UR-MK115 to the wild-type U-373 cells after 28 min of incubation: 
(A) total and (B) unspecific binding (after 1 min of preincubation with 5 µM BIBP 3226). Plan-
Apochromat 63x/1.4 oil, Ar 488, HFT 488, LP650. 
 
   
Fig. 3.3.21. Mitochondrial ECFP in the transiently transfected U-373 cells: (A) fluorescence of 
ECFP (Ar 458, HFT 458, LP 475); (B) fluorescence of the nuclear dye DRAQ5 (HeNe 543, HFT 
UV/488/543/633, LP650); (C) merged images. Plan-Apochromat 63x/1.4 oil. 
 
In contrast, UR-MK115 revealed a clear difference between total and unspecific binding 
to the membranes of breast cancer MCF-7-Y1 cells, as shown in Fig. 3.3.22. In order to 
additionally increase the expression of Y1 receptors, the ER positive MCF-7-Y1 cells 
were cultured in the presence of 1 nM estradiol 2 days prior to experiments. Cross-talk 
activation pathways between estrogen and NPY Y1 receptors have been namely re-
ported before (Memminger, 2009). Moreover, in MCF-7 breast cancer cells the Y1R 
mRNA was shown to be up-regulated by estrogen (Amlal et al., 2006). Therefore, the 
observed binding of the fluorescent ligand UR-MK115 might depend not only on the used 
cell line, but also on the Y1 receptor density. 
A B
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Fig. 3.3.22. Binding of 70 nM UR-MK115 to the MCF-7-Y1 cells after 10 min of incubation: 
(A) total and (B) unspecific binding (after 1 min of preincubation with 5 µM BIBP 3226). Plan-
Apochromat 63x/1.4 oil, Ar 488 (5%), HFT 488, NFT 545, LP 650. 
 
3.3.2.5 Internalization of the NPY hY1R 
 
The breast cancer MCF-7- Y1 cells were used again as a control system for the investi-
gation of the Y1 receptor internalization, showing high binding of the fluorescently la-
belled endogenous agonist, Cy-5-pNPY (Fig. 3.3.23 A and B). However, under the same 
conditions, there was only weak binding of Cy-5-pNPY on the stably transfected U-373 
hY1R-EYFP cells (Fig. 3.3.23 C), perhaps due to low receptor density equalling to 
approx. 30,000 receptors per cell (cf. Table 3.3.3 – B1). For comparison, MCF-7-Y1 cells 
showed approx. 300,000 sites per cell (determined by radioligand binding studies), when 
cultured with 1 nM estrogen (Keller, 2008; Memminger, 2009). Thus, the MCF-7-Y1 cells 
revealed to be the more suitable cell line for imaging of the Y1 receptor endocytosis in-
duced by the far-red fluorescent agonist. 
 
   
Fig. 3.3.23. Binding of 10 nM Cy-5-pNPY after 7 min of incubation with the MCF-7-Y1 cells: 
(A) total binding, (B) unspecific binding (after 1 min of preincubation with 10 µM BIBP 3226) as 
well as with the U-373 hY1R-EYFP cells (C). C-Apochromat 40x/1.4 W corr, HeNe 633 (10%), 
HFT 514/633, NFT 545, LP 650. 
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Incubation with Cy-5-pNPY for a longer period of time led to the internalization of Y1 
receptors in the MCF-7-Y1 cells (Fig. 3.3.24 A). Similar effect was observed after 
prolonged incubation with the unlabelled pNPY on the transfected U-373 cells, as 
the fluorescence of the hY1R-EYFP fusion proteins was detected mainly in vesicles 
(Fig. 3.3.24 B). 
 
  
Fig. 3.3.24. Agonist-induced internalization (A) in the MCF-7-Y1 cells after 15 min of incubation 
with 10 nM Cy-5-pNPY (C-Apochromat 40x/1.2 W: HeNe 633 (10%), HFT 514/633, LP650) and 
(B) in the U-373 hY1R-EYFP cells after 3 hours of incubation with 500 nM of pNPY (Plan-
Apochromat 63x/1.4 oil, Ar 488 (6%), HFT 488, BP 505-550). 
 
In later studies, the MCF-7- Y1 cells were labeled with the LysoTracker Green, a fluores-
cent dye staining preferably the lysosomes, as described in subsection 6.2.6. After 
4 hours of incubation with 10 nM Cy-5-pNPY, the far-red fluorescent ligand was localized 
exclusively in vesicles, but no colocalization with lysosomes (green) could be detected 
(Fig. 3.3.25). Thus, it can be concluded that human Y1 receptors undergo an NPY-
induced internalization, but are not the trafficked to lysosomes for enzymatic degradation 
within a few hours of exposure to the endogenous agonist (cf. Fig. 1.1.7 and agonist-
induced internalization of human H2Rs, Fig. 6.3.23). 
 
 
 
Fig. 3.3.25. Agonist-induced Y1R internalization in the 
MCF-7-Y1 cells. No colocalization of the internalized 
hY1Rs (red) and lysosomes (green) could be detected 
after 230 min of incubation with 10 nM Cy-5-pNPY. The 
cells were stained for 2 hours with 50 nM LysoTracker 
Green. Plan-Apochromat 63x/1.4 oil; LysoTracker 
Green: Ar 488 (5%), HFT 488, BP 505-530; Cy-5-pNPY: 
HeNe 633 (10%), HFT 514/633, NFT 545, LP 650. 
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3.4 Summary and conclusion 
 
In order to obtain single-labelled receptors (controls) for FRET-based measurements of 
receptor dimerization, human U-373 brain tumor cells were stably transfected with either 
hY1R-pECFP-N1 or hY1R-pEYFP-N1 plasmids (Dinger et al., 2003). The results of bind-
ing and functional studies on living cells expressing human Y1 receptors tagged with 
ECFP or EYFP indicate that: 
 
1) The membranal localisation of the hY1R-ECFP and hY1R-EYFP fusion proteins 
was confirmed in radiochemical binding studies by using the selective radioligand 
Y1R Nω-([2,3-3H]propionyl)-BIBP 3226 (Fig. 3.3.3; [3H]UR-MK114; cf. Keller et al., 
2008) as well as in flow cytometric binding assays with the fluorescent ligand 
Dy-635-pNPY (Fig. 3.3.6; Schneider, 2005; Schneider et al., 2006); however, the 
second method was applicable for the hY1R-EYFP only after cell sorting. 
2) As the U-373 MG cells involve calcium ions as a second messenger (Kracht, 
2001), it was possible to perform a functional assay using the calcium-chelating 
dye fura-2 (Schneider, 2005). Weak calcium signal detected in the transfected 
cells confirmed at least functionality of the fusion proteins (Fig. 3.3.7). 
3) Nevertheless, confocal microscopy imaging of U-373 hY1R-ECFP and U-373 
hY1R-EYFP cells revealed that the Y1 receptors fluorescently tagged with ECFP 
or EYFP were located mostly in the intracellular compartments (Fig. 3.3.9 B and 
3.3.12). The membranal expression of Y1 binding sites (detected by colocalization 
studies with the far-red fluorescent ligand UR-MK131, Fig. 3.3.16–17; cf. Keller, 
2008, Keller et al., 2011) could not be improved by cell sorting (FACS). 
4) Similarly, the hY1R-EYFP fusion proteins were found in both the cell membrane 
and intracellular compartments of the transiently transfected CHO cells 
(Fig. 3.3.13 B). However, neither the U-118 (Fig. 3.3.10) nor the A-431 cells 
(Fig. 3.3.13 A), transfected with hY1R-pECFP-N1 or hY1R-pEYFP-N1 plasmids, 
respectively, revealed the membranal expression of the fluorescently tagged Y1 
receptors. 
5) The hY1R-EYFP fusion proteins underwent agonist-induced internalisation in the 
transfected U-373 cells (Fig.. 3.3.24 B), but low receptor density disabled further 
imaging of the internalization with the far-red fluorescent agonist Cy-5-pNPY 
(Fig. 3.3.23 C; cf. Schneider, 2005; Schneider et al., 2006). 
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The human Y1 receptors tagged with either ECFP or EYFP were distributed not ex-
clusively in the cell membrane, but also in the intracellular compartments of the 
stably transfected U-373 cells (Fig. 3.3.9 B and 3.3.12, respectively). The same ex-
pression pattern of the hY1R-EYFP fusion proteins was found in the transiently 
transfected CHO cells (Fig. 3.3.13 B), showing serious limitations on the use of 
GFP-like proteins in the FRET-based investigation of receptor dimerization in the 
cell membranes. On account of that, the present data confirm reports on possible 
drawbacks of this approach (Maurel et al., 2008). 
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4 Radioligand binding studies of bivalent histamine H2 
and H4 receptor ligands at (pre)equilibrium conditions 
 
4.1 Introduction 
 
NG-Acylated hetarylpropylguanidines represent a new class of H2R agonists with im-
proved pharmacokinetic properties compared to the corresponding guanidines due to 
substantially reduced basicity (Ghorai et al., 2008; Kraus et al., 2009). Very recently, a 
tremendous increase in potency was achieved by applying the bivalent ligand approach 
to acylguanidine-type H2R agonists (Birnkammer et al., 2008). These compounds, com-
posed of two sets of pharmacophoric groups joined with an alkanedioic linker, are up to 
4000-fold more potent than HIS (Kraus, 2007; Birnkammer et al., 2010), both, on the 
isolated guinea-pig right atrium (cf. Fig. 1.2.7 A) and in steady-state GTPase assays on 
hH2R- and gpH2R-GsS fusion proteins expressed in Sf9 cells (cf. Fig. 1.2.7, panels B–G; 
Wenzel-Seifert et al., 2001). Initially, such “twin compounds” were designed as potential 
tools to study putative H2R dimers. However, as shown in Fig. 4.1.1 B, in the most potent 
bivalent H2R ligands the linkers, connecting the carbonyl functions, comprise only 6–8 
methylene groups. Hence, those compounds cannot bridge H2R dimers in a manner pro-
posed by Portoghese and colleagues (Fig. 4.1.1 A; cf. Bhushan et al., 2004; Daniels, 
2005 a; Shonberg et al., 2011).  
 
Fig. 4.1.1. Relationship between spacer length and potency of symmetric bivalent ligands. 
(A) Relative agonist and antagonist potencies of of different series of bivalent ligandsat opioid 
receptors. The potencies of bivalent compounds (normalized to morphine) were related to the 
potencies of monovalent counterparts of intermediate-length spacers (normalized to morphine); 
adopted from Portoghese et al., 1986 and Portoghese, 2001, with modifications. (B) Agonist po-
tencies at the gpH2R-GsαS (in red – ligands containing 2-amino-4-methylthiazole, in blue – 
2-aminothiazole and in green – imidazole rings, adopted from Birnkammer et al., 2010, with mod-
ifications). Similar results were obtained at the hH2R-GsαS. 
A B
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The present investigation was focused on a more detailed analysis of the binding of 
mono- and bivalent ligands at the H2R. Since the imidazolylpropylguanidine moiety 
turned out to be a privileged structure with respect to histamine receptors, the investiga-
tions were extended to the H4R (Kraus, 2007). 
 
4.1.1 Explanatory power of the Hill slope in radioligand saturation and competi-
tion binding assays at equilibrium 
 
4.1.1.1 Indicators of cooperativity and ligand–receptor stoichiometry 
 
Estimation of the inflection points of semilogarithmic binding curves provides information 
on ligand affinities (Fig. 4.1.2 A). It is assumed that binding has reached equilibrium, 
thereby obeying the law of mass action and that ligand-receptor interactions occur ac-
cording to a 1:1 stoichiometry. Therefore, the Hill slope (nH) is usually adjusted to unity 
and the competition curve between 10% and 90% displacement covers approx. a hun-
dredfold range of ligand concentrations (between 0.1- and 10-fold·IC50; cf. Lazareno, 
2001), as depicted in Fig. 4.1.2 B (“normal" curve is linear between approx. 20 and 80% 
displacement). However, algorithms for fitting experimental data by a four-parameter 
logistic curve with a variable slope often yield a slope different from unity (Prinz and 
Schönichen, 2008). In such cases, curves do not cover 10–90% occupancy over a range 
of 2 log units (Lazareno, 2001; cf. shallow and steep curves in Fig. 4.1.2 B). 
 
 
Fig. 4.1.2. Pharmacologic parameters derived from the analysis of competition binding curves: 
(A) the inflection point (IC50) and (B) Hill slope nH (adopted from Limbird, 2004 with modifications). 
  
A B
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Table 4.1.1. Various possible explanations for nH ≠ 1 (cf. Repke and Liebmann, 1987). 
The value of nH Possible explanations 
0.5 
Heterogenic ligand binding sites 
Negative cooperativity 
1 Homogenic population of ligand binding sites 
2 Positive cooperativity 
 
Derived from the Hill equation, the Hill slope corresponds to the number of ligand mole-
cules interacting with a receptor in an “all or none” reaction, and therefore it might reflect 
the actual ligand-receptor stoichiometry (cf. Eq. 4.1.1–2). 
RARnA n     (Eq. 4.1.1) 
 
  nHnH
nH
max KA
A
B
B
     
(Eq. 4.1.2) 
Depending on the position of the binding pockets for the two pharmacophoric moieties of 
a twin compound on a single receptor molecule, two independent receptors or a receptor 
dimer, the value of nH could vary between 0.5 and 2, as shown in Fig. 4.1.3. Neverthe-
less, apart from the ligand-receptor stoichiometry, other important factors should be con-
sidered as well, for example cooperativity (Table 4.1.1; cf. Repke and Liebmann, 1987). 
 
Fig. 4.1.3. Possible spatial arrangements of ligands (mono- or bivalent) and receptors (a single 
receptor, two non-linked receptors or a conformationally linked receptor dimer). The values of Hill 
slopes correspond to the number of ligand molecules interacting with a receptor in an “all or none” 
reaction (Eq. 4.1.1). The classical situation with the 1:1 ligand-receptor stoichiometry is high-
lighted by a red box. 
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4.1.1.2 Biphasic Scatchard plots 
 
The analysis of saturation binding curves might also elucidate the binding mode of a ra-
dioligand. According to Scatchard, in case of a competitive ligand-receptor interaction 
with 1:1 stoichiometry, the classical linearizing transformation of the radioligand satura-
tion curve gives a single straight line, as shown in Fig. 1.3.1 B, where the dissociation 
constant Kd equals the negative inverse of the slope (Lazareno, 2001). However, a pre-
vious study by Monczor et colleagues on U-937 cells, using [3H]TIO as the radioligand, 
revealed a convex (biphasic) shape of the Scatchard plot (Fig. 4.1.4 A). This phenome-
non might be explained either by incorrectly determined unspecific binding (competitor 
concentration too low) or by the existence of binding sites with different affinity for the 
radioligand (Repke and Liebmann, 1987). Indeed, low and high affinity binding sites were 
found for [3H]TIO, with the high-affinity binding site disappearing in the presence of 
10 µM GTPγS. Thus, binding of TIO to H2Rs present in the free and in the G-protein-
coupled form is a plausible explanation of these results. The obvious preference of TIO 
for G-protein-bound receptors indicates an inverse agonism of TIO, as predicted by the 
extended ternary complex model (cf. Fig. 1.1.6), assuming the existence of two classes 
of interconverting binding sites (Fig. 4.1.4 B; cf. Monczor et al., 2003). 
 
 
Fig. 4.1.4. Biphasic Scatchard plots: (A) saturation binding of [3H]TIO at the H2R in U-937 cells. 
Purified fractions of U-937 membranes were incubated for 2 hours (adopted from Monczor et al., 
2003 with modifications). (B) Two-site model of ligand-receptor interactions. The slopes of the red 
lines equal the negative inverses of the affinity constants of high-affinity (KdH) and low-affinity (KdL) 
binding sites (adopted from http://www.chemistry.emory.edu/justice/test/receptor_measurement. 
htm with modifications). 
 
N.B. Hill slopes of competition curves smaller than unity can also result from the exis-
tence of two non-interconverting (ortho- and allosteric) binding sites on the same recep-
tor molecule. The hypothesis of allosterism will be addressed in chapter 5. 
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4.2 Materials and methods 
 
4.2.1 Materials 
 
Sf9 cells and high-titer baculovirus stocks, encoding H2Rs, GsαS , Giα2, Gβ1γ2 proteins as 
well as H2R-GsαS and hH4R-GAIP fusion proteins, were kindly provided by Prof. Dr. Ro-
land Seifert (Institute of Pharmacology, Medical School of Hannover, Germany). The 
generation of the baculoviruses encoding the hH2R-GsαS and the gpH2R-GsαS has been 
described elsewhere (Kelley et al., 2001). 
The mono- and bivalent H2R ligands (Fig. 1.2.4) were synthesized and provided by Dr. 
Anja Kraus (Kraus, 2007; Kraus et al., 2009) and Mr. Tobias Birnkammer (cf. prospective 
doctoral thesis of T. Birnkammer). HIS was from Acros Organics (Geel, Belgium). RAN 
and FAM were obtained from Sigma (St. Louis, MO, USA). TIO was donated by Prof. Dr. 
Sigurd Elz (Institute of Pharmacy, University of Regensburg, Germany). GTPγS 
(Fig.1.1.4) was from Roche Diagnostics (Mannheim, Germany). Radioactive tracers 
[35S]GTPγS (1100 Ci/mmol), [3H]HIS (14.2 Ci/mmol) and [3H]TIO (77.2 and 82.2 
Ci/mmol) were from PerkinElmer Health Sciences (Boston, MA, USA) and [3H]TIO (82.2 
Ci/mmol) was from American Radiolabeled Chemicals (St. Louis, MO, USA). [3H]UR-
DE257 (69.3 Ci/mmol) and the red fluorescent H2R ligands were synthesized by Dr. 
Daniela Erdmann in our laboratory as described previously (Fig. 1.2.5; Erdmann, 2010). 
Insect-Xpress medium for Sf9 cells was from Lonza (Verviers, Belgium). BSA was from 
Behringwerke (Marburg, Germany). FCS was obtained from Biochrom (Berlin, Ger-
many). Gentamicin was from Lonza (Walkersville, MD, USA). Tris was purchased from 
USB (Cleveland, OH, USA). MgCl2 and EDTA were from Merck (Darmstadt, Germany). 
Polyethylenimine (PEI) and phenylmethylsulfonyl fluoride (PMSF) were from Sigma-
Aldrich (Steinheim, Germany). Benzamidine was from Acros Organics (Geel, Belgium). 
Leupeptin was obtained from Gerbu Biotechnik (Gaiberg, Germany). DC protein assay 
kit was purchased from Bio-Rad Laboratories (Munich, Germany) Round-bottom poly-
propylene test tubes (4 mL) were from Kabe Labortechnik (Nümbrecht, Germany). Nee-
dles Neolus were from VWR International (Ismaning, Germany). GF/B glass-fibre filters 
were purchased from Brandel (Gaithersburg, MD, USA). The 6-mL scintillation counting 
vials were obtained from Sarstedt (Nümbrecht, Germany). Scintillation cocktail Rotiszint 
eco plus was from Carl Roth (Karlsruhe, Germany). High purity water, used in all assays, 
was prepared with Milli-Q Reagent Water System from Millipore (Molsheim, France). 
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The human promonocytic U-937 cell line was a kindly provided by Prof. Dr. Roland 
Seifert. CHO-rH2R-A2 cells (Traiffort et al., 1992) were a gift by Dr. Jean-Michel Arrang 
(Institut National de la Santé et de la Recherche Médicale, Paris, France). The genera-
tion of CHO-hH2R-Gα16 cells was described before (Schneider, 2005). CHO cells were 
from the DSMZ (Deutsche Sammlung für Mikroorganismen und Zellkulturen, 
Braunschweig, Germany). The pcDNA3.1(+)-Neo-hH4R plasmid was from the Guthrie 
cDNA Resource Center (Sayre, USA; cf. Mosandl, 2009). The jetPEI transfection re-
agent, from Polyplus-transfection (Illkirch, France), was donated by Peqlab Biotechnolo-
gie (Erlangen, Germany). DMEM and Ham’s F12 nutrient mixtures were purchased from 
Sigma-Aldrich. FCS and geneticin (G418) were from Biochrom (Berlin, Germany). Hy-
gromycin B was obtained from Mobitec (Göttingen, Germany). Trypsin-EDTA (10x) was 
from PAA Laboratories (Pasching, Austria). Leibovitz' L-15 medium, without phenol red, 
was from Invitrogen (Karlsruhe, Germany). Transparent 6-well and 96-well plates were 
purchased from Greiner (Frickenhausen, Germany), whereas transparent 24-well plates 
were from Becton Dickinson (Heidelberg, Germany). Safety-Multifly needles (21G) and 
4-mL S-Monovettes (for blood collection by venous puncture) were from Sarstedt. Lym-
phoprep solution was from Axis-Shield PoC (Oslo, Norway). 
All experimental data were analyzed with the Prism 5 program (GraphPad Software, San 
Diego, CA, USA). 
 
4.2.2 Membrane Preparation 
 
Sf9 cells were seeded in Insect-Xpress medium supplemented with 5% (v/v) FCS and 
0.1 mg/ml gentamicin in 250- or 500-mL Erlenmeyer flasks at the density of 3 million 
cells/mL and infected with a 1:100 dilution of high-titer baculovirus stocks, encoding the 
H2R (hH2Rs or gpH2Rs either alone, as -GsαS fusion proteins or coexpressed with GsαS) or 
the H4R (hH4R-GAIP fusion proteins coexpressed with Giα2 and Gβ1γ2). 
After 48 hours of incubation at 28 ºC under rotation at 150 rpm in an Excella E24R incu-
bator shaker from New Brunswick Scientific (Edison, NJ, USA), Sf9 membranes were 
prepared from the transfected cells as described previously (Seifert et al., 1998), using 
1 mM EDTA as well as protease inhibitors: 0.2 mM PMSF, 10 μg/ml benzamidine and 
10 μg/ml leupeptin. Membranes were suspended in binding buffer (12.5 mM MgCl2, 
1 mM EDTA and 75 mM Tris/HCl, pH 7.4) and stored at -80 °C in 1-mL aliquots until use. 
Protein concentration of each membrane preparation was determined in triplicate by Lo-
wry’s protein assay (Lowry et al., 1951), using a Bio-Rad DC protein assay kit according 
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to the manufacturer’s protocol (http://wolfson.huji.ac.il/). Absorbance was measured at 
750 nm. Each time the assay was performed, a calibration curve with different concen-
trations of BSA (150-2000 µg/mL) was prepared to assign absorbance values to protein 
concentrations. 
 
4.2.3 Radioligand binding assays with Sf9 membranes 
 
If not otherwise stated, binding assays were carried out at room temperature (20–23 ºC) 
in 4-mL polypropylene tubes in triplicate and set up to fit the format of an M-48 harvester 
from Brandel (Gaithersburg, MD, USA). Each tube (total volume of 250 μL) contained 
50-200 µg of protein in case of the H2R and 30–100 µg of protein in case of the H4R. 
 
4.2.3.1 Competition binding assay 
 
Firstly, 25 μL of a feed solution of an unlabeled ligand, 10-fold concentrated compared to 
the final concentration, were pipetted into tubes. For the determination of unspecific bind-
ing, the highest concentration of an unlabeled ligand or final concentrations of 100 µM 
FAM (in case of the H2R) or 10–20 µM THIO (in case of the H4R) was chosen. In order to 
determine total binding of the radioactive tracer, 25 μL of water were used instead of an 
unlabeled competitor. Secondly, an appropriate volume of BSA dissolved in binding 
buffer was added to each tube to give a BSA final concentration of 0.2% (m/v). Addition 
of BSA prevents adsorption of membranes and lipophilic compounds, especially at low 
concentrations, to the tube material (Seifert and Wieland, 2005). To determine the effect 
of exogenous guanine nucleotides in competition binding assays at the H2R, 25 µL of 
GTPγS (final concentration: 10 µM) or water were pipetted into the tubes. 
Thereafter, 25 µL of the radioactive tracer dissolved in binding buffer were added to each 
tube. In case of the H2R, the radioligands were diluted with the respective unlabelled 
ligand (reduction of specific activity to save radiotracers: [3H]TIO plus unlabeled TIO 
were used to obtain a final ligand concentration of 10–30 nM, [3H]HIS plus HIS yielding a 
final agonist concentration of 1 µM, and [3H]UR-DE257 plus unlabeled UR-DE257 to 
yield a final concentration of 25 nM. In assays at the H4R, [3H]HIS was added as ob-
tained from the manufacturer to get final concentrations from 10 to 100 nM. Parallel to 
the dilution of the radioligand, Sf9 membranes were allowed to thaw, put on ice and gen-
tly suspended (using a 1-mL syringe: 4 times with a 0.7-mm needle and 4 times with a 
0.4-mm needle). Then membranes were centrifuged at 4 ºC and 15000 g (13000 rpm) 
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and resuspended in an appropriate volume of the ice-cold binding buffer. This washing 
step was performed in order to remove residual endogenous guanine nucleotides, which 
could disturb the the effect of exogenous GTP or GTPγS on the binding of an agonist or 
an inverse agonist (Seifert and Wieland, 2005). To obtain homogenous suspensions, 
membranes were resuspended 30 times with the same syringe (0.4-mm needle) shortly 
before incubation. The incubation for 90–450 min (at 20–23 ºC under shaking at 
250 rpm) was started by addition of 50 μL of the membrane suspension to each tube. 
The reaction was stopped by addition of approx. 2 mL of ice-cold binding buffer. The 
bound radioligand was separated from the free radioligand by rapid filtration through a 
GF/B glass-fibre filter followed by two washes with approx. 2 mL of ice-cold binding 
buffer. The filter was pretreated with ice-cold 0.3% (v/v) polyethyleneimine (PEI) to re-
duce unspecific binding of positively charged radioligands to negatively charged silanol 
(-SiO-) groups of the filter material. Although [3H]TIO was found to bind to the pretreated 
filters to the same extent as to untreated filters (data not shown), PEI pretreatment was 
always done as a standard procedure. 
Thereafter, filter discs were allowed to equilibrate overnight with 3 mL of Rotiszint eco 
plus in 6-mL mini-vials. Filter-bound radioactivity was measured in a LS 6500 Liquid 
Scintillation Counter from Beckman Coulter (Krefeld, Germany) for 5 min. To avoid radio-
ligand depletion, the experimental settings were adjusted to ensure that no more than 
5% of the total radioligand added to test tubes were bound to the filter. 
 
4.2.3.2 Saturation binding of [3H]tiotidine 
 
Experiments were essentially performed as described for competition binding assays. 
For the determination of total binding, the tubes contained: 25 µL of water, 150 µL of 
BSA in binding buffer, 25 µL of the radioligand (0.3 to 40 nM [3H]TIO plus unlabeled TIO 
to yielding final ligand concentrations  200 nM) and 50 µL of an appropriate membrane 
suspension. Unspecific binding was examined in the presence of 100 µM FAM (final). 
Samples were incubated for 90 min. Specific binding of the radioligand to the H2R was 
obtained by subtracting unspecific binding from total binding for each given [3H]TIO con-
centration. 
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4.2.4 [35S]GTPγS binding assay with Sf9 membranes 
 
Experiments were performed as described previously (Schnell et al., 2010) with a few 
modifications: 25 μL of water or HIS (final 100 μM) as well as 150 µL of binding buffer, 
containing BSA (final 0.05%) and GDP (final 1μM), were added into each tube. For un-
specific binding, 25 μL of unlabeled GTPγS in binding buffer were used (10 μM final). 
The samples were completed by addition of 25 μL of an appropriate membrane suspen-
sion (3–4 μg of protein), prepared as described for [3H]TIO binding, and incubation was 
started by addition of 25 μL of [35S]GTPγS (1 nM final) diluted with unlabeled GTPγS 
(9 nM final). Incubation was performed in quadruplicate for 120 min at room temperature 
(20–23 ºC) under shaking at 250 rpm. Subsequently, the reaction was terminated, and 
the bound radioactivity was measured as described for [3H]TIO binding assays. 
 
4.2.5 Cell culture and transfection 
 
Cells were maintained in the culture media (listed in Table 4.2.1) at 37 °C in the humidi-
fied atmosphere containing 5% CO2. Every 4–7 days, cells were trypsinized and pas-
saged (1:10) to a fresh 25-cm2 culture flask, except for U-937 cells, growing in suspen-
sion, which were passaged to a fresh 75-cm2 culture flask. 
 
Table 4.2.1. Cell culture conditions of the used cell lines. 
Cell line Cell culture conditions 
U-937 RPMI + 5% FCS 
CHO-rH2R-A2 DMEM / Ham’s F12 (1:1) + 10% FCS 
CHO-hH2R-Gα16 Ham’s F12 + 10% FCS +400 μg/mL G418 +400 μg/mL hygromycin B 
CHO-K1 Ham’s F12 + 10% FCS 
CHO-hH4R Ham’s F12 + 10% FCS+ 400 μg/mL G418 
 
CHO-K1 cells were transfected using the jetPEI transfection reagent according to the 
manufacturer’s protocol. The cells were seeded one day prior to transfection in a 24-well 
plate in Ham’s F12 medium containing 10% FCS. On the day of transfection, 4 µL of the 
pcDNA3.1(+)-Neo-hH4R plasmid (1 µg/µL) were mixed with 200 µL of 150 mM NaCl so-
lution and 8 µL of the jetPEI reagent (7.5 mM solution of nitrogen residues) were added 
to 200 µL of 150 mM NaCl solution. The amounts of DNA and jetPEI were adjusted to 
provide ionic balance between the nitrogen residues of jetPEI (one third of N atoms are 
cations) and the phosphate anions of the DNA backbone. Optimal transfection efficiency 
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was obtained at the N/phosphate ratio of 5. Then, both solutions were combined and 
incubated for 30 min. Afterwards, 50 µL (in duplicate), 100 µL (in duplicate) or 0 µL (con-
trol in unicate) of the mixture were added per well onto the confluent cells (for optimal 
transfection with jetPEI, 50-60% confluent cells are recommended). 
The selection of the stably transfected CHO-hH4R cells was done with the aminoglyco-
side antibiotic geneticin (G418), as described in subsection 6.2.5. Briefly, on the next day 
the transfected cells were passaged into a new 6-well plate, and two days later each of 
the 5 transfectant clones was passaged into a fresh 25-cm2 culture flask. On two subse-
quent days, the culture medium was changed against medium containing G418 
(400 µg/mL). Six days after transfection, all non-transfected cells (the control) were 
killed. Only a few cells transfected with 50 µL of the mixture survived, but among the 
cells transfected with 100 µL of the mixture groups of living cells were found. These cells, 
bearing the genes for the hH4R and the resistance against antibiotic geneticin (G418), 
were passaged into a fresh 75-cm2 culture flask (always in the culture medium with 
400 µg/mL G418). 
Due to the limited stability of antibiotics in culture media (e.g. 5 days for the aminoglyco-
sides kanamycin and neomycin at 37 °C; Lindl, 2000) and to avoid underdosing of the 
antibiotic, the respective selection media, listed in Table 4.2.1, were always prepared 
immediately before passaging of the cells.  
 
4.2.6 Radioligand binding assays with whole cells 
 
Radioligand binding on whole cells was determined as described by Dr. Johannes 
Mosandl (Mosandl, 2009). 4–6 days prior to an experiment, appropriate cells were pas-
saged to 1–3 fresh 175-cm2 culture flasks and cultivated in the absence of antibiotics. On 
the day of experiment, cells were trypsinized, centrifuged for 5 min at 1000 rpm (300 g), 
washed with L-15 medium and centrifuged again. Subsequently, the cells were resus-
pended in fresh L-15 medium to obtain the required density. 20 µL of either a 10-fold 
concentrated FAM solution (in PBS or L-15, for unspecific binding) or the corresponding 
solvent (for total binding) as well as 160 µL of the cell suspension and 20 µL of a 10-fold 
concentrated radioligand solution (cf. subsection 4.2.3) were added per well of a 96-well 
plate. Incubation was conducted for 90 min at room temperature (20–23 ºC) under shak-
ing at approx 100 rpm. The reaction was terminated with a cell harvester by rapid filtra-
tion through a GF/B glass-fibre filter, pretreated with the ice-cold 0.3% (v/v) PEI. The 
harvested cells were immediately washed with ice-cold PBS for approx. 10 s. The filter-
bound radioactivity was estimated by means of liquid scintillation, as described for Sf9 
84 Chapter 4 
membrane preparations in subsection 4.2.3. The corresponding receptor number per cell 
(RN) was calculated by using the total amount of radioactivity added to the tubes (TA) 
(Eq. 4.2.1) or, more accurately, by involving the specific radioactivity of the radioligand 
(Eq. 4.2.2): 
     
   well/1 cells10dpm TA
NL VnM TAdpm binding .specRN 9
A

   (Eq. 4.2.1) 
 
   well/1 cells1060nmol/Bq activity.spec
Ndpm binding.specRN 9
A

   (Eq. 4.2.2) 
where V is the volume of the incubation mixture (2·10-4 L) and NA the Avogadro constant 
(6.022·1023 mol-1). The calculations always considered the reduction of the specific activ-
ity of the radioligand (cf. subsection 4.2.3). 
 
4.2.7 Isolation of human neutrophilic granulocytes from whole blood 
 
Neutrophils were isolated from venous blood as described (Seifert et al., 1989) with mi-
nor modifications. At 9 a.m. (after having breakfast) 20 mL of blood were obtained from 
the medial cubital vein of a healthy male volunteer (age of 28; without medication for at 
least one month), by using a Safety-Multifly needle (21G) and 4-mL S-Monovettes (con-
taining EDTA as an anticoagulant). All following isolation steps were carried out at room 
temperature (approx. 20 ºC). Each 10 mL of blood were diluted with 25 mL of PBS (1x) 
and then carefully layered on top of 15 mL of Lymphoprep solution (density of 1.077 
g/mL, osmolality of 290 mOsm) in a 50-mL centrifuge tube. This centrifugation step was 
performed at 400 g for 30 min in a swing-out rotor. After centrifugation, a distinct lym-
phocyte layer had formed at the interface between the plasma and the Lymphoprep 
phase, whereas granulocytes and erythrocytes were in the pellet as shown in Fig. 4.2.1. 
 
 
 
Fig. 4.2.1. Distribution of blood components after 
centrifugation with Lymphoprep separation fluid. Neu-
trophilic granulocytes and red blood cells were in the 
pellet.  
 
 
 
 
 Materials and methods 85 
 
 
Then, the three upper layers were completely removed with an electronic dispenser (first, 
the lymphocytes, by moving the dispenser in a sweeping motion; next, the plasma; and 
finally, the Lymphoprep solution) and the granulocyte-erythrocyte pellet was suspended 
in 20 mL of Millipore water. After 60 s of haemolysis (longer incubation could lead to the 
lysis of granulocytes), 2 mL of 10x PBS were added for equilibration and the mixture was 
centrifuged for 5 min at 300 g. The supernatant was discarded and the erythrocytes, re-
maining in the diffuse pellet, were lysed by addition of 10 mL of Millipore water. After 
30 s of gentle agitation, 1 mL of 10x PBS was added for equilibration, and the mixture 
was centrifuged for 5 min at 300 g. The supernatant was carefully discarded and the 
granulocytes were washed with 5 mL of PBS. After centrifugation (5 min at 300 g) the 
upper part of the supernatant was carefully discarded with the dispenser and the rest of 
the supernatant (and some hemoglobin over the pellet) was removed with a 1-mL Ep-
pendorf pipette. Finally, the granulocytes were resuspended in 1 mL of PBS and counted 
with a Casy 1 TTC cell counter from Schärfe System (Reutlingen, Germany), yielding 
approx. 33 million cells/mL. 
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4.3 Results and discussion 
 
4.3.1 Saturation binding assays on H2Rs 
 
The investigation of agonists and antagonists on H2R-GsαS fusion proteins expressed by 
means of the Sporodoptera frugiperda cell/baculovirus system is a very useful alternative 
to the classical testing on isolated animal organs. It provides defined receptor-to-
G-protein stoichiometry and very efficient coupling, which can be measured by GTP hy-
drolysis (Wenzel-Seifert et al., 2001). The presence of G proteins is essential for func-
tional studies, such as steady-state GTPase assays, but should be dispensable for bind-
ing studies. Nevertheless, the receptor-to-G-protein stoichiometry may affect the shape 
of binding curves (Kenakin, 1997 and 2006; Lazareno, 2001). Therefore, saturation bind-
ing studies were performed at gpH2R-GsαS fusion proteins and at gpH2Rs coexpressed 
with GsαS proteins. This could be useful to elucidate the competition experiments con-
ducted in the presence of GTPγS on Sf9 membranes expressing gpH2R-GsαS fusion pro-
teins, gpH2Rs alone or coexpressing gpH2Rs and GsαS proteins (cf. subsection 4.3.2). As 
the pretreatment of glass-fibre filters with PEI has become a standard procedure, the 
estimated radioligand affinities might slightly differ from the values from literature, which 
were determined without PEI treatment (Kelley et al., 2001). This improvement should be 
considered, when analyzing binding data from competition assays. 
 
4.3.1.1 Saturation binding of [3H]tiotidine 
 
The gpH2R-GsαS fusion protein, expressed in Sf9 membranes, bound [3H]TIO with a Kd of 
40.0 ± 6.3 nM and a Bmax of 0.66 ± 0.04 pmol/mg of membrane protein (Fig. 4.3.1). This 
was in line with data from the literature (reported: Kd 34.4 ± 8.4 nM, Bmax 0.72 ± 0.02 
pmol/mg; Kelley et al., 2001). 
 
 
Fig. 4.3.1. Saturation binding of [3H]TIO. 
Sf9 membranes expressing the gpH2R-
GsαS were incubated with [3H]TIO for 
90 min. Unspecific binding was deter-
mined in the presence of 100 μM FAM. 
Data were analyzed by nonlinear regres-
sion (one-site model) and are mean val-
ues ± SEM of an experiment performed in 
triplicate. 
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Similarly, the analysis of the saturation binding data of [3H]TIO at the hH2R-GsαS revealed 
a Kd of 43.3 ± 17.9 nM and a Bmax of 0.54 ± 0.09 pmol/mg of membrane protein (raw data 
kindly provided by Dr. Heidrun Appl, Institute of Pharmacy, University of Regensburg; cf. 
Appl, 2010), which is in agreement with data reported previously (Kd: 32.0 ± 4.6 nM, 
Bmax: 0.43 ± 0.02 pmol/mg; Wenzel-Seifert et al., 2001). Therefore, in competition binding 
assays at gpH2R-GsαS and hH2R-GsαS, the Kd values of [3H]TIO of 40 and 43 nM, respec-
tively, were used for calculation of Ki values from IC50 values of unlabeled test com-
pounds according to the Cheng-Prusoff equation (Cheng and Prusoff, 1973). 
In order to investigate whether the GsαS protein C-terminally fused to receptor could alter 
the binding of [3H]TIO, saturation binding of the radioligand was performed in Sf9 mem-
branes coexpressing gpH2Rs and GsαS proteins. The radioligand was bound with a Kd of 
40.1 ± 6.4 nM and a Bmax of 0.37 ± 0.02 pmol/mg of membrane protein (Fig. 4.3.2). 
The gpH2R-GsαS bound [3H]TIO with the same affinity as the gpH2R coexpressed with 
the G protein (Kd = 40 nM), but the expression level of the fusion protein was in-
creased, compared to the coexpressed receptors. N.B. similar effects were observed 
previously in case of hH4R-RGS4 and hH4R-GAIP fusion proteins, when compared to 
the hH4R in the standard co-expression system (Schneider and Seifert, 2009). 
 
 
Fig. 4.3.2. Saturation binding of [3H]TIO. 
Sf9 membranes coexpressing gpH2Rs 
and GsαS proteins were incubated with 
[3H]TIO for 90 min. Unspecific binding 
was determined in the presence of 
100 μM FAM. Data were analyzed by 
nonlinear regression (one-site model) and 
are mean values ± SEM of two independ-
ent experiments performed in triplicate. 
 
Scatchard representations of the binding of [3H]TIO to both the gpH2R-GsαS and the 
gpH2R (coexpressed with GsαS proteins) revealed convex curves, transformed as de-
scribed before (Motulsky and Christopoulos, 2004). For classical competitive binding 
(single-site model), straight lines are expected. Therefore, the data points were refitted 
according to Graphpad Prism’s built-in two-site binding equation (Eq. 4.3.1): 
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Two different binding sites were obtained for [3H]TIO at the gpH2R coexpressed with the 
GsαS protein (Fig. 4.3.3 B): a high-affinity (Kd 7.5 ± 1.1 nM, Bmax 0.11 ± 0.01 pmol/mg) and 
a low-affinity binding site (Kd 146.8 ± 21.1 nM, Bmax 0.38 ± 0.01 pmol/mg). The fitting 
failed in case of data from gpH2R-GsαS; thus only a single line, corresponding to the non-
linear regression fit (single-site), was graphed on the Scatchard plot (Fig. 4.3.3 A). 
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Fig. 4.3.3. Binding data from Fig. 4.3.1 (A) and Fig. 4.3.2 (B) analyzed according to Scatchard. 
For the gpH2R coexpressed with GsαS, two binding sites were found (red dashed lines). 
 
Scatchard plots for binding of [3H]TIO on gpH2R-GsαS fusion proteins and gpH2R + 
GsαS coexpressed in Sf9 cells revealed a convex (biphasic) shape of the lines. Bi-
phasic Scatchard representation was also found for [3H]TIO on hH2R-GsαS fusion 
proteins (raw binding data kindly provided by Dr. Heidrun Appl, University of Re-
gensburg). The shape of the Scatchard plots could result either from the incorrectly 
determined unspecific binding (too low competitor concentration) or from the exis-
tence of multiple binding sites for the radioligand (Repke and Liebmann, 1987).  
 
The first possible explanation could be rejected, as the unspecific binding of [3H]TIO was 
determined using 100 μM FAM (a concentration approx. 2000-fold higher than the Ki) 
after 90 min of incubation. The concentration of the unlabeled competitor was in the 
same range as that used in the previously reported studies on H2R-GsαS fusion proteins 
(100 μM of unlabeled TIO, equalling to a 3000-fold Kd, 90 min incubation; Kelley et al., 
2001) and by far exceeded the competitor concentration used at whole cells expressing 
H2Rs (1 μM of unlabeled TIO referring to a 50-fold Kd, 40 min incubation at 4 ºC; Leg-
nazzi et al., 2000). In this context it is indispensable to mention that, after 3 hours of in-
cubation with 10 nM [3H]TIO in Sf9 membranes expressing gpH2R-GsαS, FAM behaved 
different than expected from a competitive antagonist, revealing a slope of the competi-
tion curve smaller than unity (-0.71 ± 0.06, cf. Fig. 4.3.10) and stabilizing the ternary 
complex (Fig. 4.3.11 B). However, the determined Ki value for FAM of 17 ± 3 nM was in 
the same range as the functional (Kb 38 ± 3 nM; Table 4.3.3; cf. Kelley et al., 2001) and 
A B
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the binding data published before (Ki of 6 nM in membranes of the guinea-pig brain cor-
tex after 60 min incubation at 37 ºC, Krielaart et al., 1990). 
As [3H]TIO reveals a more complex binding behavior than described by the law of mass 
action, the existence of two distinct binding sites for the radioligand is proposed (cf. Fig. 
4.3.3). This finding is in agreement with recently published results for [3H]TIO at whole 
promonocytic U-937 cells, bearing the endogenous hH2R (Kd of 2.2 ± 0.8 nM for the high-
affinity binding site and 20 ± 3 nM for the low-affinity binding site, Monczor et al., 2006). 
Previous studies indicate that the high-affinity binding site for [3H]TIO at U-937 cell mem-
branes disappeared after addition of 10 μM GTPγS, indicating a typical agonist binding 
profile. Moreover, TIO was able to reduce the increased basal cAMP levels in both the 
forskolin-stimulated U-937 cells and in the mammalian COS-7 cells, expressing het-
erologous H2Rs (Monczor et al., 2003) in a dose-dependent manner. TIO also reduced 
basal GTPase activity on hH2R-GsαS and gpH2R-GsαS fusion proteins (Kelley et al., 2001). 
Taken together, TIO behaves as an inverse H2R agonist. This contributes to the com-
plexity of the H2R signal transduction pathway and should be taken into account, when 
interpreting radioligand binding data. 
 
4.3.1.2 (Functional) H2R/G-protein stoichiometry: coexpressed and fused proteins 
 
The receptor-to-G-protein ratio can influence the shapes of saturation and competition 
curves. In systems with limited capability of G-protein coupling, binding isoterms of a 
ligand that produces a ternary complex will not be monophasic (Kenakin, 1997 and 2006; 
Lazareno, 2001). 
 
Fig. 4.3.4. Total (blue) and unspecific (red) 
binding of [35S]GTPγS to membranes co-
expressing gpH2Rs and GsS proteins. Spe-
cific binding in the absence of HIS amounted 
to 2.46 ± 0.07 pmol/mg and increased to 
2.59 ± 0.06 pmol/mg after stimulation with 
100 μM HIS. Data shown are mean values 
of an experiment performed in quadrupli-
cate. The same membrane preparations 
were used as in [3H]TIO binding assays. 
 
 
Therefore, apart from quantifying the number of receptors via the [3H]TIO binding, the 
total content of functional G proteins was estimated, using a saturating concentration of 
[35S]GTPγS/GTPγS (final 10 nM). Unspecific binding was determined in the presence of 
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10 μM of unlabeled GTPγS. Noticeably, in membranes coexpressing gpH2R and GsS, 
only a minor difference (0.13 ± 0.09 pmol/mg) was found between the HIS-stimulated 
and ligand-independent [35S]GTPγS binding to GsS (Fig. 4.3.4). For this reason, in simi-
lar experiments on the gpH2R-GsS, the addition of HIS was resigned. 
The number of specific [35S]GTPγS binding sites, detected in the absence of ago-
nists, was 1.76 ± 0.09 pmol/mg for gpH2R-GsS fusion proteins and 2.46 ± 0.07 
pmol/mg in membranes coexpressing gpH2Rs and GsS proteins (Fig. 4.3.4). These 
results, disproving the hypothesis of limited G-protein coupling, showed that there 
are more functional G proteins than functional gpH2Rs, determined by [3H]TIO satu-
ration binding: Bmax of 0.66 ± 0.04 pmol/mg (Fig. 4.3.1) and 0.37 ± 0.02 pmol/mg 
(Fig. 4.3.2), respectively. Surprisingly, in preliminary experiments the ratio of gpH2Rs 
to (functional) G proteins was about 1:3 for the fusion protein, whereas it amounted 
to about 1:7 for the coexpression. The last finding was in good agreement with the 
data reported previously for other histamine receptor subtypes coexpressed with 
appropriate G proteins (hH3R, Schnell et al., 2010; hH4R, Schneider et al., 2009). 
 
 
4.3.2 Competition binding assays on the H2R non-fused and fused to the GsαS 
 
4.3.2.1 GTPγS-dependent shift of [3H]tiotidine competition curves 
 
Because acylguanidines are generally more potent at gpH2R-GsαS than hH2R-GsαS fusion 
protein (Xie et al., 2006; Kraus, 2007), the investigations with guanine nucleotides (cf. 
Fig. 1.1.4) were done preferably on gpH2Rs. It is also noteworthy that in the binding ex-
periments the incubation period was set to 90 min, considered sufficient to reach the 
equilibrium (Lazareno, 2001) as it exceeded a five-fold dissociation half-value period for 
[3H]TIO, which was found to be not longer than 11 min (Fig. 5.3.1; cf. Foreman et al., 
1985). 
The detailed analysis of the binding curves of HIS and the symmetric bivalent imidazole-
type compound 4 at hH2R-GsαS and gpH2R-GsαS fusion proteins revealed Hill coefficients 
smaller than unity (nH of HIS: 0.5; nH of agonist 4: 0.6–0.8; Fig. 4.3.5 A–D). In the pres-
ence of 10 µM GTPS the binding curves of HIS at hH2R-GsαS and gpH2R-GsαS fusion 
proteins were, however, shifted to the right, and the Hill coefficients increased approxi-
mating unity (cf. Fig. 4.3.5 B: pIC50 of HIS at the gpH2R-GsαS: 6.17 ± 0.09, Hill 
slope: -0.49 ± 0.05; in the presence of 10 µM GTPγS: pIC50 5.03 ± 0.05, Hill slope -1.15 
± 0.16). As expected for an antagonist, the competition curve of TIO was not affected by  
 Results and discussion 91 
 
 
0
50
100
-8 -7 -6 -5 -4 -3 -2 
log [HIS] (M)
%
 s
pe
ci
fic
 b
in
di
ng
 o
f [
3 H
]ti
ot
id
in
e
0
50
100
-8 -7 -6 -5 -4 -3 -2 
log [HIS] (M)
%
 s
pe
ci
fic
 b
in
di
ng
 o
f [
3 H
]ti
ot
id
in
e
0
50
100
-9 -8 -7 -6 -5 
log [4] (M)
%
 s
pe
ci
fic
 b
in
di
ng
 o
f [
3 H
]ti
ot
id
in
e
0
50
100
-10 -9 -8 -7 -6 -5 
log [4] (M)
%
 s
pe
ci
fic
 b
in
di
ng
 o
f [
3 H
]ti
ot
id
in
e
0
50
100
-9 -8 -7 -6 -5 -4 
log [1] (M)
%
 s
pe
ci
fic
 b
in
di
ng
 o
f [
3 H
]-t
io
tid
in
e
0
50
100
-10 -9 -8 -7 -6 -5 
log [1] (M)
%
 s
pe
ci
fic
 b
in
di
ng
 o
f [
3 H
]ti
ot
id
in
e
 
Fig. 4.3.5. Effect of HIS (A, B), the bivalent agonist 4 (C, D) and the monovalent agonist 1 (E, F) 
on the displacement of [3H]TIO (10 nM) from hH2R-GsαS or gpH2R-GsαS fusion proteins as well as 
from the gpH2R alone (panels B and D, in blue) in the absence (circles) or presence (squares) of 
10 µM GTPγS. Data shown are mean values ± SEM of two independent experiments performed 
in triplicate (panel C and E – one experiment, respectively). Best fit with a variable slope. 
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guanine nucleotides and the Hill slope equalled 1, Fig. 4.3.6 A). In case of the monova-
lent agonist 1, the curves at both hH2R-GsαS and gpH2R-GsαS fusion proteins were shifted 
to the right (Fig. 4.3.5 E and F) as for HIS. Nevertheless, the binding curve of the biva-
lent agonist 4 at the gpH2R-GsαS was not affected by GTPγS at all, indicating rather an-
tagonistic properties (cf. Fig. 4.3.5 D: pIC50 of 4 at gpH2R-GsαS: 8.39 ± 0.07, Hill 
slope: -0.81 ± 0.09; in the presence of 10 µM GTPγS: pIC50 8.34 ± 0.04, Hill slope -0.77 
± 0.05). In contrast, addition of 10 μM GTPγS led to a small rightward shift and a steep-
ening of the curve for ligand 4 at the hH2R-GsαS (Fig. 4.3.5 C). Such species differences 
in sensitivity to GTPγS were reported previously for NG-acylated guanidines (Xie et al., 
2006). The affinities of HIS and the bivalent compound 4 were similar at the gpH2R ex-
pressed alone (Fig. 4.3.5 B and D, in blue) and at the gpH2R-GsαS in the presence of 
10 μM GTPγS (Fig. 4.3.5 B and D, in red). Moreover, no GTPγS-dependent rightward 
shift was observed for HIS at the gpH2R in the absence of GsαS protein (Fig. 4.3.5 B, in 
blue). 
Similar results were found in another experiment at the gpH2R-GsαS. As depicted in Fig. 
4.3.6 B, HIS and the monovalent agonist 1 showed the highest sensitivity to GTPγS at 
concentrations close to their Ki values, whereas binding of the bivalent agonist 4 and 
FAM remained unchanged in the presence of GTPγS at concentration up to 10 µM, con-
firming the insensitivity towards guanine nucleotides. The results are summarized in Ta-
ble 4.3.1. 
Similar differences in sensitivity to GTPγS were reported previously for arpromidine, im-
promidine and monovalent NG-acylguanidines at the hH2R-GsαS and the gpH2R-GsαS, as 
some of the tested agonists revealed no GTPγS-dependent shift, indicating rather an-
tagonistic properties (Fig. 4.3.7, cf. Kelley et al., 2001; Xie et al., 2006). It may be specu-
lated that the effect of G protein on ligand binding might be too low to be detectable, due 
to the relatively short third intracellular loop (IL3) of the H2R (Prof. Dr. Stefan Dove, Uni-
versity of Regensburg, personal communication). Another possible explanation could be 
that bivalent H2R agonists are able to stabilize distinct ligand-specific H2R conformations 
(cf. chapter 6). 
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Table 4.3.1. The rightward shift of the competition curves of H2R ligands at the gpH2R-GsαS fusion 
proteins in the presence of 10 µM GTPγS. 
 HIS 1, monovalent 
agonist 
4, bivalent 
agonist 
FAM 
GTPγS-dependent 
shift 
yes§ yes no no 
§ the same effect observed also at the hH2R-GsαS and the gpH2R coexpressed with the GsαS 
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Fig. 4.3.6. The effect of GTPγS on the displacement of [3H]TIO (10 nM) from the gpH2R-GsαS after 
addition of (A) TIO and (B) representative H2R ligands at the concentrations indicated in paren-
theses (close to their Ki values). Data shown are mean values ± SEM of an experiment performed 
in triplicate (A) or duplicate (B). Binding isotherms in the presence of TIO, HIS and compound 1 
were analyzed by nonlinear regression with a variable slope. 
 
log [UR-PG146] (M) 
Fig. 4.3.7. Effect of the NG-acylated guanidine UR-PG146 (H2R agonist, carbonyl derivate of IMP) 
on the binding of 10 nM [3H]TIO in the presence or absence of 10 μM GTPγS at hH2R-GsS (A) 
and gpH2R-GsS (B) fusion proteins expressed in Sf9 cells (adopted from Xie et al., 2006 with 
modifications). 
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A B
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4.3.2.2 Impact of (functional) receptor/G-protein stoichiometry on the Hill slope 
 
In theory, the shape of a curve in the absence of guanine nucleotides depends on the 
ratio of receptors to G proteins. In systems with limited G proteins (or with over-
expressed receptors), usually a non-radioactive agonist displaces an antagonist 
radioligand with a Hill slope less than unity (Fig. 1.1.5; Kenakin, 1997 and 2006; 
Lazareno, 2001). The assumption that the presented flat competition curves of HIS could 
result from insufficient amounts of functional G proteins would, however, contradict the 
previous findings. As shown in subsection 4.3.1, no limited coupling of G proteins to 
receptors was found on Sf9 membranes expressing both the gpH2R-GsαS fusion proteins 
and the gpH2Rs coexpressed with the GsαS proteins. 
Therefore, it was necessary to compare the Hill slopes of the endogenous ligand and 
bivalent H2R agonists at receptors fused to G proteins and in standard coexpression sys-
tems. Like at gpH2R-GsαS fusion proteins, the competition curve of HIS at Sf9 
membranes coexpressing gpH2Rs and GsαS proteins revealed a Hill slope significantly 
smaller than unity (95% CI: 0.32–0.65). Similarly, in the presence of 10 µM GTPγS, the 
binding curve of the natural ligand at the coexpressed receptors was significantly shifted 
to the right and the Hill coefficient increased approximating unity (cf. Fig. 4.3.8: pIC50 of 
HIS at gpH2R + GsαS: 6.12 ± 0.15, Hill slope: -0.49 ± 0.08; in the presence of 10 µM 
GTPγS: pIC50 4.67 ± 0.17, Hill slope -0.98 ± 0.31). This again confirms the aforemen-
tioned behaviour of the radioligand, independent of the expression pattern (cf. subsec-
tion 4.3.1). 
 
 
Fig. 4.3.8. Effect of HIS on the displacement of 
[3H]TIO (10 nM) from Sf9 membranes coex-
pressing gpH2Rs and GsαS proteins in the ab-
sence (circles, solid line) or presence (open 
squares, dashed line) of 10 µM GTPγS. Data 
shown are mean values ± SEM performed in 
three independent experiments. Binding curves 
were analyzed by nonlinear regression with a 
variable slope. 
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The endogenous ligand displaced 10 nM [3H]TIO in the same manner (IC50 of 
approx. 0.2–0.7 µM; Hill slope of about 0.5) at the hH2R-GsαS (Fig. 4.3.5 A), the 
gpH2R-GsαS (Fig. 4.3.5 B) and the gpH2R coexpressed with the GsαS protein in Sf9 
membranes (Fig. 4.3.8). Also the effect of 10 µM GTPγS – rightward shift and stee-
pening of HIS binding curves – was the same at these membranes. Surprisingly, the 
binding of the bivalent agonist 4, at the gpH2R-GsαS was not affected by GTPγS at 
all, suggesting rather antagonistic than agonistic properties (cf. Fig. 4.3.5 D). Con-
trary to that, in the presence of GTPγS, the competition curve for ligand 4 at the 
hH2R-GsαS was slightly shifted to the right and steepened (Fig. 4.3.5 C). Similar dis-
crepancies were reported previously for some monovalent NG-acylguanidines at the 
hH2R-GsαS and the gpH2R-GsαS (Xie et al., 2006). 
Given that the relative G protein concentration is low anyway, there should be a 
discrepancy in the displacing potency of an unlabelled agonist, when using an agonist 
vs. antagonist radioligand (Kenakin, 1997). Both unlabelled and radioactively labelled 
agonists would preferentially bind to the small part of receptors coupled to G protein. As 
a result, a monophasic competition curve should be observed. Contrary to that, an 
antagonistic radioligand should bind to all forms of receptors, not discriminating between 
the G-protein coupled and the free receptor fraction. 
 
 
Fig. 4.3.9. Predicted competition curves of a non-
radioactive agonist when using an agonist (dashed 
line) or an antagonist (solid line) radioligand: (A) in 
the system with limited G proteins (G-protein level 
is 30% that of the receptor) the curve for an 
antagonist radioligand is flat and rightward shifted; 
(B) if G proteins are not limiting, both curves 
overlap (adopted from Kenekin, 1997 with modi-
fications). (C) Homologous competitive binding. 
1 µM of labelled HIS (1 + 9 mixture of [3H]HIS/HIS) 
was displaced by unlabelled HIS at the gpH2R-GsαS. 
Data are mean values ± SEM of two independent 
experiments performed in triplicate (150 µg or 
200 µg protein per sample, respectively). 
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As already mentioned, a non-radioactive agonist would displace the radioligand 
preferably from G-protein-complexed receptors. In systems provided with unlimited 
amounts of G proteins, full agonists could stabilize all receptors in the G-protein-coupled 
form (as ternary complexes). However, if there were a shortage of G proteins, only a 
small portion of receptors would exist in complexes with G proteins. Therefore, much 
higher concentrations of an agonist competitor would be required to displace the 
radioligand from the rest of its binding sites. This should in turn result in a flattening and 
a rightward shift of the agonist competition curve (Fig 4.3.9 A). Assuming that there were 
enough G proteins for all receptors, competition curves for agonist and antagonist 
radioligands should overlap (Fig. 4.3.9 B). 
The homologous displacement of [3H]HIS by non-radioactive HIS at the gpH2R-GsαS 
revealed a monophasic curve (nH = 1), as shown in Fig. 4.3.9 C. Under the assumptions 
that both the tritiated and the unlabelled ligands had the same affinity to the receptor (Kd 
= Ki) and that there was no cooperativity, the Kd value of HIS could be calculated 
according to the simplified Cheng-Prusoff equation (Eq. 4.3.2; cf. Motulsky and Christo-
poulos, 2004): 
 d radioliganICK 50d      (Eq. 4.3.2) 
The determined Kd value of 0.40 ± 0.13 µM was not significantly different from the Ki 
value, obtained for HIS at the gpH2R-GsαS using [3H]TIO (Ki of 0.63 ± 0.26 µM, cf. Table 
4.3.3). This again contradicts the aforementioned hypothesis of an insufficient supply of 
G proteins. A plausible explanation of the flat [3H]TIO competition curves for HIS 
(Fig. 4.3.5 A, B and Fig. 4.3.8) could be the inverse agonism of TIO rather than the 
receptor/G-protein ratio. This would be in line with the biphasic Scachard plots in the 
saturation studies (cf. Fig. 4.3.3) and with results from the literature (Kelley et al., 2001; 
Monczor et al., 2003). 
 
4.3.2.3 Ternary complex model for the H2R 
 
The presented binding curves of HIS in the absence of GTPγS revealed Hill slopes sig-
nificantly smaller than unity upon incubation with 10 nM [3H]TIO for 90 min (Fig. 4.3.5 A, 
B and Fig. 4.3.8). As mentioned above, this might reflect a more complex binding 
mechanism than described by the simple law of mass action (Lazareno, 2001) and could 
be taken as a hint to negative cooperativity between two non-interconverting binding 
sites at the same receptor molecule (Repke and Liebmann, 1987). However, the GTPγS-
dependent shift and the steepening of the shallow binding curve of HIS, might be better 
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explained by the ternary complex model, proposing two independent non-interacting 
binding sites with different affinities for the natural ligand (cf. Fig. 1.1.3). According to this 
two-site model, agonists should bind to those receptors, which are coupled to G proteins, 
with much higher affinity than to the free receptors. Therefore, the formation of ternary 
agonist-receptor-G-protein complexes is promoted and two maxima of the biphasic 
curve, corresponding to the two classes of binding sites, can be observed. However, in 
the presence of exogenous GTPγS, a non-hydrolyzable analogue of GTP, receptors 
cannot couple to G proteins and ternary complexes are disrupted (Lazareno, 2001). The 
high-affinity binding site, corresponding to the subset of gpH2Rs coupled to G proteins, 
disappears (Monczor et al., 2003) and only the low-affinity binding site can be detected 
(Kenakin, 2006). As a result, a steep and rightward-shifted curve can be seen as in 
Fig. 4.3.5 A–B. 
 
 
Fig. 4.3.10. Competition of test com-
pounds with 30 nM [3H]TIO for binding at 
the gpH2R-GsαS after 3 hours of incuba-
tion. Data shown are mean values ± SEM 
of two independent experiments for each 
ligand (using different membrane prepara-
tions). Binding curves were analyzed by 
nonlinear regression with a variable slope.  
 
 
 
To exclude any artefacts resulting from the premature termination of the incubation, 
three representative compounds were incubated for 3 hours. Additionally, the final con-
centration of the radioactive tracer was increased to 30 nM, to expedite equilibration of 
the system. Fitting of the data according to the logistic curve with a variable slope re-
vealed for HIS a slight increase in both the affinity and the Hill slope, with the latter, how-
ever, still remaining significantly smaller than unity. For FAM, no significant change was 
observed, but for the bivalent compound 4 the Hill coefficient of the binding curve in-
creased, approximating to unity, whereas its affinity remained unchanged (cf. Fig. 4.3.10: 
pIC50 of HIS: 6.33 ± 0.11, Ki: 270 nM, Hill slope: -0.67 ± 0.10; pIC50 of FAM: 7.55 ± 0.06, 
Ki: 17 nM, Hill slope: -0.71 ± 0.06; pIC50 of compound 4: 8.31 ± 0.06, Ki: 3 nM, Hill slope: 
-1.05 ± 0.13). This indicates a very slow equilibration of the bivalent ligand. Interestingly, 
a latency period had also been observed in experiments on the guinea-pig right atrium, 
where at low concentrations the positive inotropic effects of bivalent H2R agonists 
reached a plateau not before 2.5 to 3 hours of incubation (Prof. Dr. Sigurd Elz, University 
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of Regensburg, personal communication). However, with respect to an interpretation of 
the impact of prolonged periods of incubation, additional investigations with other biva-
lent H2R agonists should be done (cf. subsection 4.3.3). 
A prolonged incubation period (from 90 min to 3 hours) had a minor effect on HIS bind-
ing. Only a small increase in the proportion of high-affinity binding sites for HIS from 48% 
to 67% was observed (cf. Table 4.3.2). The prevalence of high-affinity sites for the biva-
lent NG-acylated guanidine 4 changed slightly from 82% to 94%, suggesting a stronger 
stabilizing effect on the ternary complex than in the case of HIS. This was in line with the 
previous studies, in which some monovalent NG-acylguanidines were found to stabilize 
the ternary complex on hH2R-GsαS and/or gpH2R-GsS fusion proteins expressed in Sf9 
cells, as indicated by the biphasic shapes and the GTPγS-dependent rightward shifts of 
their competition curves (cf. Fig. 4.3.7 B; Xie et al., 2006). 
Table 4.3.2. The distribution of high- and low-affinity binding sites for HIS as well as the corre-
sponding IC50 values ± SEM in the absence of GTPγS (calculated separately for the experiments, 
shown in Fig. 4.3.11 A and B, and then averaged). 
Competition curves of HIS 90 min incubation
(cf. Fig. 4.3.11 A) 
180 min incubation 
(cf. Fig. 4.3.11 B) 
Fraction of high-affinity sites 48% 67% 
high-affinity IC50  104 ± 83 nM 69 ± 11 nM 
low-affinity IC50  9.7 ± 7.1 μM 3.3 ± 0.3 μM 
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Fig. 4.3.11. Competitive binding with [3H]TIO after 90 min (A) and 180 min (B) of incubation. The 
data from Fig. 4.3.5 B and Fig. 4.3.10, fitted according to the two-site model. 
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Fitting of the binding data from Fig. 4.3.5 B (90 min of incubation) and Fig. 4.3.10 
(180 min of incubation) with biphasic curves (Graph Prism: “Two sites – Fit logIC50”) 
revealed the existence of two binding sites for both HIS and the bivalent agonist 4 at 
the gpH2R-GsαS in the absence of GTPγS (Fig. 4.3.11 A and B, respectively). After a 
prolonged incubation period the Hill slope of HIS remained smaller than unity, 
whereas that of the bivalent agonist 4 increased, approximating unity. Additionally, 
the bivalent H2R agonist 4 was found to be an efficient stabilizer of the ternary com-
plex (Fig. 4.3.11 B). 
 
The H2R agonists, tested at the hH2R-GsαS, the gpH2R-GsαS, the gpH2R expressed alone 
and the gpH2R coexpressed with GsαS, showed similar binding behaviour, consistent with 
the ternary complex model. The calculated high and low affinity values of the bivalent 
compound 4 were similar at the gpH2R expressed alone and at the gpH2R-GsαS fusion 
protein (cf. Fig. 4.3.5 D). Only the percentage of the high-affinity binding sites was re-
duced at the gpH2R (54%), when compared with the fusion proteins (83%). Additionally, 
a minor rightward shift of the binding curve of the monovalent agonist 1, observed at 
both hH2R-GsαS and gpH2R-GsαS fusion proteins in the presence of GTPγS, indicated less 
efficient stabilization of the ternary complex than in the case of HIS (Fig. 4.3.5 E and F). 
Moreover, a pronounced rightward shift and steepening of the competition curve for HIS, 
observed in case of coexpressed gpH2R + GsαS after addition of unlabeled GTPγS (cf. 
Fig. 4.3.8), was similar to that at the gpH2R-GsαS fusion protein. Contrary to that, the af-
finity of HIS at the gpH2R expressed alone was decreased (approx. 8 µM, cf. Fig. 4.3.5 
B, in blue) – when compared with both fusion proteins and the gpH2R coexpressed with 
the GsαS – and was almost not affected by addition of 10 μM GTPγS. In the latter case 
the high-affinity binding site, predicted for agonists by the ternary complex model, was 
not detectable. Probably, due to the lack of G protein, the formation of the ternary com-
plex was impossible in the respective test system. However, the relatively high disper-
sion of data points precludes a detailed analysis. 
The ternary complex model seems to be a valuable concept for the interpretation of the 
binding behaviour of various H2R ligands. For example, the prototypical imidazolylpropyl-
guanidine ARP was previously reported to be a partial agonist at gpH2R-GsS fusion pro-
teins expressed in Sf9 cells, efficiently stabilizing the ternary complex (76% high-affinity 
binding sites). However, there was no characteristic rightward shift of the agonist binding 
curve after addition of GTPγS (Xie et al., 2006). The apparently flat competition curve of 
ARP, found at hH2R-GsαS fusion proteins, expressed in Sf9 membranes (Mosandl, 2009), 
revealed two distinct binding sites, when the experimental data were fitted as a biphasic 
competition curve (Fig. 4.3.12). The calculated Ki values were 140 nM (95% CI: 
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40-495 nM) for the high-affinity binding site and 6.6 μM (95% CI: 0.4 – 103.7 μM) for the 
low-affinity binding site. In theory, the latter value should be the “true” ligand affinity 
(Lazareno, 2001). Indeed, ARP bound to hH2Rs with Ki of 5.4 ± 1.3 μM, when the ex-
periment was performed on the intact cells (Mosandl, 2009). In such a case, the rela-
tively high intracellular concentration of GTP leads to the disruption of the ternary com-
plex and, therefore, only the low-affinity binding site can be detected. Contrary to that, 
when a membrane preparation is used, G-protein coupling and the resulting two inde-
pendent non-interacting binding sites can be observed (Kenakin, 2006). 
 
 
 
Fig. 4.3.12. Displacement of 
10 nM [3H]TIO by ARP on 
hH2R-GsαS fusion proteins ex-
pressed in Sf9 membranes 
(Mosandl, 2009); as indicated, 
binding data were fitted ac-
cording to different models. 
 
 
 
 
 
 
4.3.3 Detailed analysis of Hill slopes in case of the bivalent H2R ligands 
 
4.3.3.1 Affinities and Hill slopes of monovalent and bivalent H2R ligands 
 
Bivalent ligands are considered pharmacological tools for investigation of hypothetical 
GPCR dimers. Applying this approach to NG-acylated gunanidines yielded compounds 
which are up to 4000-fold more potent than HIS at the isolated guinea-pig right atrium as 
well as at hH2R-GsS and gpH2R-GsS fusion proteins expressed in Sf9 cells (Kraus, 
2007; Birnkammer et al., 2008). However, this behaviour could not be explained by si-
multaneous interaction with neighbouring GPCRs. As shown for opioid receptors, only 
bivalent compounds possessing a linker of about 21 carbon atoms in length between 
both sets of pharmacophoric groups, are capable of bridging the binding pockets of δ-κ 
opioid receptor heterodimers (Daniels et al., 2005 b). Among the bivalent NG-acylated 
guanidines, possessing 4 to 20 methylene groups as linkers between the carbonyl func-
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tions, the highest potency at both, the hH2R-GsS and the gpH2R-GsS, has been found 
for ligands with octamethylene spacers, which are too short to allow the bridging of the 
two adjacent receptor molecules (Fig. 4.1.1 B; cf. Kraus, 2007; Birnkammer et al., 2010). 
As shown before, one of the most potent bivalent agonists, compound 4, revealed a Hill 
slope smaller than 1 after 90 min of incubation at gpH2R-GsS. The interpretation of such 
a finding, rarely described in the literature (Prinz and Schönichen, 2008), is not simple. If 
only the artefacts (e.g. incomplete equilibration, cf. Fig. 4.3.23) could be excluded, this 
result might hint at divergences from the standard model of receptor binding, allowing 
exclusively monophasic curves (Lazareno, 2001). The Hill coefficient approximated unity 
only after 3 hours of incubation (cf. Fig. 4.3.10). Additionally, the binding of the bivalent 
agonist 4 was insensitive towards GTPγS and there was a detectable alteration of the 
[3H]TIO dissociation rate in the presence of the ligand 4 (cf. Fig. 5.3.2 B). In order to elu-
cidate these findings, also other bivalent H2R agonists with octamethylene linkers, their 
monovalent counterparts and standard H2R ligands were investigated by way of example 
for their affinity and nH on the Sf9 membranes expressing hH2R-GsS and gpH2R-GsS 
fusion proteins. 
In competition binding assays with [3H]TIO (after 90 min of incubation), the affinities 
of the investigated H2R ligands were approximately in the same range as the func-
tional data from GTPase assays (two-digit nanomolar at the hH2R-GsS and one-digit 
nanomolar at the gpH2R-GsS, cf. Table 4.3.3 and Fig. 4.3.13). Most of the tested 
agonists revealed Hill slopes significantly smaller than 1 (Table 4.3.3–4 and 
Fig. 4.3.14). 
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Fig. 4.3.13. Correlation between the potencies (FAM and TIO – antagonistic activities) and the 
affinities of representative ligands from Table 4.3.3: (A) at the hH2R-GsαS (slope: 0.53; r2: 0.77) 
and (B) at the gpH2R-GsαS (slope: 0.54; r2: 0.69); 95% CI of the regression lines (dashed). 
A B 
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Table 4.3.3. Potencies (EC50), efficacies, antagonistic activities (Kb), affinities (Ki) and slopes of 
displacement curves of representative ligands determined at the hH2R-GsαS and the gpH2R-GsαS 
fusion proteins expressed in Sf9 cell membranes. Efficacy in GTPase assays: the maximum 
stimulatory effect of HIS was set to 1.00 and the stimulatory effects of other agonists were re-
ferred to this value (Kelley et al., 2001; Birnkammer et al., 2008; Kraus et al., 2009). Binding as-
says: the hH2R-GsαS and the gpH2R-GsαS fusion proteins bound [3H]TIO with a Kd of 43 nM and 
40 nM respectively; incubation time 90 min; binding data are mean values ± SEM from at least 
two independent experiments performed in triplicate (*compound 2 – one experiment). Binding 
curves were analyzed by nonlinear regression with a variable slope. 
hH2R-GsαS 
Compound EC50 / Kb [nM] Efficacy Ki [nM] Slope 
TIO 60 (30–130) inv. -0.04 ± 0.09 48.5 ± 0.2 -1.08 ± 0.14 
HIS 990 ± 92 1.00 283 ± 92 -0.59 ± 0.07 
1 22.2 ± 5.1 0.79 ± 0.02 39 ± 5 -0.44 ± 0.03 
4 6.3 ± 0.9 0.82 ± 0.04 12 ± 3 -0.53 ± 0.07 
5 12.4 ± 6.4 0.53 ± 0.04 45 ± 12 -0.79 ± 0.11 
6 7.4 ± 0.6 0.79 ±0.06 19 ± 8 -0.57 ± 0.05 
7 22.1 ± 3.4 0.76 ± 0.03 36 ± 1 -0.71 ± 0.03 
8 13.8 ± 3.5 0.77 ± 0.03 36 ± 2 -0.66 ± 0.02 
FAM 48 ± 10 inv. -0.10 ± 0.02 58 ± 5 -0.51 ± 0.01 
 
gpH2R-GsαS 
Compound EC50 / Kb [nM] Efficacy Ki [nM] Slope 
TIO 50 (30–90) inv. -0.12 ± 0.08 27 ± 1 -0.95 ± 0.04 
HIS 850 ± 340 1.00 628 ± 260 -0.47 ± 0.02 
1 7.5 ± 0.9 0.76 ± 0.02 6 ± 1 -0.94 ± 0.13 
4 1.2 ± 0.4 0.98 ± 0.05 2 ± 1 -0.58 ± 0.09 
5 0.5 ± 0.1 0.79 ± 0.07 5* -0.60 ± 0.09 
6 0.9 ± 1.1 1.01 ± 0.03 n.d. n.d. 
7 6.2 ± 2.3 0.94 ± 0.01 n.d. n.d. 
8 5.5 ± 3.7 0.89 ± 0.04 n.d. n.d. 
FAM 38 ± 3 inv. -0.10 ± 0.01 39 ± 23 -0.73 ± 0.08 
 
The affinity of the monovalent acylguanidine-type ligand 7, containing a small propionyl 
moiety, at the hH2R-GsαS fusion protein was comparable to that of the natural ligand. 
Surprisingly, in case of monovalent agonist 1, the presence of an aromatic ring in the 
acyl portion led to a 10-fold increase in affinity, which was almost comparable to that of 
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the bivalent H2R ligands. Interestingly, the presence of the second set of pharmacophoric 
groups (as in compound 5) did not result in any significant further increase in affinity (Fig. 
4.3.14). 
 
Fig. 4.3.14. Hill plots of binding data 
corresponding to 16-84% displace-
ment of 10 nM [3H]TIO at the hH2R-
GsαS by the monovalent agonists 1, 
(6 experiments) and 2 (1 experiment) 
as well as their bivalent counterpart 5, 
(4 experiments). Data are mean val-
ues ± SEM; 95% CI of the regression 
lines (dashed). Hill coefficients are 
negative, because the linearized 
competition curves go downhill (cf. 
Table 4.3.3–4, Fig. 4.3.20 A and B as 
well as Fig. 4.3.22 B). 
 
 
Table 4.3.4. Affinities (Ki), Hill slopes and coefficients of determination (r2, goodness of fit) of the 
binding data transformed according to Hill, as shown in Fig. 4.3.14. 
 
Parameters 1 2 5 
Ki 46 nM 388 nM 37 nM 
Hill slope -0.47 ± 0.02 -0.56 ± 0.02 -0.85 ± 0.06 
95% CI of Hill slope -0.52 to -0.43 -0.61 to -0.51 -0.97 to -0.73 
r2 0.831 0.975 0.824 
 
4.3.3.2 Impact of the linker length on affinities and Hill slopes of bivalent H2R 
ligands 
 
Due to the inverse agonism of [3H]TIO, complicating the interpretation of pharmacologi-
cal data (cf. subsection 4.3.1), its high costs and frequent shortages, the usage of other 
H2R radioligands, such as tritiated HIS, was considered. However, [3H]HIS has a weak 
micromolar affinity to the H2R, which makes its utilization very expensive. Additionally, as 
an agonist, it binds preferably to the subpopulation of receptors coupled to G proteins. 
This results in a complete loss of affinity in the presence of guanine nucleotides and pre-
cludes the observation of GTPγS-dependent rightward shifts of the competition curves 
(Fig. 4.3.15). 
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Fig. 4.3.15. Influence of TIO on the binding 
of 100 nM [3H]HIS (added as obtained from 
the manufacturer) at the gpH2R-GsαS in the 
presence or absence of GTPγS. Data are 
mean values ± SEM of two independent 
experiments (100 µg protein per sample) 
performed in triplicate. 
 
 
 
 
 
Therefore, further binding experiments were performed with the new tritiated H2R an-
tagonist [3H]UR-DE257, which was recently developed in our research group by 
Dr. Daniela Erdmann (cf. Fig. 1.2.5; Erdmann, 2010). Competition binding studies with 
10 nM [3H]TIO at the hH2R-GsαS revealed a Ki value of 12.7 ± 0.2 nM (Fig. 4.3.16), 
whereas saturation experiments at the hH2R-GsαS afforded a Kd value of 27 nM (Erd-
mann, 2010). Thus, for competition binding assays [3H]UR-DE257 was used at a con-
centration of 25 nM. 
 
 
 
Fig. 4.3.16. Displacement of 10 nM [3H]TIO by 
non-radioactive UR-DE257 at the hH2R-GsαS in 
the presence of 1% DMSO. Data are mean val-
ues ± SEM of two independent experiments 
(100 µg protein per sample) performed in tripli-
cate. 
 
 
 
 
In theory, bivalent ligands containing a 20-membered spacer between the carbonyl 
groups, like compound 11, could bridge the binding pockets of two neighbouring receptor 
molecules (Daniels et al., 2005 b). Surprisingly, the displacement curve of 11 at the 
gpH2R-GsαS was extremely steep (nH of 2.26; 95% CI: 1.86 to 2.67), indicating positive 
cooperativity. Additionally, there was no rightward shift in the presence of 10 µM GTPγS 
(Fig. 4.3.17). In this context, it is indispensable to mention that this compound showed 
partial agonistic activity (EC50 of 46 nM; efficacy 22%) at the gpH2R-GsαS in GTPase as-
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says, whereas at the hH2R-GsαS it behaved as an antagonist (Kb of 371 nM; cf. Birnkam-
mer et al., 2010). 
 
 
 
Fig. 4.3.17. Displacement of 25 nM 
[3H]UR-DE257 by the bivalent ligand 11 
at the gpH2R-GsαS in the presence or 
absence (control) of 10 µM GTPγS. Data 
are mean values ± SEM of two inde-
pendent experiments performed in tripli-
cate. 
 
 
 
 
A steep competition curve was also obtained for the bivalent H2R agonist 9, containing a 
tetradecamethylene spacer between the C=O groups (nH of 1.72; 95% CI: 1.15 to 2.28), 
but not for the bivalent agonist 4 which has an octamethylene linker (nH not statistically 
different from 1). Moreover, the longer the alkanediyl spacer, the lower was the affinity of 
the bivalent competitor. On one hand, these data confirmed previous observations from 
GTPase assays (Birnkammer et al., 2010). On the other hand, the results raised doubts 
whether the model proposed by Portoghese is suitable for the bivalent H2R ligands, as 
the highest affinity at the gpH2R-GsS has been found for ligands with octamethylene 
spacers, which are too short to allow the bridging of the two adjacent receptor molecules. 
The corresponding curves of the symmetric bivalent ligands containing an imidazole 
moiety are shown in Fig. 4.3.18.  
 
 
Fig. 4.3.18. Relationship between the 
spacer length of the bivalent ligand 
and the Hill coefficient at the gpH2R-
GsαS. Data are mean values ± SEM of 
one (compound 4), two (compound 9) 
and three (compound 11) independent 
experiments performed in triplicate. 
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Fig. 4.3.19. Relationship between spacer lengths 
and affinities of the symmetric bivalent ligands, con-
taining different heterocycles, measured at the 
gpH2R-GsαS fusion protein. The pKi values are mean 
values ± SEM of 1-3 displacement experiments for 
each compound. Asterisk (*) corresponds to the bi-
valent ligand 14, containing a hydrophilic 24-atom 
linker between the carbonyl groups, instead of an 
alkanediyl spacer. 
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Fig. 4.3.20. Relationship between spacer lengths and Hill slopes of the symmetric bivalent li-
gands, containing different heterocycles (cf. Fig. 4.3.19), measured at the gpH2R-GsαS (A) and the 
hH2R-GsαS (B). The Hill slopes are mean values ± SEM of 1-3 displacement experiments for each 
compound. Asterisk (*) in panel A corresponds to the bivalent ligand 14, containing a hydrophilic 
24-atom linker between the carbonyl groups, instead of an alkanediyl spacer. 
 
After a 90-min incubation with gpH2R-GsαS, the bivalent ligands of the imidazole se-
ries, compounds 9 and 11, possessing a 14- and a 20-atom linker, respectively, re-
vealed a nH value significantly higher than 1 (Fig. 4.3.17 and Fig. 4.3.18). Further 
studies at the hH2R-GsαS as well as at the gpH2R-GsαS with other homobivalent 
ligands, belonging to the aminothiazole and the aminomethylthiazole series, were in 
line with the results, already observed at the gpH2R-GsαS fusion protein for the 
ligands of the imidazole series (Fig. 4.3.19). Some of the ligands with longer linkers 
revealed apparent positive cooperativity, as their Hill slopes were greater than unity 
(Fig. 4.3.20). 
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4.3.4 Competition binding assays at the H4R  
 
4.3.4.1 Impact of incubation time on affinities and Hill slopes of bivalent H4R 
ligands 
 
The imidazolylpropylguanidine moiety is a priviliged structure in terms of histamine re-
ceptor binding. NG-acylated imidazolylpropylguanidines turned out to be highly potent 
ligands also at the H4R (Igel et al., 2009). For example, the bivalent compound 4 with an 
octamethylene linker, known for its high affinity towards H2Rs (cf. Table 4.3.3), revealed 
a one-digit nanomolar potency at the hH4R (EC50 of 3 nM, efficacy: 0.36; Kraus, 2007). 
Therefore, to expand the pharmacological characterisation of our bivalent ligands, two 
compounds (one with a shorter and one with a longer spacer) were investigated for their 
affinities and Hill slopes at the hH4R, C-terminally fused to the GAIP (RGS19) and coex-
pressed with Giα2 and Gβ1γ2 proteins in Sf9 membranes, as described before (Schneider 
and Seifert, 2009). Competition experiments were performed with 10 nM [3H]HIS as radi-
oligand (cf. Kd of 9.8 ± 0.9 nM at the hH4R + Giα2 + Gβ1γ2 + GAIP; cf. Schnell et al., 2011) 
with varying time periods of incubation. N.B. the kinetics of [3H]HIS at the hH4R-GAIP+ 
Giα2 + Gβ1γ2 (e.g. dissociation half-value period) is described in subsection 5.3.1. 
After 90 min of incubation in the presence of hH4R-GAIP + Giα2 + Gβ1γ2, the bivalent 
ligand 4 showed a Ki value of 7 nM (similar to EC50) and a Hill slope of 1.44 (95% CI: 
1.21–1.67), whereas the bivalent compound 11 revealed a Ki value of 57 nM and a 
Hill slope of 2.22 (95% CI: 1.69–2.74). Thus, in both cases an apparent positive 
cooperativity was observed, as shown in Fig. 4.3.21 and Fig. 4.3.22. However, a 
prolonged incubation period (3 to 7.5 hours) led to the alteration of the Hill slopes, 
approximating unity (Fig. 4.3.22 B). At the same time, the affinity remained almost 
unchanged (Fig. 4.3.22 A). 
 
 
Fig. 4.3.21. Displacement of 10 nM [3H]HIS 
by the imidazole-type bivalent ligands 4 
and 11 (with a different length of a linker) 
at Sf9 membranes expressing the hH4R-
GAIP + Giα2 + Gβ1γ2 after 90 min of incuba-
tion. Each curve is representative of two 
independent experiments performed in 
triplicate. Data shown are mean values ± 
SEM. 
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Fig. 4.3.22. Effect of a prolonged incubation period of representative bivalent ligands on their 
affinity (A) and the Hill slope (B) in the presence of  hH4R-GAIP + Giα2 +Gβ1γ2. Competition assays 
with 10 nM [3H]HIS. The data are mean values ± 95% CI of two experiments for each incubation 
time; performed in triplicate (only the data at 90 and 450 min were from single experiments). Aste-
risks (*) in panel B indicate the Hill slopes significantly different from the unity (details in the text). 
 
4.3.4.2 Artefacts at pre-equilibrium 
 
As already mentioned, a prerequisite for competition and saturation studies is the as-
sumption that the system is at equilibrium at the time point of the measurement. Only 
then, the observed Hill slope can be correctly interpreted, as suggested in Table 4.1.1. 
The period of time, required for equilibration can be estimated by multiplying the known 
half-life of the dissociation of the radioligand by 5 (cf. subsection 1.3.1). However, the 
presence of additional competitors prolongs the time required for equilibration, as the 
apparent value of Kd of the radioligand increases, in turn leading to a decrease in kobs 
(limited by the value of k2), which corresponds to slower association (cf. Eq. 1.3.6). Addi-
tion of a compound with a k2 smaller than that of the radioligand initially leads to a rela-
tive increase in radioligand binding, before it decreases at equilibrium to the correct val-
ue (Lazareno, 2001). The accompanying changes of the nH value are shown in Fig. 
4.3.23 A. Thus, the binding experiments at pre-equilibrium lead to an underestimation of 
the competitor´s affinity (rightward shift) and in a steepening of the competition binding 
curve (artefactual positive cooperativity). Contrary to that, in the presence of a faster 
component (higher k2 indicative of a faster dissociation compared to the radioligand), the 
initially low rate of radioligand binding increases, when the radioligand slowly equili-
brates. Therefore, at pre-equilibrium the apparent affinity of the competitor is higher, 
leading to a leftward shift and a steepening of the inhibition curve, which can be misin-
terpreted as positive cooperativity (Fig. 4.3.23 B). 
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Fig. 4.3.23. The presence of slower (A) and faster (B) components leads at pre-equilibrium to the 
artefactual changes in the competitor affinity (under- and overestimation, respectively) and to 
apparent positive cooperativity (adopted from Hulme, 1992). 
 
 
Fig. 4.3.24. Simplified molecular model of R (receptor or enzyme) with one active site (blue) and 
two different binding patches (green and red). Before the agonist A reaches the active site (blue), 
it binds with its corresponding ‘side’ (green or red) to one binding patch. Different inhibitors I 
(green, blue, or red) are specific for the active site (blue) but also for a corresponding binding 
patch (green or red). Binding of agonist A and one type of inhibitors I to the receptor R is illu-
strated for one possible complex ARI2. Although a classical model for 1:1 competition predicts a 
similar endpoint, it does not consider different binding patches as drug targets (adopted from 
Prinz and Schönichen, 2008 with modifications). 
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The slowly altering Hill slopes of the competition binding curves, observed for the biva-
lent ligands at the H2R and the H4R, indicate the failure to obtain equilibrium and might 
be a sign of delayed changes of receptor conformation. These, in turn, might be a con-
sequence of allosterism (chapter 5), existence of ligand-specific conformations (chapter 
6) or simply toxicity. Namely, the amphiphilic character of the bivalent ligands might ac-
count for changes in the receptor protein structure, especially as a cytotoxic potential 
was confirmed for some of the bivalent ligands depending on their physicochemical 
properties (Ms. Melanie Kaske and Mr. Tobias Birnkammer, University of Regensburg, 
personal communication). Nevertheless, considering the size of the twin compounds, the 
additional temporary interactions with the extracellular domains of GPCRs seem to be 
inevitable (Fig. 4.3.24). Such interactions and ligand-receptor binding dynamics have 
been recently considered to be crucial for ligand efficacy and subtype selectivity (Bokoch 
et al., 2010). 
 
 
4.3.5 Screening of various cell lines for the expression of H2R and H4R 
 
As already mentioned in section 1.3, experiments performed on whole cells and broken-
cell membrane preparation can result in different results. Intact cells – due to their higher 
complexity – reveal closer similarity to physiological conditions (Kenakin, 2006). There-
fore, characterization of cells expressing the receptor of interest as surrogate systems for 
the H2R and the H4R was performed by means of radioligand and flow cytometric binding 
studies (cf. subsection 4.2.6). 
 
4.3.5.1 CHO-hH2R-Gα16 cells 
 
Binding experiments on the CHO cells, stably expressing the hH2R and the promiscuous 
Gα16 protein (clone 4; Schneider, 2005), yielded 15,000 receptors per cell (Fig. 4.3.25). 
The difference between the total and the unspecific binding, encountered for 20 nM 
[3H]TIO (cf. Fig. 4.3.25 B), should enable the analysis of competition binding data. An 
example is a monophasic competition curve of FAM, depicted in Fig. 4.3.26 (nH of 0.91 ± 
0.13; Ki of 15 nM, counted according to the Cheng-Prusoff equation, where the IC50 was 
31 nM, 95% CI: 22-43 nM, and the Kd for TIO was set to 20 nM; cf. Monczor, 2006). 
However, the determined binding constant for FAM was lower than the Kb values found 
previously on CHO-hH2R-Gα16 expressing cells (where FAM suppressed an ARP-induced 
Ca2+ mobilization with a Kb of 143 nM; Schneider, 2005) and at the gpH2R-GsαS fusion 
protein (Kb of 48 ± 10 nM; Preuss et al., 2007). 
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Fig. 4.3.25. Binding assays on the CHO-hH2R-Gα16 cells, clone 4. The radioligand was used at a 
saturating concentration for the estimation of the number of H2Rs per cell (A) as well as at con-
centrations used in competition assays (B). The binding of [3H]TIO (added as obtained from the 
manufacturer; specific activity: 82.2 Ci/mmol = 3041.4 kBq/nmol) was measured in the presence 
of PBS (total) or 1 mM FAM (unspecific). Data from each panel are mean values ± SEM of a sin-
gle experiment performed in triplicate (500,000 cells in 200 µL). 
 
 
 
Fig. 4.3.26. Effect of famotidine (FAM) on 
the displacement of 20 nM [3H]TIO from 
the CHO-hH2R-Gα16 cells clone 4. Data 
are mean values ± SEM of an experiment 
performed in duplicate (500,000 cells in 
200 µL). 
 
 
 
 
4.3.5.2 CHO-rH2R-A2 cells 
 
CHO cells, stably expressing the rH2R (Traiffort et al., 1992,) were previously used in our 
research group for the functional characterisation of H2R ligands in cAMP assays 
(Kracht, 2001). The binding of the specific H2R radioligand [3H]UR-DE257 on these cells 
revealed the density of 30,000  binding sites per cell (Fig. 4.3.27). 
Earlier studies on the transfected CHO cells revealed that 100 µM CIM and 10 µM RAN 
concentration-dependently increased the number of the constitutively active rH2Rs, whe-
reas 100 µM HIS reduced the receptor density (cf. Fig. 6.3.11; Smit et al., 1996 a). 
Moreover, the maximal effect was observed, when the ligands were preincubated for 
periods longer than 16 hours (Smit et al., 1996 b). Therefore, 1.2 µM of the bivalent H2R 
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antagonist 11 (cf. Kb of 371 nM; Birnkammer et al., 2010), 60 µM FAM and 60 µM HIS 
(cf. Table 4.3.3) were incubated with the cells for 24 hours, before the binding of [3H]UR-
DE257 was measured, as shown in Fig. 4.3.28. 
 
Fig. 4.3.27. Estimation of the rH2R number per cell 
at CHO-rH2R-A2 cells. Binding of 100 nM [3H]UR-
DE257/UR-DE257 (1 + 1 dilution, undiluted specific 
activity: 69.3 Ci/mmol = 2564.1 kBq/nmol) was 
tested in the presence of PBS (total) or 100 µM 
FAM (unspecific). Data are mean values ± SEM of 
an experiment performed in sextuplicate (500,000 
cells in 200 µL). 
 
 
Fig. 4.3.28. Influence of incuba-
tion of CHO-rH2R-A2 cells for 24 
hours with different H2R ligands 
on the receptor density. The 
binding of 100 nM of the tracer 
[3H]UR-DE257/UR-DE257 was 
determined in the presence of 
PBS (total) or 100 µM FAM (un-
specific). Data are mean values 
± SEM of an experiment per-
formed in triplicate (250,000 cells 
in 200 µL). 
 
After incubation with different ligands for 24 hours, rH2Rs were still available on the cell 
surface. However, the presented results barely confirmed the ligand-dependent mecha-
nism of the rH2R redistribution, as also HIS increased the specific binding of [3H]UR-
DE257. This might at least partially result from the ligand-independent H2R internaliza-
tion (cf. Fig. 6.3.4-5). On the other hand, the relatively high errors precluded a detailed 
analysis. Further investigations of the H2R endocytic cycle are described in subsection 
6.3.2. 
4.3.5.3 U-937 cells (endogenously expressing the H2R) 
 
As the human monocytic U-937 cells endogenously express functional hH2Rs (cf. sub-
section 1.2.2.2), the question was raised, whether these cells can be used as a model for 
the investigation of H2R ligands. Possible advantages over recombinant systems, such 
as transfected CHO cells, might result from the natural regulation of receptor biosynthe-
sis, trafficking, signal transduction, up- and down-regulation. Fig. 4.3.29 illustrates the 
binding experiments with [3H]TIO, which revealed approx. 10,000 receptors per cell. This 
result is comparable with the reported number of low-affinity binding sites on U-937 cells 
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(Bmax of 23,000 ± 3000 sites per cell; Kd of 20 ± 3 nM; Monczor et al., 2006). Neverthe-
less, the determined receptor density is considered too low for the performance of stan-
dard competition assays, utilizing 10-20 nM [3H]TIO. 
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Fig. 4.3.29. [3H]Tiotidine ([3H]TIO) binding experiments on U-937 cells. (A) Estimation of the 
number of H2Rs per U-937 cell. Binding of 200 nM [3H]TIO (added as obtained from the manufac-
turer, specific activity: 77.2 Ci/mmol = 2856.4 kBq/nmol) was tested in the presence of PBS (total) 
or 1 mM FAM (unspecific). Data are mean values ± SEM of an experiment performed in triplicate 
(1.5 million cells in 200 µL). (B) The saturation binding (the same radioligand batch as in Fig. 
4.3.25; Kd value of 61 ± 48 nM). Data are mean values ± SEM of two independent experiments 
performed in triplicate (750,000 cells in 200 µL). 
 
The application of the red fluorescent H2R ligands, developed in our research group by 
Dr. Daniela Erdmann (cf. Fig. 1.2.5; Erdmann, 2010), allowed a nonradioactive investi-
gation of H2R binding e.g. by means of flow cytometry or confocal microscopy (cf. sub-
section 6.3.1). Thus, flow cytometric binding assays were performed, as described under 
Materials and methods (section 3.2), with the fluorescent squaramide derivatives UR-
DE56 and UR-DE108 (Kd of approx. 170 nM and 180 nM, respectively; Mosandl, 2009; 
Erdmann, 2010). Unfortunately, the U-937 cells showed only poor specific binding as 
illustrated by Fig. 4.3.30 and Fig. 4.3.31.  
 
 
Fig. 4.3.30. Binding of UR-DE56 determined by 
flow cytometry on U-937 cells. The binding of 
UR-DE56 was estimated after 40 min of incu-
bation in the absence (total) or presence of 
100 µM FAM (unspecific). Data are mean val-
ues ± SEM of an experiment performed in qua-
druplicate. 
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Fig. 4.3.31. Binding of UR-DE108 de-
termined by flow cytometry on U-937 
cells. The binding of UR-DE108 was 
estimated after 30 min of incubation in 
the absence (total) or presence of 
500 µM FAM (unspecific). Data are 
mean values ± SEM of an experiment 
performed in duplicate. 
 
 
 
4.3.5.4 Human neutrophils 
 
Previous studies of guanidine-type H2R agonists showed that human neutrophils are a 
valuable model for functional investigations on endogenously expressed H2R, in particu-
lar by measuring superoxide (O2–) formation (Burde et al., 1990). In the current study, an 
attempt was made towards the estimation of the hH2R number by using the above-
mentioned red fluorescent H2R ligands (cf. Erdmann, 2010), similarly to the experiments 
on U-937 cells. The isolation of neutrophils from whole blood was performed in coopera-
tion with Ms. Irena Brunskole (Institute of Pharmacy, University of Regensburg), as de-
scribed in subsection 4.2.7. The flow cytometric binding experiment was conducted with-
in 3.5 hours after the isolation. Unfortunately, almost no difference between total and 
unspecific binding of the three red fluorescent ligandes could be detected on neutrophils 
after 37 min of incubation as shown in Fig. 4.3.32 A (cf. 37 min of incubation; Mosandl, 
2009). 
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Fig. 4.3.32. Flow cytometric binding assay on human neutrophils. (A) The binding of 500 nM of 
the red fluorescent H2R ligands: UR-DE54 (Fl-4), UR-DE74 (Fl-4) and UR-DE108 (Fl-3) was esti-
mated after 37 min of incubation in the absence (total) or presence of 30 µM FAM (unspecific). 
Data were calculated for the cell population shown in the red gate (B) and are mean values ± 
SEM of an experiment performed in duplicate. 
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In order to find out the reason for the merely detectable specific binding of the fluores-
cent H2R ligands, neutrophils were imaged by means of confocal microscopy, as de-
scribed in subsection 3.2.7. Surprisingly, red autofluorescence of granula was almost as 
high as fluorescence of the cells labeled with 200 nM UR-DE74 (Fig. 4.3.33). These ob-
servations correlated well with the results from flow cytometric binding assays, shown in 
Fig. 4.3.34 A. Further experiments revealed also time-dependent penetration of the fluo-
rescent ligands into the cells, disabling competitive binding (Fig. 4.3.34 B). 
 
   
Fig. 4.3.33. Confocal imaging of human neutrophils: autofluorescence (A) as well as the cells 
labelled with 200 nM UR-DE74 after 3 min of incubation (total binding, B) or after 38 min of incu-
bation in the presence of 100 µM FAM (unspecific binding, C). Plan-Apochromat 63x/1.4 oil, 
HeNe 633 (15–18%), HFT UV/488/543/633, NFT 545, LP 650, pinhole = 1 a.u. 
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Fig. 4.3.34. Flow cytometric binding assay on human neutrophils. (A) Histograms for neutrophils: 
unlabelled (autofluorescence) or labelled with 150 nM UR-DE74 after 10 min of incubation in the 
absence (total) or presence of 30 µM FAM (unspecific). (B) Binding of 200 nM UR-DE54 after 
different incubation periods in the absence (total) or presence of 30 µM FAM (unspecific). Data 
are mean values ± SEM of an experiment performed in 1–3 replicates. Fluorescence intensity Fl-4 
was calculated for the cell population shown in the red gate in Fig. 4.3.32 B. 
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4.3.5.5 CHO-hH4R cells 
 
As described in section 4.3.4, the imidazole-type bivalent NG-acylated hetarylpropyl-
guanidines proved to be also active as a hH4R agonists at nanomolar concentrations. 
Therefore, an attempt was made to obtain a cellular system for the testing of the H4R 
ligands. CHO cells were stably transfected with the pcDNA3.1(+)-Neo-hH4R plasmid as 
described under Materials and methods (subsection 4.2.5). Unfortunately, the CHO-
hH4R cells revealed only approx. 2000 receptors per cell (measured as [3H]HIS binding 
sites, Fig. 4.3.35). This number might be underestimated, as the used agonistic radioli-
gand preferably binds to the subpopulation of receptors coupled to G protein (Kenakin, 
1997). However, the results are in accordance with a low expression of functional H4R by 
transfected cells reported by Dr. Johannes Mosandl (Mosandl, 2009). As specific binding 
of 10 nM [3H]HIS was not detectable (Fig. 4.3.36), competition binding studies were dis-
continued. 
 
 
Fig. 4.3.35. Saturation binding on CHO-hH4R 
cells. The binding of 100 nM [3H]HIS (added as 
obtained from the manufacturer, specific activ-
ity: 14.1 Ci/mmol = 521.7 kBq/nmol) was esti-
mated in the presence of PBS (total) or 50 µM 
of the H3/H4 antagonist THIO (unspecific). Data 
are mean values ± SEM of an experiment per-
formed in sextuplicate (500,000 cells in 200 µL). 
 
 
 
 
Fig. 4.3.36. Binding of 10 nM [3H]HIS on the 
CHO-hH4R cells (added as obtained from the 
manufacturer, specific activity: 14.1 Ci/mmol = 
521.7 kBq/nmol). The unspecific binding was 
estimated in the presence of 10 µM THIO. Data 
are mean values ± SEM of an experiment per-
formed in sextuplicate (170,000 cells per sam-
ple). 
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The genetically engineered cells CHO-hH2R-Gα16 and CHO-rH2R-A2 revealed hH2R 
densities of approx. 15,000 and 30,000 receptors per cell, respectively, sufficient to 
perform binding studies with [3H]TIO and [3H]UR-DE257 (cf. Fig. 4.3.25 and 4.3.27). 
In contrast, the amount of approx. 10,000 H2Rs per cell, endogenously expressed by 
the human monocytic U-937 cell line, was too low for the characterization of ligands, 
as shown in radioligand and flow cytometric binding assays (cf. Fig. 4.3.29–31). Due 
to the high autofluorescence of human neutrophils and the time-dependent penetra-
tion of the fluorescent ligands (cf. Fig. 4.3.32–34), no binding studies could be per-
formed on these cells. Unfortunately, an attempt to establish a cell line stably ex-
pressing the hH4R was not successful (cf. Fig. 4.3.35–36), similar to findings re-
ported previously in terms of functional H4Rs (Mosandl, 2009). 
 
118 Chapter 4 
4.4 Summary and conclusion 
 
The Hill slope, obtained from radioligand saturation and competition binding assays at 
equilibrium, is a very useful pharmacological parameter, with respect to the explanation 
of a more complicated binding behaviour than predicted by the law of mass action 
(cf. Table 4.1.1; Repke and Liebmann, 1987; Lazareno, 2001; Motulsky and Christopou-
los, 2004; Kenakin, 2006). However, for the correct interpretation of the experimental 
binding data, it is essential to provide that there is no radioligand depletion and that incu-
bation time is sufficient to reach equilibrium at the time point of the measurement 
(Hulme, 1992; cf. Fig. 4.3.23). 
 
A) If ligands bind to receptors in a competitive manner (without any cooperativity), 
the competition curve is monophasic with the nH equalling 1 and the Scatchard 
representation of binding data is linear (Fig. 4.4.1 A). 
B) However, if nH is smaller than 1, a curvilinear saturation curve and a biphasic 
(convex) Scatchard plot are expected (Fig. 4.4.1 B). Additionally, a competition 
curve might reveal a more or less clear biphasic course, when fitted to two-site 
model instead of logistic function. This could be due to negative cooperativity (al-
losterism), but other possible reasons for the acquisition of flat competition curves 
have to be considered too, such as the existence of various receptor subtypes or 
different conformations of the same receptor, characterized by different affinities 
to the G protein (ternary complex model). 
C) Finally, if nH > 1, a concave Scatchard plot and a bell-shaped competition curve 
are common (Fig. 4.4.1 C). These findings could be consistent with the positive 
cooperativity. However, also the premature termination of incubation may lead to 
apparently similar results.  
 
Moreover, the phenomenon of cooperativity might occur not only when ligands bind to 
the distinct binding sites at the same receptor (Repke and Liebmann, 1987), but also if 
they interact with different protomers within receptor dimers or even dimeric receptors 
(Albizu et al., 2006). 
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Fig. 4.4.1. Predicted binding behaviour of radioligand (L1*) and unlabelled ligand (L2) in saturation 
(middle, Scatchard plots as inset) and competition assays (bottom) in the case of (A) lacking, 
(B) negative or (C) positive cooperativity (adopted from Albizu et al., 2006 with modifications). 
 
Addressing dimers of G-protein-coupled receptors has been suggested as a very promis-
ing concept in drug discovery (Daniels et al., 2005 a; Shonberg et al., 2011). Thus, biva-
lent NG-acylated guanidines were developed in our research group as pharmacological 
tools for exploration of the putative H2R dimerization (Fukushima, 1997). However, the 
most potent bivalent ligands had only 6- to 8-membered linkers connecting the two sets 
of pharmacophoric groups, i. e. the acylguanidine moieties. This is considered insuffi-
cient for the bridging the receptor molecules of a H2R dimer (Fig. 4.1.1 B and Fig. 4.3.19; 
cf. Kraus, 2007). The presented radioligand binding studies provided new insights into 
the mode of action of the bivalent ligands at the H2R and the H4R. The investigation of 
the latter became possible with imidazole-type bivalent acylguanidines which, in addition 
to H2R agonistic properties, turned out to possess rather high H4R potency in functional 
assays: 
 
 
A B C 
120 Chapter 4 
1) All of the tested bivalent agonists with octamethylene linkers as well as HIS 
showed flat competition curves on Sf9 membranes, expressing hH2R-GsαS or 
gpH2R-GsαS fusion proteins, after 90 min of incubation with [3H]TIO (Table 4.3.3). 
From a theoretical point of view, one could argue against a simple model of com-
petitive binding, as equilibrium should have been already reached at this incuba-
tion time (t0.5 of [3H]TIO dissociation of approx. 10 min; Fig. 5.3.1; cf. Foreman et 
al., 1985). However, after prolonged (up to 3 hours) incubation period with 
[3H]TIO, the Hill slope of HIS remained smaller than 1, whereas that of the biva-
lent agonist 3 increased, approximating unity (Fig. 4.3.10). 
2) This phenomenon cannot be explained by the peculiarities of the fusion proteins: 
a. Saturation binding of [3H]TIO and [35S]GTPγS revealed the resemblance 
between the gpH2R-GsαS fusion protein and the gpH2R coexpressed with 
GsαS in Sf9 membranes, as [3H]TIO bound to both receptor forms with a Kd 
of 40 nM (Fig. 4.3.1-2). This is in agreement with previous studies (Kd value 
of 34.4 ± 8.4 nM reported by Kelley et al., 2001). The estimated H2R-to-
(functional)G-protein ratios for the fusion protein (unexpectedly 1:3, single 
experiment only) and for the coexpressed proteins (about 1:7; Fig.4.3.4) 
contradicted the hypothesis that flat competition curves resulted from the 
limited G proteins. Moreover, the coupling factor for the coexpressed gpH2R 
was in line with the literature (cf. other coexpressed histamine receptor sub-
types: hH3R, Schnell et al., 2010; hH4R, Schneider et al., 2009). 
b. The competition binding curves of HIS were shallow at both fused 
(Fig. 4.3.5 A and B) and coexpressed H2Rs (Fig. 4.3.8). Fitting the data to 
the two-site binding equation revealed two independent non-interacting 
binding sites for HIS in the absence of GTPγS. Additionally, GTPγS-
dependent shift and steepening of the binding curve of the natural ligand 
were observed, as predicted by the ternary complex model (Fig. 4.3.11 A). 
The bivalent H2R agonist 4 with an octamethylene linker was found to be an 
efficient stabilizer of the ternary complex at the gpH2R-GsαS (Fig. 4.3.11 B), 
but its binding was insensitive towards 10 µM GTPγS, indicating antago-
nism rather than agonism (Fig. 4.3.5 D). By contrast, in the presence of 
GTPγS, the competition curve for ligand 4 at the hH2R-GsαS was slightly 
shifted to the right and steepened (Fig. 4.3.5 C). Such species-dependent 
differences in sensitivity to GTPγS were reported previously for some mo-
novalent NG-acylguanidines at the hH2R-GsαS and the gpH2R-GsαS (Xie et 
al., 2006). 
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c. The biphasic Scatchard representations of [3H]TIO binding to the gpH2R-
GsαS fusion proteins and the gpH2R coexpressed with GsαS (Fig. 4.3.3), con-
sistent with the ternary complex model, were in line with previous studies 
reporting the inverse agonism of TIO (Monczor et al., 2003). 
3) The bivalent compound 11 with a 20-membered alkanediyl linker, which is sup-
posed to be sufficiently long to bridge the binding pockets of two dimerised recep-
tor molecules (Bhushan et al., 2004), revealed apparent positive cooperativity af-
ter 90 min of incubation at the hH2R-GsαS, the gpH2R-GsαS and the hH4R-
GAIP + Giα2 + Gβ1γ2 fusion proteins (Hill slopes of the binding curves greater than 
2, cf. Fig. 4.3.17–21). However, the extension of the incubation period at the 
hH4R to 3-7.5 hours resulted in classical monophasic competition curves 
(Fig. 4.3.22 B). 
 
Binding studies of mono- and bivalent ligands support the ternary complex model 
(two non-interacting binding sites at the H2R), but not the hypothetical “bridging” of 
H2R dimers. Ligand affinity dropped with increasing the number of methylene groups 
in the linker up to 20 (Fig. 4.3.19), which is the expected the optimum length to en-
able simultaneous occupation of the binding sites in two neighbouring protomers by 
twin compounds (Bhushan et al., 2004). The analysis of the slopes of competition 
binding curves (after 90 min of incubation) indicated the apparent negative coopera-
tivity for the shorter bivalent ligands at the H2R (Table 4.3.3). However, this effect de-
pended on the used radioligand (nH < 1 for [3H]TIO in Fig. 4.3.5 C and D; nH > 1 for 
[3H]UR-DE257 in Fig. 4.3.20). By contrast, apparent positive cooperativity was ob-
served for the higher homologues among the bivalent ligands at the H2R and the H4R 
(Fig. 4.3.17–21). Nevertheless, after extended incubation periods, the Hill slopes 
changed in both cases, approximating unity (Fig. 4.3.10 and Fig. 4.3.22 B, respec-
tively), whereas the affinity of the bivalent ligands did not significantly alter, suggest-
ing unexpectedly slow equilibration. 
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5 Radioligand binding kinetics at histamine H2 and H4 
receptors 
 
5.1 Introduction 
 
The spacers of the most potent bivalent NG-acylated guanidines comprised only 6–8 me-
thylene groups (cf. Fig. 4.1.1 B; Kraus, 2007; Birnkammer et al., 2010) and thus cannot 
bridge H2R dimers in a manner proposed by Portoghese and colleagues (Bhushan et al., 
2004). Therefore, the shallow binding curves of the most potent bivalent H2R ligands (cf. 
Table 4.3.3) could not be explained by the interaction of a single bivalent ligand with two 
adjacent receptor molecules at the same time (cf. Fig. 4.1.3). Other possible binding 
modes of bivalent ligands are illustrated in Fig. 1.1.2 and include allosteric and univalent 
binding. As already mentioned in subsections 4.1.1 and 4.3.2, an explanation of Hill 
slopes < 1 (with [3H]TIO as radioligand) may be provided either by the ternary complex 
model or by allosteric interactions. 
Allosterism might result from negative cooperativity between two non-overlapping and 
non-interconverting binding sites on the same receptor molecule. Indeed, this was postu-
lated previously at the α2A-adrenoreceptor (Leppik et al., 1998) and the dopamine D2 
receptor (Hoare and Strange, 1996). Moreover, simultaneous interactions of both phar-
macophoric moieties of bivalent compounds with ortho- and allosteric binding sites have 
been recently reported for the muscarinic M2 receptor (Valant et al., 2008; Antony et al., 
2009). The allosteric sites of the rhodopsin-like subfamily of GPCRs are believed to be 
located at the extracellular loops, as well as at the top of transmembrane domain 7 (May 
et al., 2007). Due to the relatively low sequence conservation among receptor subtypes, 
an allosteric binding site seems to be a very promising target for the discovery of new 
therapeutics with improved selectivity, when compared with the orthosteric binding site 
(Avlani et al., 2004; Smith and Milligan, 2010). 
 
5.1.1 Radioligand dissociation kinetics 
 
Whereas binding to the orthosteric site can be easily followed by the competitive dis-
placement of a radioactive tracer, the interaction with an allosteric site is sometimes ca-
mouflaged by neutral equilibrium binding cooperativity, as shown in Fig. 5.1.1. Therefore, 
 Introduction 127 
 
 
the putative allosteric behaviour should rather be investigated by the radioligand dissoci-
ation kinetics (Kostenis and Mohr, 1996). 
 
 
 
Fig. 5.1.1. Binding of an allosteric 
modulator, at M2 muscarinic recep-
tors. The neutral equilibrium bind-
ing cooperativity with [3H]N-methyl-
scopolamine ([3H]NMS) masked its 
allosteric properties, which could 
be revealed only by association or 
dissociation kinetics of [3H]NMS 
(adopted from May et al., 2007 
with modifications). 
 
 
 
Given that ligands bind only to a single class of receptor binding sites in a classical com-
petitive manner, there should be no change of the radioligand dissociation rate (k2, koff), 
when the respective receptors are incubated with unlabelled competitors (Kostenis and 
Mohr, 1996; Valant et al., 2008). In such cases, monophasic dissociation curves of the 
orthosteric radioligand should be expected (Lazareno, 2001). 
 
5.1.1.1 Pharmacological implications of changes in the radioligand dissociation 
rate 
 
In the presence of an allosteric modulator, the radioligand off-rate might be changed in a 
concentration-dependent manner (Kenakin, 2006). The quantification of these changes 
is usually a cumbersome procedure. Nevertheless, it can be simplified by extrapolation 
on condition that the dissociation curves (specific binding vs. time), acquired in the ab-
sence and in the presence of putative allosteric modulators, fulfill the requirement of mo-
nophasicity (Fig. 5.1.2 A). As shown in Fig. 5.1.2 B, these monophasic curves can be 
easily linearized by logarithmization (Eq. 5.1.1, where B0 and Bt refer to specific binding 
observed at times 0 and t, respectively). The half-life time of radioligand dissociation (t0.5) 
is given by Eq. 5.1.2 (Lazareno, 2001): 
t-k
B
Bln     eB B 2
0
ttk-
0t
2    (Eq. 5.1.1)
2
5.0 k
2lnt   (Eq. 5.1.2)
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Fig. 5.1.2. Radioligand dissociation kinetics represented by (A) monophasic curves and (B) their 
linearizing transforms (cf. Eq. 5.1.1; adopted from Kostenis and Mohr, 1996 with modifications). 
 
As in geometry any straight line is defined by 2 points, the laborious experimental proce-
dure can be reduced to a minimum by performing so called “two-point kinetics”. The ex-
perimentator has to obey the following procedure (detailed protocol in subsection 5.2.2): 
1) Acquisition of initial binding data (before dissociation) and after a defined period 
of dissociation (as shown in Table 5.2.2) corrected for unspecific binding. 
2) Transformation of the data according to Eq. 5.1.1 yielding k2 values (Fig. 5.1.3 A). 
3) Plotting the relative k2 values (as percentage of control) against the logarithmized 
modulator concentration (Fig. 5.1.3 B) and fitting the data by non-linear regres-
sion. 
 
Fig. 5.1.3. Two-point kinetics of radioligand dissociation: (A) logarithmized binding data for the 
calculation of k2 (koff) values, (B) the effect of the modulator concentration on the rate constant of 
radioligand dissociation k2 (adopted from Kostenis and Mohr, 1996, with modifications). 
  
A B
A B
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5.1.2 Association kinetics 
 
In addition to radioligand dissociation, association kinetics allows the verification of the 
pharmacological model chosen for the interpretation of binding data (cf. subsection 
1.4.2). Assuming the competitive binding to a single class of binding sites, the rate con-
stant of radioligand association k1 (kon) could be counted from association experiments 
performed with at least two different concentrations of a radioligand (Fig. 5.1.4). The ob-
served rate constant (kobs) should namely increase linearly with the concentration of radi-
oligand, thus allowing the quantification of k1 and k2 (cf. Eq. 1.3.5). Otherwise, the k1 
value has to be calculated by using the k2 (koff) value obtained from dissociation experi-
ments. Additionally, if ligand-receptor interactions follow the law of mass action, the radi-
oligand affinity constant Kd determined by saturation binding should match the Kd value 
assessed by kinetic experiments (cf. Eq. 1.3.4; Motulsky and Christopoulos, 2004). 
 
 
Fig. 5.1.4. Radioligand association kinetics performed 
with high and low concentrations of radioligand. The k1 
and k2 values can be calculated from the exponential 
association curves (cf. Eq. 1.3.5). 
 
 
 
5.1.2.1 Kinetics of competitive binding 
 
Competition studies with bivalent acylguanidines revealed a complex binding behaviour 
of these ligands. The found Hill slopes were significantly greater than one after a stan-
dard incubation period of 90 min at both the H2R and the H4R (with [3H]UR-DE257 and 
[3H]HIS as radioligands, respectively; cf. subsections 4.3.3 and 4.3.4), but approximating 
unity when extending the incubation time longer than 3 hours (cf. Fig. 4.3.22 B). These 
changes of the Hill coefficients may suggest that competitors dissociate more rapidly or 
slowly than the radioligand. 
In order to determine the kinetics of an unlabelled ligand, radioligand association expe-
riments have to be conducted in the presence of a constant concentration of a radioli-
gand and at least two different concentrations of a “cold” compound (Motulsky and Ma-
han, 1984; Motulsky and Christopoulos, 2004). Given that binding follows the law of 
mass action, the on- and off-rates of an unlabelled ligand (k3 and k4) as well as its affinity 
constant (Ki) could be calculated from kinetics of competitive binding according to the 
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following equations (Eq. 5.1.3–6; under assumption that the concentrations of a radioli-
gand A and an unlabelled ligand B are constant): 
 
A+B+R AR+BR
k1, k3
k2, k4
(Eq. 5.1.3)
]AR[k])BR[]AR[R(]A[k
dt
d([AR])
201   (Eq. 5.1.4)
]BR[k])BR[]AR[R(]B[k
dt
d([BR])
403  (Eq. 5.1.5)
3
4
i k
kK   (Eq. 5.1.6)
 
As shown in Fig. 5.1.5, in the presence of both slowly and rapidly dissociating competi-
tors, time required for equilibration with a radioligand would be increased. This could be 
the reason for the underestimated affinity of a “slow competitor” as well as the overesti-
mated affinity of a “fast competitor”, measured in competition experiments after the pre-
mature termination of incubation (Hulme, 1992). Moreover, the failure to obtain equili-
brium might result in the steepening of displacement curves, also referred to as the ap-
parent positive cooperativity (cf. Fig. 4.3.23). 
 
 
 
Fig. 5.1.5. The kinetics of competitive radi-
oligand binding as predicted by the law of 
mass action (adopted from Motulsky and 
Mahan, 1984 with modifications). 
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5.2 Materials and methods 
 
5.2.1 Materials 
 
All dissociation and association binding experiments at the hH4R-GAIP + Giα2 + Gβ1γ2, ex-
pressed in the insect Sf9 membranes, were performed using the same chemicals as 
described in subsection 4.2.1. Assays were carried out at room temperature (20–23 ºC) 
in a total volume of 250 μL and set up to fit the 48 wells of a M-48 harvester from Brandel 
(Gaithersburg, MD, USA). 
 
5.2.2 Kinetics of radioligand dissociation at the gpH2R and the hH4R 
 
To study the kinetics of radioligand dissociation, assays were carried out, according to 
the protocols kindly provided by Ms. Dorina Kaufel (Institute of Pharmacy, University of 
Bonn, Germany) with following modifications. 
 
5.2.2.1 Radioligand dissociation from the gpH2R-GsαS and the hH4R 
 
For experiments with [3H]TIO, 150 µL of 0.33% BSA in binding buffer (0.2% BSA final) 
and 50 µL of Sf9 membrane suspension (gpH2R-GsαS; cf. subsection 4.2.3) were pipetted 
into 4-mL polypropylene tubes. Then, at different periods of time (0–30 min), 25 µL of the 
radioactive tracer ([3H]TIO with unlabeled TIO in binding buffer to obtain a final ligand 
concentration of 10 nM) were added to each tube. Addition of the radioligand was per-
formed in reverse chronological order (first for the samples with longer association times, 
then for those with shorter association times). Equilibration with the radioligand was per-
formed in duplicate at room temperature (20–23 ºC) under shaking at 250 rpm within 
30 min for each sample. Dissociation started by addition of 25 µL of a 10-fold concen-
trated feed solution of FAM (100 μM final) in the presence or absence of HIS (100 μM 
final) or the bivalent compound 4 (1 μM final). The reaction was terminated simultane-
ously for all samples by addition of ice-cold binding buffer and rapid filtration with a M-48 
harvester, providing appropriate dissociation times, as indicated on abscissa. Filter-
bound radioactivity was measured in a LS 6500 Liquid Scintillation Counter from Beck-
man Coulter as described in subsection 4.2.3. 
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Dissociation kinetics of [3H]UR-DE257 (Kd value of 27 nM; Erdmann, 2010) was per-
formed similar to [3H]TIO with minor modifications: the radioligand at the final concentra-
tion of 25 nM (7–10 nM of radioactive + 15–18 nM of non-radioactive tracer) was added 
to gpH2R-GsαS membranes at different time points between 0 and 90 min. As the radioli-
gand association and dissociation kinetics were quite slow (association half-life of 64 min 
and dissociation half-life of 122 min; cf. Erdmann, 2010), membranes were equilibrated 
with the radioligand for 100 min, prior to the addition of unlabelled competitors. 
Kinetics of [3H]HIS dissociation was carried out by analogy with the procedure for the 
investigation of [3H]UR-DE257 (cf. Table 5.2.1). Unspecific binding at the hH4R was de-
termined in the presence of 10–20 µM THIO. 
 
Table 5.2.1. Experimental setup for the radioligand dissociation kinetics.  
Radioligand Final conc. 
Cold 
tracer 
added 
Preincub. 
time 
Sf9 membrane 
(protein content) 
[3H]TIO 10 nM no 30 min gpH2R-GsαS 100 µg/sample 
[3H]UR-DE257 25 nM yes 100 min gpH2R-GsαS 100 µg/sample 
[3H]HIS 10 nM no 60–90 min hH4Ra 33–40 µg/sample 
a hH4R-GAIP+ Giα2 + Gβ1γ2 
 
5.2.2.2 Simplified measurement of [3H]HIS dissociation (“two-point kinetics”) 
 
In order to investigate the influence of competitor concentration on the dissociation of 
[3H]HIS at the hH4R, “two-point kinetic experiments” were carried out (Kostenis and 
Mohr, 1996) according to the time schedule presented in Table 5.2.2. Each sample con-
tained 150 µL of 0.3% BSA in binding buffer (0.2% BSA final), 25 µL of [3H]HIS solution 
in binding buffer (without reduction of specific activity, 10 nM final), 25 µL of the hH4R-
GAIP + Giα2 + Gβ1γ2 membrane (35–40 µg protein per sample, freshly resuspended be-
fore addition; cf. subsection 4.2.3), 25 µL of either THIO solution (20 µM final) or Milli-
pore water (for total binding) and 25 µL of either a 10-fold concentrated feed solution of 
an unlabelled competitor in 10% DMSO (1% DMSO final) or 10% DMSO only 
(1% DMSO final for total and unspecific binding). The addition of DMSO improved the 
solubility of the tested bivalent compounds. The equilibration of the membrane with the 
radioligand was conducted at 20-23 ºC with shaking at 250 rpm either in test tubes (for 
control samples: total and unspecific binding) or together in a separate vessel (for other 
samples). Dissociation was started by addition of the radioligand-receptor complexes to 
the competitor-THIO mixtures in triplicate and terminated by rapid filtration after the next 
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28 min (the most significant changes of the filter-bound radioactivity were observed in 
kinetic experiments at approx. 28–30 min of [3H]HIS dissociation). The filtration of sam-
ples and the determination of the specific [3H]HIS binding (at 0 and 28 min of dissocia-
tion) were performed as described for the complete kinetic experiments. The value of 
radioligand off-rate measured under control conditions (20 µM THIO in the absence of 
modulators) was set to 100%. 
 
Table 5.2.2. Time schedule for the “two-point kinetics” of radioligand dissociation. 
min Procedures 
0 Equilibrate 2700 µL of 0.3% BSA and 450 µL of membrane in a separate 15-mL 
vessel with 450 µL of radioligand for 90 min (Master-Mix) 
30 Add radioligand (25 µL per sample) and membrane (25 µL per sample) to the 
prepared tubes with mixtures for total (0.3% BSA, water) and unspecific binding 
(0.3% BSA, water, THIO) and incubate for 90 min 
92 Add 200 µL of Master-Mix (per sample) to the prepared tubes with competitor-
THIO mixtures to start the dissociation 
120 Filtration 
 
5.2.3 Radioligand association at the hH4R 
 
5.2.3.1 Association kinetics 
 
First, 175 µL of BSA solution in binding buffer (0.2% BSA final) and 50 µL of the hH4R-
GAIP + Giα2 + Gβ1γ2 membrane suspension (cf. subsection 4.2.3) were added to each 
4-mL polypropylene tube. Immediately afterwards the tubes were shaken at 250 rpm for 
15 min, while the Sf9 membranes were allowed to adsorb at the sides of tubes until addi-
tion of the radioligand. This initial shaking provided the constant amounts of receptor 
protein during the subsequent incubation with the radioligand. Concomitantly, 100 µL of 
an auxiliary radioligand feed solution were prepared in a 1.5-mL reaction vessel by dilu-
tion of the stock solution of [3H]HIS in binding buffer. To receive 750 µL of the [3H]HIS-
binding buffer mixtures for both total and unspecific binding, 550 µL of binding buffer and 
150 µL of either Millipore water (for total binding) or 1 mM THIO (for unspecific binding, 
20 µM THIO final) were added to two separate 2-mL reaction vessels and supplied by 
50 µL of the (previously prepared) auxiliary radioligand feed solution. The obtained mix-
tures contained a 10-fold concentrated solution of the radioligand (the final concentration 
of [3H]HIS was 10, 30 or 100 nM, depending on the experiment). At the defined time 
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points between 0 min and 230 min, 25 µL of the appropriate mixture were added in tripli-
cate to the membrane suspensions with BSA (in reverse chronological order: first for the 
samples with longer association times, then for those with shorter association times) and 
the samples were shaken at 250 rpm. The termination of [3H]HIS association and the 
measurement of the filter-bound radioactivity were performed as described in subsection 
4.2.3. The experimental settings (amount of membrane protein, [3H]HIS concentration) 
were chosen to ensure that no more than 5% of the radioactivity added to test tubes 
were bound to filters. 
 
5.2.3.2 Kinetics of competitive binding 
 
Kinetic measurements of competitive binding of [3H]HIS in the presence of the bivalent 
H2R ligand 11 were performed as described above for [3H]HIS association kinetics, with 
minor modifications. The appropriate volume of binding buffer in the mixtures for both 
total and unspecific binding was replaced by 10 µM or 100 µM solution of ligand 11, to 
obtain a 10-fold concentrated feed solution of compound 11. Association was started at 
the defined time points between 0 min and 230 min by addition of 25 µL of the mixtures 
for both total and unspecific binding to the membrane suspensions with BSA. The final 
concentration of compound 11 was – depending on the experiment – 50, 150 or 500 nM. 
 
 Results and discussion 135 
 
 
5.3 Results and discussion 
 
5.3.1 Kinetics of radioligand dissociation at the gpH2R and the hH4R 
 
5.3.1.1 Kinetics of [3H]tiotidine dissociation at the gpH2R-GsαS 
 
With respect to an explanation of the peculiarities of the bivalent acylguanidine-type H2R 
agonists, the dissociation kinetics at the gpH2R-GsαS was determined to distinguish be-
tween ortho- and allosteric ligands (Valant, 2008). As expected, [3H]TIO dissociated ac-
cording to the one-phase exponential decay after addition of 100 µM FAM (approx. 2000-
fold Ki). The rate constant of radioligand dissociation amounted to 0.076 ± 0.003 min-1 
(95% CI of k2: 0.068–0.084 min-1, dissociation half-life time of 9 min; results from six in-
dependent experiments performed with 100 µM FAM in the presence or absence of 
100 µM HIS), which was in good agreement with data from the literature (k2 of [3H]TIO of 
0.063 ± 0.005 min-1 for guinea pig lung parenchyma; Foreman et al., 1985). No signifi-
cant difference in k2 was observed when a mixture of 100 µM FAM and 100 µM HIS 
(approx. 250-fold Kd; cf. Fig. 4.3.9) was added instead of 100 µM FAM only, confirming 
the classical competitive behaviour of HIS (Fig. 5.3.1 A and Fig. 5.3.2 A; k2 with 100 µM 
FAM: 0.080 ± 0.002 min-1; k2 with 100 µM FAM and 100 µM HIS: 0.080 ± 0.002 min-1). 
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Fig. 5.3.1. Dissociation of [3H]TIO from the gpH2R-GsαS after addition of 100 µM FAM in the ab-
sence (control) or presence of either (A) 100 µM HIS or (B) 1 µM of the bivalent 4. Data are 
means ± SEM of two experiments performed in duplicate. 
Statistically different dissociation rates were found when, apart from FAM, 1 μM of 
the bivalent compound 4 (approx. 500-fold Ki) was added (k2 with 100 µM FAM: 
0.066 ± 0.002 min-1; k2 with 100 µM FAM and 1 µM of the ligand 4: 0.076 ± 
0.002 min-1; P<0.0001), giving a hint to a weak allosteric interaction (Fig. 5.3.1 B and 
Fig. 5.3.2 B). 
B A 
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Fig. 5.3.2. The linearized data from Fig. 5.3.1, transformed according to Eq. 5.1.1. B0 was unin-
hibited specific binding of [3H]TIO shortly before addition of the unlabeled competitor(s) (t=0 min); 
Bt was specific binding of [3H]TIO remaining at time t after addition of 100 µM FAM in the absence 
(control) or presence of either (A) 100 µM HIS or (B) 1 µM of the bivalent 4. Results are means ± 
SEM. The rate constants of [3H]TIO dissociation (slopes) in panel B are statistically different 
(P<0.0001). 
 
5.3.1.2 Kinetics of [3H]UR-DE257 dissociation from the gpH2R-GsαS 
 
Unspecific binding, determined after addition of unlabelled compounds (5-100 µM FAM 
alone or in combination with other ligands) prior to the preincubation with [3H]UR-DE257 
(cf. subsection 5.2.2), yielded approx. 10–30% of the uninhibited total binding. However, 
kinetic experiments revealed a relatively high amount of residual binding after 90 min of 
radioligand dissociation, equalling to approx. 50% of the uninhibited total binding 
(cf. control, HIS and RAN in Fig. 5.3.4). This observation was in close agreement with 
the findings from previous studies, suggesting apparent insurmountable antagonism of 
[3H]UR-DE257, probably due to its slow kinetics (Erdmann, 2010). Nevertheless, inter-
pretation of these results was possible, as k2 values obtained in the presence of modula-
tors were always compared with control off-rates (in the absence of modulators) within 
the same experiment. This comparison helped also to avoid artefacts, resulting from the 
inter-experimental fluctuations of the radioligand dissociation rate. In some experiments, 
the value of uninhibited binding (residual binding at the time point 0 min of dissociation) 
deviated strongly from other data points. In such cases, unhibited binding was excluded 
and the maximal binding was set to the next data point (e.g. residual binding at 2 min), to 
avoid the analysis of data sets including outliers. 
The dissociation rate of [3H]UR-DE257 at the gpH2R-GsαS, measured after addition of 
5 µM FAM (approx. 100-fold Ki; cf. Table 4.3.3), was the same as in the presence of 
250 µM HIS (approx. 600 Kd, achieving saturation of the receptors; cf. Fig. 4.3.9). Thus, 
A B 
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a concentration of 5 µM was chosen as the minimal concentration of FAM (unlabelled 
competitor) for the estimation of the [3H]UR-DE257 control off-rate at the gpH2R-GsαS. 
As shown in Fig. 5.3.3 A, no change of the radioligand dissociation rate could be ob-
served also in the presence of 3 µM of the monovalent agonist 1 (500-fold Ki, cf. Table 
4.3.3). As expected for competitive binding, radioligand off-rates were not significantly 
different (k2 for FAM alone: 0.0103 ± 0.0010 min-1; k2 for FAM with compound 1: 0.0106 ± 
0.0008 min-1; P = 0.8394) and corresponded to 67 min and 66 min of the dissociation 
half-life time (t0.5 counted according to Eq. 5.1.2). 
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Fig. 5.3.3. Dissociation of [3H]UR-DE257 from gpH2R-GsαS after addition of 5 µM FAM in the ab-
sence (control) or presence of (A) 3 µM of monovalent agonist 1 and (B) 1 µM of bivalent agonist 
4. Results in both panels are means ± SEM of an experiment performed in duplicate, respectively. 
Linearization was performed as in Fig. 5.3.2. 
 
By contrast, significantly different off-rates values of the radioligand were obtained at 
1 µM (approx. 500-fold Ki; cf. Table 4.3.3) of the bivalent agonist 4 (k2 for FAM alone: 
0.0117 ± 0.0006 min-1; k2 for FAM with compound 4: 0.0156 ± 0.0006 min-1; P = 
0.00014), corresponding to 59 min and 45 min of half-life time of radioligand dissociation 
(Fig. 5.3.3 B). This confirmed the results obtained with [3H]TIO after addition of ligand 4 
(cf. Fig. 5.3.2 B). 
 
Fig. 5.3.4. Dissociation of [3H]UR-
DE257 from gpH2R-GsαS after 
addition of 5 µM FAM in the ab-
sence (control) or presence of 
different ligands. The values of 
residual binding are means ± SEM 
of an experiment performed in 
duplicate. Best fit with the one-
phase exponential decay. 
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As shown in Fig. 5.3.4, the radioligand dissociation, commenced by addition of 5 µM 
FAM, was mostly not affected in the presence of an excess of HIS and RAN, as ex-
pected for competitive binding. By contrast, 6 µM (16-fold Kb; Birnkammer et al., 2010) of 
the bivalent compound 11, which has a 20-membered linker, accelerated dissociation of 
[3H]UR-DE257 and replaced the radioligand more efficiently than the standard H2R 
ligands. 
 
Fig. 5.3.5. Dissociation of [3H]UR-
DE257 from gpH2R-GsαS after addi-
tion of 100 µM FAM in the absence 
(control) or presence of 6 µM of the 
bivalent compound 11. Data are 
means ± SEM of an experiment 
performed in duplicate. 
 
 
 
 
It is also noteworthy that concentration-dependent changes of the radioligand off-rate in 
the presence of two unlabelled ligands were previously reported at the muscarinic M2 
receptor (Kostenis et al., 1996). The dissociation of [3H]NMS, commenced by addition of 
the competitive antagonist atropine, was considerably slowed down by ring-substituted 
bispyridinium compounds (Fig. 5.3.6). 
 
Fig. 5.3.6. Dissociation of 0.2 nM [3H]NMS 
from porcine cardiac membranes, expressing 
M2 muscarinic receptors, in the presence of 
1 µM atropine and the indicated concentra-
tions of a ring-substituted bispyridinium com-
pound. The addition of atropine is indicated 
by an arrow (adopted from Kostenis et al., 
1996 with modifications). 
 
 
Dissociation kinetics of [3H]UR-DE257, performed with 100 µM FAM and 6 µM of 
the bivalent compound 11 (16-fold Kb; Birnkammer et al., 2010) was accelerated by 
up to 7 times, when compared with control (k2 for FAM alone: 0.0105 ± 0.0012 min-1; 
k2 for FAM with compound 11: 0.0753 ± 0.0128 min-1; P < 0.0001). The half-life time 
of radioligand dissociation was reduced from 66 min to only 9 min, respectively 
(Fig. 5.3.5). Similar results were obtained also for 5 µM of the bivalent ligand 9 with 
a 14-membered linker (data not shown). 
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Similarly, concentration-dependent changes of the radioligand off-rate were observed at 
the α2A-adrenoreceptor (Leppik et al., 1998; Kenakin, 2006). However, in the latter case, 
the dissociation rate constant of [3H]yohimbine, determined after addition of an excess of 
the α-adrenoreceptor antagonist phentolamine, was increased in the presence of amilo-
ride and its analogues (Fig. 5.3.7). Interestingly, amiloride also increased the dissociation 
rate of [3H]spiperone at the dopamine D2 receptor (Hoare and Strange, 1996). Further 
examples of GPCR ligands, showing such a non-competitive behaviour in kinetic binding 
studies, have been reviewed elsewhere (May et al., 2007). 
 
 
 
Fig. 5.3.7. The dissociation of 
[3H]yohimbine in the presence of 20 µM 
phentolamine (control) and the indi-
cated concentrations of the amiloride 
analogue EPA. Membranes expressing 
the α2A-adrenoreceptor were first pre-
equilibrated with the radioligand. Dis-
sociation started by addition of phentol-
amine and EPA (adopted from Leppik 
et al., 1998 with modifications). 
 
 
 
 
5.3.1.3 Kinetics of [3H]histamine dissociation from the hH4R 
 
The imidazole-type acylguanidines contain imidazolylpropylguanidine, a privileged struc-
ture with respect to histamine receptor binding. The ligands 3, 4, 9 and 11 are highly 
potent ligands also at the H4R (cf. subsection 4.3.4). As shown in Fig. 5.3.8 A, tritiated 
HIS revealed monophasic dissociation curves at the hH4R-GAIP+ Giα2 + Gβ1γ2, but the 
residual binding after 1.5 hour of radioligand dissociation was still relatively high and 
equalled to approx. 40% of the uninhibited total binding (N.B. similar to the dissociation 
of [3H]UR-DE257 at the gpH2R-GsαS). At the same time, unspecific binding (determined 
by the addition of unlabelled competitors prior to equilibration with [3H]HIS) equalled to 
only 4% of the uninhibited total binding. 
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Kinetic experiments at the hH4R-GAIP+ Giα2 + Gβ1γ2 revealed the rate constant of 
[3H]HIS dissociation of 0.0126 ± 0.0003 min-1 (95% CI of k2: 0.0118 to 0.0135; data 
from 5 independent experiments, performed in duplicate with 10 µM HIS and/or 
10-20 µM of the standard H3R and H4R antagonist THIO; cf. Fig. 5.3.8 B and Fig. 
5.3.9 A), corresponding to the half-life time of radioligand dissociation of 55 min 
(95% CI of t0.5: 51-59 min).  
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Fig. 5.3.8. Dissociation of [3H]HIS from the hH4R-GAIP+ Giα2 + Gβ1γ2 after addition of 10 µM HIS 
in the absence (control) or in the presence of 10 µM THIO (Ki of HIS: 8 nM, Ki of THIO: 60 nM; cf. 
Thurmond et al., 2008): (A) uncorrected data of the radioligand residual binding fitted to the equa-
tion of one-phase exponential decay, (B) the same data after correction for unspecific binding and 
linearization. Results are means ± SEM of an experiment performed in duplicate. 
 
In this context it is indispensable to mention that so far the only published results for ra-
dioligand kinetics at the H4R refer to [3H]UR-PI294, a novel H3R and H4R radioligand 
developed recently in our research group (cf. Fig. 1.2.6; Igel et al., 2009). 
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Fig. 5.3.9. Dissociation of [3H]HIS from the hH4R-GAIP+ Giα2 + Gβ1γ2: after addition of 20 µM THIO 
in the absence (control) or in the presence of either (A) 5 µM JNJ7777120 or (B) 30 µM of the 
bivalent 11 (for better solubility, 11 and control contained 1% DMSO). Results in both panels are 
means ± SEM of an experiment performed in duplicate, respectively. 
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As expected for an orthosteric ligand, 5 µM JNJ7777120 (Ki of approx. 4 nM; Thur-
mond et al., 2008) did not change [3H]HIS dissociation from the hH4R (Fig. 5.3.9 A). 
Contrary to that, 30 µM of the homobivalent ligand 11 with a 20-atom spacer (500-
fold Ki; cf. Fig. 4.3.21) induced the 1.7 times faster dissociation of the radioligand 
when compared with the control (k2 for THIO alone: 0.0108 ± 0.0007 min-1, 95% CI: 
0.0094 to 0.0123 min-1; k2 for THIO with compound 11: 0.0186 ± 0.0011 min-1, 95% 
CI: 0.0163 to 0.0210 min-1; P < 0.0001), resulting in the reduction of the half-life time 
of radioligand dissociation from 64 min to 37 min (Fig. 5.3.9 B). This finding was in 
line with the results obtained with [3H]UR-DE257 at gpH2R-GsαS after addition of the 
bivalent ligand 11 (cf. Fig. 5.3.5). 
 
5.3.1.4 Influence of bivalent ligands on the [3H]histamine off-rate at the hH4R 
 
As the kinetic experiments at the hH4R revealed monophasic dissociation curves for both 
mono- and bivalent ligands, it was possible to perform so called ”two-point kinetic” as-
says (cf. subsection 5.1.1 and Table 5.2.2). This method, apart from being time- and 
material-saving, enables closer inspection of the effect of modulator concentration on the 
radioligand dissociation rate (Kostenis and Mohr, 1996). 
 
Fig. 5.3.10. The effect of different 
mono- and bivalent ligands on [3H]HIS 
dissociation from the hH4R-GAIP+ 
Giα2 + Gβ1γ2 membranes. The linker 
lengths of the bivalent ligands 9 and 11 
are indicated in parentheses as num-
bers of C-atoms. The acylguanidine 3 
was tested as the monovalent counter-
part. The results are means ± SEM of 
an experiment performed for each li-
gand in triplicate. The radioligand off-
rate under control conditions was set to 
100%. 
 
As shown in Fig. 5.3.10, two-point kinetic experiments confirmed that the selective 
H4R ligand JNJ7777120 up to a concentration of 100 µM had no effect on the rate of 
[3H]HIS dissociation from Sf9 cell membranes expressing the hH4R-GAIP+ 
Giα2 + Gβ1γ2, as expected for the competitive mode of binding. Contrary to that, the 
bivalent NG-acylated guanidines 9 and 11 induced significantly faster kinetics of the 
radioligand dissociation with EC50,diss values of approx. 10–20 µM, suggesting allos-
teric interactions with the hH4R. However, their monovalent counterpart 3 did not 
exert any influence on the radioligand off-rate up to the concentration of 300 µM, 
contradicting rather the interaction with the allosteric binding site at the hH4R. 
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Except for allosteric ligands possessing efficacy and true allosteric/orthosteric ligands, 
the effects of allosteric interactions could be observed only in the presence of an orthos-
teric ligand (May et al., 2007; Smith and Milligan, 2010). Bivalent compounds could be 
considered as dualsteric ligands with one pharmacophore addressing the orthosteric and 
the other interacting with the allosteric binding site (Valant et al., 2008). In that case, a 
mixture of monovalent orthosters and allosters should exhibit similar behaviour (in terms 
of allosterism) as would do a pure (hetero)bivalent ligand. In theory, non-linked pharma-
cophores should even more easily dock to their orthosteric and (putative) allosteric bind-
ing sites than two covalently bound pharmacophores. Indeed such complementation 
binding studies with a mixture of monovalent ligands were done previously at the human 
M2 muscarinic receptor (Valant et al., 2008). However, all pharmacophoric moieties of 
our bivalent NG-acylated guanidines, being bioisosters, possess very similar structures. 
This means that the same compound might function concurrently as an orthosteric as 
well as an allosteric ligand. Therefore, complementation experiments could be actually 
performed, using an excess of a monovalent acylguanidine only. In theory, accelerated 
dissociation in the presence of a monovalent ligand 3 should be expected, as in the case 
of the bivalent compounds 9 and 11. Nevertheless, a very weak effect of compound 3 
showed that the bivalent ligands are not simply “doubled” pharmacophores, but rather 
new chemical entities with different pharmacological properties. Another interpretational 
difficulty resulted from the similar kinetic effects, observed at both the H2R and the H4R 
(cf. Fig. 5.3.5 and 5.3.7 B, respectively). Namely, for the putative allosteric binding sites, 
a higher subtype specificity of ligand-receptor interactions should be expected (May et 
al., 2007). 
 
5.3.1.5 Haemolytic properties of bivalent acylguanidines 
 
Significant acceleration of radioligand off-rates, observed at both the H2R and the H4R in 
the presence of the bivalent NG-acylated guanines, necessarily indicated some confor-
mational changes of those receptors. However, aside from the apparent allosterism, this 
kinetic phenomenon could be simply caused by the toxicity of the bivalent ligands. Actu-
ally, polar character of both pharmacophoric groups and a hydrophobic alkanediyl linker 
(cf. Fig. 1.2.4) might be responsible for strong tensidic properties of these compounds. 
When used at high concentrations, such amphiphilic ligands could exert a range of un-
specific effects (from the minor alterations of the receptor protein conformation to the 
significant destabilization of the cell membrane – haemolysis), only imitating an allosteric 
interaction. Noteworthy, 10 µM of the bivalent ligand 9 with a 14-membered linker 
caused 5% lysis of the exposed erythrocytes (increasing to about 45% at 100 µM), 
whereas the bivalent compounds 11 and 13 with 20-membered linkers induced approx. 
25% haemolysis at concentrations as low as 10 µM. At the same time, four monovalent 
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and three bivalent ligands with octamethylene spacers possessed negligible haemolytic 
properties (0–10% haemolysis at 100 µM; Mr. Tobias Birnkammer and Ms. Melanie 
Kaske, Institute of Pharmacy, University of Regensburg, personal communication). 
 
5.3.1.6 Allosteric ternary complex model 
 
As shown schematically in Fig. 5.3.11 A, the addition of orthosteric competitors to radio-
ligand-receptor complexes should not change the value of k2 (Valant et al., 2008). There-
fore, any alteration of the radioligand off-rate in the presence of other unlabelled ligands 
(modulators) is unequivocally indicative of the adoption of another conformation by re-
ceptors. This might be, for example, an indication of the existence of different ligand-
specific conformations of GPCRs (functional selectivity, cf. Rajagopal et al., 2010). How-
ever, other authors hold the view that the radioligand and the unlabelled modulators 
have to bind simultaneously to the same receptor molecule, inevitably utilizing topo-
graphically distinct, but conformationally linked, recognition sites (Kostenis and Mohr, 
1996; Kenakin, 2006; May et al., 2007). According to this hypothesis, the orthosteric 
binding site can be occupied either by the radioligand or by another orthosteric competi-
tor (e.g. the endogenous ligand), whereas the allosteric binding site is interacting with the 
modulators (Fig. 5.3.11 B). The formed allosteric ternary complexes (orthoster-receptor-
alloster) are characterized by altered values of k2: either increased, as shown for the α2A-
adrenoreceptor (Kenakin, 2006), or decreased with a prolonged half-life time of radioli-
gand dissociation, which is valid e.g. for muscarinic receptors (Valant et al., 2008). 
 
Fig. 5.3.11. Radioligand dissociation commenced by the addition of an orthosteric competitor “C” 
in the presence of either (A) endogenous (orthosteric) ligand “E” or (B) an allosteric modulator “A”. 
N.B. the hypothesis of the existence of ligand-specific receptor conformations (functional 
selectivity) at the H2R and the H4R will be discussed in chapter 6.  
A 
B 
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5.3.2 Association kinetics at the hH4R 
 
5.3.2.1 [3H]Histamine association limited by a slowly dissociating competitor 
 
Kinetics of unlabelled compounds might be roughly estimated by following the procedure 
proposed by Hulme and Birdsall (Hulme, 1992). According to this protocol, after incuba-
tion with a cold competitor (at a concentration saturating approx. 90% of receptors) and 
subsequent centrifugation, receptors were labeled with the radioligand, used in an 
excess (10-fold Kd). The measured association time-course was then compared with that 
of the untreated receptors (control) and shown in Fig. 5.3.12. Given, that an unlabelled 
ligand exerts slower kinetics than a radioligand, the apparent association rate of a radio-
ligand is retarded in the presence of a slower ligand (Fig. 5.3.13). 
 
 
Fig. 5.3.12. Association kinetics of 
100 nM [3H]HIS at the hH4R-GAIP + 
Giα2 + Gβ1γ2. Membranes were not 
pretreated (control) or pretreated for 
1 hour at 4° C with 150 nM of com-
pound 11 (cf. IC50 value of 116 nM; 
Fig. 4.3.22 A) and washed. Results 
are means ± SEM of an experiment 
performed for each curve in duplicate. 
 
 
 
Fig. 5.3.13. Interaction of a fast radioligand and a slow biva-
lent compound with a single receptor binding site. The asso-
ciation (black arrow) of a highly concentrated radioligand 
(10 Kd) is limited only by dissociation (blue arrow) of a slowly 
dissociating component. 
 
 
 
 
 
At the hH4R membranes, pretreated with the bivalent 11 (containing a 20-atom link-
er), the apparent rate of [3H]HIS association was slower than at the untreated mem-
branes (Fig. 5.3.12 and 5.3.13), perhaps due to the limiting slow dissociation rate of 
ligand 11. 
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5.3.2.2 Kinetics of [3H]histamine association 
 
Association of a radioligand is a reversible kinetic process, always accompanied by its 
dissociation from receptors. Therefore, performing this kind of kinetic experiments, it is 
possible to obtain both on- and off-rate constants for the used radioligand (cf. Eq. 1.3.5). 
As mentioned in subsection 5.1.2, association time-course could be also used to validate 
the test system by verifying if binding to receptors follows the law of mass action (cf. Mo-
tulsky and Christopoulos, 2004). The experiments were conducted on the Sf9 mem-
branes expressing hH4R-GAIP + Giα2 + Gβ1γ2 with 10 and 30 nM of [3H]HIS as the radioli-
gand (cf. Kd of 9.8 ± 0.9 nM at the hH4R + Giα2 + Gβ1γ2 + GAIP; cf. Schnell et al., 2011), 
as described under Material and methods (subsection 5.2.3). 
Table 5.3.1. Comparison of the k2, t0.5 and Kd values (cf. Eq. 1.3.1–5 and 5.1.1–2) determined for 
[3H]HIS on Sf9 cell membranes expressing hH4Rs. 
Parameters Association kinetics best fit (95% CI)a 
Other methods 
best fit (95% CI) 
k1 
7.6·106 M-1·min-1  
(6.6–8.7·106 M-1·min-1)  
k2 0.018 min-1 (0.009–0.027 min-1) 0.013 min-1 (0.012–0.014 min-1)b 
t0.5 38 min (25–76 min) 55 min (51–59 min)b 
Kd 2.4 nM (1.2–3.6 nM) 9.8 nM (8.0–11.6 nM)c 
Data were determined either by association (2-3 experiments at the hH4R-GAIP + Giα2 + Gβ1γ2; cf. 
Fig. 5.3.14)a or dissociation (5 experiments at the hH4R-GAIP + Giα2 + Gβ1γ2; cf. Fig. 5.3.8 B and 
5.3.9 A)b kinetics or by saturation binding (3 experiments at the hH4R + Giα2 + Gβ1γ2 + GAIP; cf. 
Schnell et al., 2011)c. 
 
 
 
Fig. 5.3.14. Association kinetics of 
[3H]HIS on Sf9 cell membranes ex-
pressing hH4R-GAIP + Giα2 + Gβ1γ2. 
Data are mean values ± SEM of 
two (10 nM radioligand) or three 
(30 nM radioligand) independent 
experiments performed in tripli-
cate. Best fit with the mass action 
model. 
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5.3.2.3 Kinetics of competitive binding 
 
The on-rate and off-rate constants (k3, k4) of cold ligands might be determined by mea-
surement of radioligand association kinetics in the presence of unlabelled compounds. 
Kinetics of competitive binding with 30 nM [3H]HIS were performed at the hH4R-GAIP + 
Giα2 + Gβ1γ2 after addition of 50–500 nM of the bivalent ligand 11 (Ki of 61 ± 4 nM; cf. Fig. 
4.3.22 A). 
Table 5.3.2. Comparison of the k4 and Ki values (cf. Eq. 5.1.3–6) of the bivalent compound 11, 
determined with [3H]HIS at the hH4R-GAIP + Giα2 + Gβ1γ2 coexpressed in Sf9 cells. 
Parameters Association kinetics best fit (95% CI)a 
Other methods 
best fit (95% CI) 
k3 5.3·106 M-1·min-1 (3.7–7.1·106 M-1·min-1) 
k4 0.024 min-1 (0.019–0.029 min-1) concentration-dependentb 
t0.5 29 min (24–36 min) 
Ki 4.5 nM (2.7–7.8 nM) 61 nM (47–74 nM)c 
 
Data determined either by association (cf. Fig. 5.3.15)a or “two-point” dissociation (cf. Fig. 5.3.10)b 
kinetics or by competition binding (4 experiments; cf. Fig. 4.3.22 A)c. 
 
 
Fig. 5.3.15. Association kinetics of 
30 nM [3H]HIS at the hH4R-GAIP + 
Giα2 + Gβ1γ2 in presence of the indi-
cated concentrations of the bivalent 
compound 11. Data are mean values 
± SEM of one (50 and 500 nM of 
compound 11) or two (150 nM of 
compound 11) independent ex-
periments performed in triplicate. 
The dashed lines correspond to the 
best fit with the mass action model 
for kinetics of competitive binding. 
 
 
As shown in Table 5.3.1, the k2 and Kd constants of the tracer ligand calculated from 
association kinetics (Fig. 5.3.14) were in the same range as the values of k2 from 
dissociation time-course and Kd from saturation binding of [3H]HIS (Kd of 9.8 ± 
0.9 nM; cf. Schnell et al., 2011), supporting competitive nature of HIS binding at the 
hH4R. 
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As shown in Fig. 5.3.15, fitting of the data points according to the mass action model 
for kinetics of competitive binding has not turned out satisfactory. Moreover, the 
comparison of the rate constants from Table 5.3.1 and 5.3.2 revealed that the biva-
lent ligand 11 associates more slowly, but dissociates more rapidly than [3H]HIS, 
contrary to previous findings (cf. Fig. 5.3.12 and 5.3.13). Also the Ki value of com-
pound 11, calculated from kinetic rate constants according to Eq. 5.1.6, was approx. 
10 times smaller than determined by competition binding at equilibrium. Thus, these 
findings did not support the competitive binding of the bivalent 11 at the hH4R. In-
deed, similar to the results from dissociation kinetics (cf. subsection 5.3.1), they 
might indicate rather an additional process following the binding to receptors (Motul-
sky and Christopoulos, 2004). 
 
 
Fig. 5.3.16. Association kinetics of 
30 nM [3H]HIS in the presence of 
150 nM of the bivalent ligand 11 at 
the hH4R-GAIP + Giα2 + Gβ1γ2. Data 
are mean values ± SEM of two inde-
pendent experiments performed in 
triplicate. 
 
 
 
 
The kinetics of [3H]HIS association in the presence of the bivalent compound 11 (Fig. 
5.3.15–17) indicated an additional process that could not be explained by the simple 
model of competitive interaction with a single class of binding sites. As described in sub-
section 5.2.3, the experiments were carried out in reverse time order (first radioligand 
was added to the samples with longer association times and then to those with shorter 
association times). Thus, to find out if the reason for these peculiarities could be the ad-
sorption of membranes to polypropylene test tubes, an additional experiment was per-
formed with siliconized tubes (series C in Fig. 5.3.17). However, neither siliconization nor 
standard experimental conditions (usage of BSA and initial shaking) could solve the 
problem. 
 
Fig. 5.3.17. Association kinetics of 
30 nM [3H]HIS in the presence of 
150 nM of the bivalent ligand 11 at 
the hH4R-GAIP + Giα2 + Gβ1γ2. 
Data are mean values ± SEM of 
an experiment performed for each 
curve in triplicate. 
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5.4 Summary and conclusion 
 
As the tested monovalent and short bivalent H2R ligands revealed Hill coefficients 
smaller than one after 90 min of incubation with [3H]TIO (cf. Table 4.3.3), one could as-
sume a negative cooperativity (allosterism) or the existence of a heterogenic population 
of the ligand binding sites at H2R-GsαS fusion proteins (Repke and Liebmann, 1987). 
Contrary to that the higher homologue 11, a bivalent acylguanidine with a 20-membered 
linker, revealed steep competition curves (Hill slopes > 1) at both the gpH2R-GsαS (cf. Fig. 
4.3.20 A) and the hH4R-GAIP + Giα2 + Gβ1γ2 (cf. Fig. 4.3.21), indicating apparent positive 
cooperativity. However, after an extended incubation period, the slope of ligand 11 ap-
proximated unity (cf. Fig. 4.3.22 B). The latter might result from the premature termina-
tion of incubation, as time required for equilibration with the radioligand would be in-
creased in the presence of both slowly and rapidly dissociating competitors (Hulme, 
1992). Hence, in order to confirm or reject the hypothesis of allosteric interactions and to 
explain the peculiarities of the bivalent H2R ligands, measurements of radioligand kinet-
ics were performed:  
1) The measurement of [3H]TIO dissociation at the gpH2R-GsαS revealed the radioli-
gand off-rate (k2) of 0.076 ± 0.003 min-1, which was in good agreement with data 
from the literature (Foreman et al., 1985). No alteration of the [3H]TIO dissociation 
rate constant (k2) was found, when FAM was added in the presence of HIS 
(Fig. 5.3.2 A), indicating a competitive interaction with the orthosteric binding site 
(Valant et al., 2008). However, a small but still significant increase in k2 was 
shown in the presence of the bivalent compound 4 (Fig. 5.3.2 B), suggesting a 
weak allosteric interaction at the gpH2R (Kostenis et al., 1996). 
2) Dissociation time-course of [3H]UR-DE257 at the gpH2R-GsαS was accelerated by 
up to 7 times in the presence of the bivalent ligand 11 (Fig. 5.3.5), whereas no 
change of k2 was found for the standard ligands HIS and RAN (Fig. 5.3.4). 
3) The dissociation rate constant of [3H]HIS at the hH4R-GAIP+ Giα2 + Gβ1γ2 (k2 of 
0.0126 ± 0.0003 min-1; half-life time of 55 min) was not altered by THIO and 
JNJ7777120 (Fig. 5.3.8 and 5.3.9 A, respectively), confirming the competitive 
binding behaviour. In contrast to these findings, the bivalent ligand 11 induced 
the 1.7 times faster dissociation of the radioligand (Fig. 5.3.9 B), unequivocally 
suggesting a conformational change of the hH4R. 
4) Similar results were obtained at the hH4R-GAIP+ Giα2 + Gβ1γ2 in “two-point kinetic” 
experiments, where the homobivalent ligands 9 and 11 increased k2 with EC50,diss 
values of approx. 10–20 µM (Fig. 5.3.10). However, the chemical nature of these 
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alterations of receptor conformation still remains unknown, as both ligands were 
able to induce haemolysis, perhaps due to their strong amphiphilic character 
(Birnkammer and Kaske, personal communications). Unexpectedly, in view of pu-
tative allosterism, the monovalent counterpart 3 did not change the radioligand 
off-rate up to 300 µM. 
5) Association kinetics of [3H]HIS at the hH4R-GAIP+ Giα2 + Gβ1γ2 revealed the k2 
value of 0.018 ± 0.005 min-1 and Kd of 2.4 ± 0.6 nM (Table 5.3.1 and Fig. 5.3.14), 
being in the same range as the values of k2 from dissociation time-course and Kd 
from saturation binding (Schnell et al., 2011), thus supporting competitive nature 
of HIS binding at the hH4R. 
6) As shown in Fig. 5.3.12, the bivalent compound 11 influenced [3H]HIS association 
in a manner similar to slowly dissociating competitors (Motulsky and Mahan, 
1984). However, the course of association curves in the presence of the bivalent 
compound 11 betrayed an additional process after ligand binding (Fig. 5.3.15), as 
the data could not be fitted by the simple mass action model (Motulsky and Chris-
topoulos, 2004). The most probable explanations are either allosteric interactions 
or tensidic properties of ligand 11, as the adsorption of membrane to the test 
tubes has to be excluded (Fig. 5.3.17). 
 
The homobivalent acylguanidines 9 and 11 with pharmacophoric moieties, being 
derived from HIS by bioisosteric replacement, altered the dissociation of orthosteric 
radioligands at both the gpH2R-GsαS ([3H]UR-DE257; Fig. 5.3.5) and the hH4R-
GAIP+ Giα2 + Gβ1γ2 ([3H]HIS; Fig. 5.3.9 B and 5.3.10) membranes. These findings 
contradicted the simple model of competitive interaction with a single class of bind-
ing sites (Kostenis and Mohr, 1996; Motulsky and Christopoulos, 2004). If artefacts 
could be excluded (e.g. unspecific changes of receptor conformation due to am-
phiphilic character of bivalent ligands), the results might be interpreted as a hint to 
allosterism at both the H2R and the H4R. Provided that the ortho- and the allosteric 
binding sites were occupied simultaneously by two pharmacophoric moieties, our 
bivalent compounds might act as true dualsteric ligands (Valant et al., 2008; An-
tony et al., 2009). However, there was no change of the radioligand off-rate in the 
presence of an excess of the monovalent acylguanidine (Fig. 5.3.10). This sug-
gests that, apart from the pharmacophoric moiety, also the length of the hydropho-
bic alkanediyl linker may play an important role in ligand-receptor interactions. 
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6 Investigations on histamine H2 receptor internaliza-
tion by confocal microscopy 
 
6.1 Introduction 
 
Bivalent NG-acylguanidines are highly potent H2R ligands not only on the isolated guinea-
pig right atrium, but also in steady-state GTPase assays on hH2R- and gpH2R-GsS fu-
sion proteins expressed in Sf9 cells (Kraus, 2007; Birnkammer et al., 2010). On the other 
hand these compounds reveal unusual binding behaviour (e.g. apparent positive coop-
erativity, equilibration period up to 3 hours, alteration of the radioligand off-rate; cf. chap-
ters 4 and 5) and still very little is known about the intracellular fate of H2Rs after expo-
sure to the bivalent ligands. Therefore, in addition to radioligand binding studies (kinetic 
and at equilibrium), the influence of mono- and bivalent ligands on H2R endocytosis was 
investigated.  
 
6.1.1 Detection of hH2R internalization by confocal microscopy 
 
6.1.1.1 Endocytosis of fluorescently labelled H2Rs 
 
Confocal microscopy offers the unique opportunity to examine the internalization of re-
ceptors in living cells in response to various ligands. However, this technique requires 
the fluorescent labelling of the receptor of interest, e.g. by tagging it with fluorescent pro-
teins (subsection 1.3.2). This implies the genetic manipulation of the receptor resulting in 
an artificial system. Nonetheless, as shown by Osawa and colleagues, the H2R 
C-terminally tagged with GFPs could be functionally expressed in CHO cells, revealing 
the same affinity towards tritiated TIO as the wild-type receptors (Osawa et al., 2005). 
Moreover, the same study demonstrated the internalization of the H2R-GFP already after 
30 min of stimulation with HIS, whereas high concentrations of CIM and FAM induced 
the recycling of the internalized receptors. Furthermore, colocalization studies revealed 
that the fluorescently labelled receptors were internalized into early endosomes (but not 
lysosomes) as shown in Fig. 6.1.1. 
Fig. 6.1.1. Colocalization studies in 
living cells revealed that H2Rs 
(green) are translocated into early 
endosomes (stained with the red 
marker EEA-1) upon stimulation with 
100 μM HIS (adopted from Osawa et 
al., 2005 with modifications). 
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6.1.1.2 Towards the detection of functional selectivity 
 
A previous study on transfected CHO cells suggests two distinct pathways for the down-
regulation of the H2R. Apart from the well known G-protein-dependent way, HIS concen-
tration-dependently induced the down-regulation of the H2R in a G-protein-independent 
manner (Smit et al., 1996 a). Hence, in the light of the recent discovery of the first H4R 
biased ligand, the antagonist JNJ7777120 (with respect to G-protein stimulation) induc-
ing the recruitment of β-arrestins in a G-protein-independent manner (Rosethorne and 
Charlton, 2011; Seifert et al., 2011), the question of the existence of biased ligands at 
the hH2R was raised. A precondition for biased signalling is the existence of different 
ligand-induced GPCR conformations (cf. subsection 1.1.3.2). In the presence of biased 
ligands, distinct prevailing receptor conformations are assumed to be stabilized, trigger-
ing the coupling of receptors to different protein effectors (Kenakin and Miller, 2010). 
Indeed, Xie and colleagues found that new H2R agonists are able to stabilize distinct 
ligand-specific H2R conformations in steady-state GTPase assays both on hH2R-GsS 
and gpH2R-GsS fusion proteins expressed in Sf9 cells. IMP- and ARP-derived monova-
lent acylguanidines stabilized the ternary complex differently than the corresponding 
guanidines (Xie et al., 2006). Moreover, some of the tested agonists revealed no GTPγS-
dependent shift, indicating rather antagonistic properties (cf. Fig. 4.3.7). 
In this context, it should be stressed that a very similar behaviour was observed in case 
of bivalent H2R agonists at the gpH2R-GsS. As shown in chapter 4, the binding curves of 
these ligands were also found to be insensitive against guanine nucleotides, which is an 
attribute of antagonists. Interestingly, in GTPase assays on the hH2R-GsS the bivalent 
compounds, containing 20-membered spacers between the carbonyl groups, turned out 
to be neutral antagonists with submicromolar activity (Kb values: compound 11: 371 nM, 
compound 12: 1679 nM, compound 13: 770 nM; cf. Birnkammer et al., 2010). Addition-
ally, the bivalent H2R agonists 4, 9 and 11 induced detectable changes of the radioligand 
dissociation rate constant at gpH2R-GsS fusion proteins (cf. chapter 5). 
Motivated by the aforementioned results, the present investigation was focused on the 
visualization of receptor internalization in response to different H2R ligands from our 
laboratory, to learn more about observed differences between monovalent and bivalent 
acylguanidines compared to the agonist histamine (cf. chapter 4 and 5). Experiments 
were performed on the CHO cells, expressing H2Rs tagged with the monomeric far-red 
fluorescent protein mKate2, because of the significantly higher signal to noise ratio when 
compared with GFP (Shcherbo et al., 2009). 
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6.2 Materials and methods 
 
6.2.1 Materials 
 
The pcDNA3.0-Neo-FLAG-hH2R-HIS6 plasmid was kindly provided by Prof. Dr. Roland 
Seifert (Institute of Pharmacology, Medical School of Hannover, Germany). The 
pcDNA3.1(+)Neo-hH2R plasmid and the hH2R sense(Kozak) primer were synthesized as 
described previously (Mosandl, 2009). The antisense (reverse) primer hH2Rnostop-rev 
was purchased from Eurofins (Ebersberg, Germany). The pmKate2-N vector was from 
Evrogen (Moscow, Russia). Phusion DNA polymerase and the corresponding HF buffer 
were from Finnzymes (Espoo, Finland). Deoxynucleotide solution mix (dNTPs) was from 
New England Biolabs (Ipswich, MA, USA) and the thermal cycler for PCR (Mastercycler) 
was from Eppendorf (Hamburg, Germany). HindIII, NheI, XhoI, 6x Loading Dye, 
10x Tango buffer and MassRuler DNA ladder mix were purchased from MBI Fermentas 
(St. Leon-Rot, Germany). ApaI and 10x BSA (0.1%) solution were from Amersham 
Pharmacia Biotech (Piscataway, NJ, USA). 1kb DNA ladder was from New England Bio-
labs, whereas PeqGOLD DNA ladder mix as well as gel chambers of the PerfectBlue 
Mini S gel system and agarose were from Peqlab (Erlangen, Germany). Ethidium bro-
mide solution was obtained from Janssen Chimica (Beerse, Belgium). Tris base was 
from USB (Cleveland, OH, USA). Glacial acetic acid and EDTA (obtained as Titriplex III) 
were from Merck (Darmstadt, Germany). T4 DNA ligase and buffer for T4 DNA ligase 
(with 10 mM ATP) were from New England Biolabs. Kanamycin was from Sigma-Aldrich 
(Steinheim, Germany). QIAquick gel extraction, QIAprep spin miniprep and QIAGEN 
plasmid maxi kits were from QIAGEN (Hilden, Germany). 
U-87 MG Katushka cells clone 3 (Kühnle, 2010) was a generous gift from Dr. Matthias 
Kühnle (Institute of Pharmacy, University of Regensburg). Cary Eclipse spectrofluorime-
ter was from Varian Inc. (Mulgrave, Victoria, Australia). CHO cells were from the DSMZ 
(Deutsche Sammlung für Mikroorganismen und Zellkulturen, Braunschweig, Germany). 
FuGENE HD transfection reagent was from Roche (Indianapolis, IN, USA). EMEM and 
Ham’s F12 nutrient mixtures were purchased from Sigma-Aldrich. FCS and geneticin 
(G418) were from Biochrom (Berlin, Germany). Trypsin-EDTA (10x) was from PAA Labo-
ratories (Pasching, Austria). The 8-well μ-slide chambers were from Ibidi (Martinsried, 
Germany). Leibovitz's L-15 medium without phenol red was from Invitrogen (Karlsruhe, 
Germany) and LysoTracker Green DND-26 was from Invitrogen (Molecular Probes; 
Eugene, OR, USA). The synthesis of the mono- and bivalent H2R ligands (Fig. 1.2.4) 
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was described before (Kraus et al., 2009). UR-DE74 was synthesized as described 
elsewhere (Erdmann, 2010). HIS was from Acros Organics (Geel, Belgium). FAM, RAN 
and concanavalin A type IV were from Sigma (St. Louis, MO, USA). Microscopic images 
were acquired with an inverted Carl Zeiss Axiovert 200M confocal laser-scanning micro-
scope, equipped with a LSM510 scanning unit and the Zeiss Meta system. 
 
6.2.2 Construction of the hH2R-pmKate2-N plasmid 
 
The human H2R gene was in the pcDNA3.0-Neo-FLAG-hH2R-HIS6 plasmid, flanked with 
the sequences of a signal peptide and a FLAG epitope at the N-terminus and a hexahis-
tidine tag at the C-terminus as shown in Fig. 6.2.1 (Schneider, 2005; Mosandl, 2009). In 
order to restore the native sequence of the receptor, the hH2R cDNA was subcloned into 
the pmKate2-N vector (Fig. 6.2.2). The removal of a stop codon at the end of the hH2R 
cDNA enabled the transcription of the hH2R-mKate2 fusion protein. 
 
Fig. 6.2.1. Fragment of the pcDNA3.0-Neo-FLAG-hH2R-HIS6 plasmid encoding the hH2R. The 
annealing regions of the primers used for PCR are indicated by the red arrows. 
 
 
 
 
Fig. 6.2.2. Schematic represen-
tation of the pmKate2-N vector. 
The hH2R cDNA was subcloned 
into the multiple cloning site 
(MCS), upstream of the mKate-
2 sequence. 
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6.2.2.1 PCR 
 
The sequence of the hH2R gene was amplified by PCR from the pcDNA3.0-Neo-FLAG-
hH2R-HIS6 plasmid template (Schneider, 2005; Mosandl, 2009). A 32-nucleotide forward 
primer contained: an overhang (lower case letters), a HindIII recognition site (AAGCTT) 
and a triplet ATT in front of a start codon ATG. As the first base downstream of the start 
codon is G, a Kozak consensus translation initiation site for an improved protein expres-
sion level in mammalian cells could be created (G/A NN ATG G, where N stands for any 
DNA base). A reverse primer was composed of 30 nucleotides, including a short over-
hang and an ApaI recognition site (GGGCCC), followed by an additional base G. This 
was inserted to avoid a shift of the open reading frame in the sequence of the red fluo-
rescent protein (mKate2). As the H2R (approx. 1100 bp) and mKate2 (approx. 700 bp) 
should be expressed as a fusion protein, the stop codon TAA had to be removed from 
the receptor sequence (the triplet TTA was missing in the reverse primer). 
Sense (forward) primer – hH2Rsense(Kozak): 
5’-gc.gcg.AAG.CTT.ATT.ATG.GCA.CCC.AAT.GGC.ACA-3’ 
Antisense (reverse) primer – hH2Rnostop-rev: 
5’-ata.taG.GGC.CCG.CCT.GTC.TGT.GGC.TCC.CTG-3’ 
PCR amplification was performed in a thermal cycler in a final volume of 50 μL, contain-
ing: 1 μL of 5 ng/μL plasmid template solution, 2.5 μL of each primer (10 μM), 10 μL of 
the 5-fold HF buffer, 1 μL of 10 mM dNTP mix, 0.5 μL of 2 U/μL Phusion DNA poly-
merase and Millipore water, according to the following conditions (respecting the Finn-
zymes guidelines):  
(1) initial denaturation: 98 °C, 30 s  
(2) denaturation: 98 °C, 10 s  
(3) annealing: 68 °C (65 + 3 °C), 30 s  
(4) extension: 72 °C, 25 s  
(5) steps (2) to (4) were repeated 30 times  
(6) final extension: 72 °C, 10 min 
(7) hold: 4 °C  
To determinine the annealing temperature for PCR, the on-line Tm calculator from the 
website of Finnzymes was used: http://www.finnzymes.fi/tm_determination.html. The 
calculated Tm values were 65 °C and 69 °C for the overlapping sequences of hH2R-rev 
and hH2Rsense(Kozak), respectively. According to the DNA polymerase manufacturer’s 
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instruction, for primers longer than 20 bases, annealing should be carried at a Tm + 3 °C 
of the lower Tm primer. Analytic agarose gel electrophoresis (150 V, 30 min) revealed the 
proper length of the PCR product, corresponding to the hH2R (Fig. 6.2.3). 
 
 
 
Fig. 6.2.3. Agarose gel electro-
phoresis of the PCR product (P). 
Uncut plasmid (T). For reference the 
peqGOLD DNA ladder mix marker 
(M) was used.  
 
 
 
 
 
6.2.2.2 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was performed as described before by Dr. Johannes 
Mosandl (Mosandl, 2009) with some modifications: 100 mL of the 50-fold concentrated 
TAE buffer were prepared by dissolving 24.2 g of tris base, 5.7 mL of glacial acetic acid 
and 10 mL of 0.5 M EDTA (pH 8.0) in Millipore water (Mülhardt, 2009). 1x TAE buffer 
was prepared by dilution of the concentrated buffer with Millipore water. For the prepara-
tion of the 1% agarose gel, 0.5 g of agarose were dissolved in 50 mL of 1x TAE buffer 
under heating (approx. 200 °C) and continuous stirring. The obtained solution was 
cooled to approx. 60 °C and 2 μL of 10 mg/mL ethidium bromide solution were added. 
The warm mixture was poured into the gel chamber and supplied with a comb to create 
pockets of an appropriate size for the application of the DNA samples. After gel solidifi-
cation, the comb was removed with caution and the chamber was filled with the 1x TAE 
buffer. Then 20 μL of each DNA sample (the PCR product and the template plasmid) 
were mixed with 4 μL of 6x loading dye solution. The stained DNA samples and 6 μL of 
the ready-to-use peqGOLD DNA ladder mix (for reference) were pipetted to separate 
pockets of the gel. Finally the voltage (150 V) was supplied and the gel was running for 
approx. 30 min. The separated DNA bands were visualized by transillumination at 
254 nm while using the Quantity One software (Gel Doc 2000; Bio-Rad Laboratories, 
Munich, Germany). 
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6.2.2.3 Double digestion 
 
Double digestion of the PCR product (the H2R) and the pmKate2-N vector (400 ng/μL) 
was performed in a final volume of 50 μL under following conditions: 28 μL of each DNA 
sample were supplied with 5 μL of 10x Tango buffer, 5 μL of 10x BSA solution, 4 μL of 
10 U/μL HindIII (a 2-fold excess) and 8 μL of 10 U/μL ApaI (a 4-fold excess). The 
amounts of restriction enzymes for preparative digestion were dictated by lower enzy-
matic activity in 1x Tango buffer. The samples were thoroughly mixed, shortly centri-
fuged and incubated for 2 hours at 37 °C. The addition of a calf intestinal phosphorylase 
(for protection of the digested plasmid against a possible self-ligation) was omitted and 
agarose gel electrophoresis was performed as described above (with an adjusted pocket 
size). The illumination of the gel revealed the expected lengths of the digested HindIII-
hH2R-ApaI (1100 bp) and the pmKate2-N vector (4700 bp) as shown in Fig. 6.2.4. 
 
 
 
Fig. 6.2.4. Analysis of the di-
gested DNA fragments after aga-
rose gel electrophoresis: the 
PCR product (P) and the lin-
earized pmKate2-N vector (V). 
For reference the peqGOLD DNA 
ladder mix marker (M) was used. 
 
 
 
 
The gel fragments containing the HindIII-hH2R-ApaI DNA and the pmKate2-N vector 
were quickly excised from the gel under UV light control (254 nm) and weighted. DNA 
was extracted using the QIAquick gel extraction kit and a microcentrifuge. The samples 
were eluted by addition of 20 μl of buffer EB (10 mM tris-HCl, pH 8.5) and DNA concen-
tration was measured by UV spectroscopy. 
 
6.2.2.4 Ligation 
 
Ligation of the digested DNA fragments was performed in a thermal cycler as follows: 
50 ng of the pmKate2-N vector, 59 ng of HindIII-hH2R-ApaI (the insert in a 5-fold excess 
over the vector regarding to molar concentrations) and 2 μL of the 10x buffer for T4 DNA 
ligase (with 10 mM ATP) were diluted with Millipore water up to 19 μL, thoroughly mixed 
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and shortly centrifuged. After an incubation period of 5 min at 45 °C, 1 μL of T4 DNA 
ligase (400 U/μL) was added. The sample was thoroughly mixed, shortly centrifuged and 
incubated at 15 °C overnight (16 hours), before the mixture was heated up to 65 °C for 
10 min in order to inactivate the enzyme and stored at -20 °C.  
 
6.2.3 Transformation of bacteria and preparation of the plasmid 
 
6.2.3.1 Transformation of bacteria 
 
LB and SOC media, selective agar plates and competent bacteria E. coli (TOP10 strain) 
were prepared as described before (Mosandl, 2009). A 1.5 mL reaction vessel with 
100 μL of competent bacteria (stored at -80 °C) was thawed on ice. After 10 min, 5 μL of 
the ligation mixture were added and the vessel was put on ice for the next 30 min. To 
allow the DNA to enter the bacterial cells, the sample was briefly heat shocked (90 s at 
42 °C and then put on ice again for 3 min). Then, 900 μL of sterile SOC medium were 
added and the mixture was incubated at 37 °C for 1 hour under shaking at 150 rpm. The 
suspension was centrifuged for 5 min at 3000 rpm and approx. 950 μL of the supernatant 
were removed. The bacterial pellet was resuspended in the residual medium and plated 
on an agar plate containing kanamycin (30 μg/mL) for selection, as the pmKate2-N vec-
tor incorporates a kanamycin/neomycin resistance gene. After the agar plate was incu-
bated overnight at 37 °C, it was stored at 4 °C for a period of 4 weeks. 
 
6.2.3.2 Mini-Prep 
 
From the bacteria grown on the selective agar plate 9 colonies were picked to inoculate 
LB medium, containing 30 μg/mL kanamycin. For each colony, 5 mL of the selective me-
dium were used. After overnight incubation at 37 °C under shaking at 250 rpm, the sus-
pensions were centrifuged for 1 min at 13000 rpm. The DNA samples were purified using 
a QIAprep spin miniprep kit and the respective concentrations were estimated by UV 
spectroscopy, all yielding approx. 300 ng/μL. Analytical digestion of DNA with restriction 
enzymes was performed as described above with minor modifications: 3 μL of a particu-
lar Mini-Prep product (approx. 1 μg DNA), 2 μL of 10x BSA solution, 2 μL of 10x Tango 
buffer, 2 μL of 10 U/μL HindIII (a 2-fold excess) and 4 μL of 10 U/μL ApaI (a 4-fold ex-
cess) were diluted in Millipore water up to a total volume of 20 μL. The samples were 
thoroughly mixed, shortly centrifuged and incubated for 1 hour at 37 °C. Analytical aga-
rose gel electrophoresis was performed, as described above, with 10 μL of ready-to-use 
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1 kb DNA ladder used for reference. The transillumination of the agarose gel revealed a 
DNA band, corresponding to HindIII-hH2R-ApaI (1100 bp), only for the clone 9 
(Fig. 6.2.5). 
 
Fig. 6.2.5. Agarose gel electrophoresis of the digested Mini-Prep products 1–9. The 1 kb DNA 
ladder was used as a DNA marker (M). A DNA band, corresponding to the HindIII-hH2R-ApaI 
(1100 bp), was found only for the clone 9 (red arrow). 
 
6.2.3.3 Maxi-Prep 
 
2 x 100 mL of selective LB medium (with 30 μg/mL kanamycin) were inoculated with 
2 x 200 μL of bacterial suspension of clone 9 and incubated overnight at 37 °C under 
vigorous shaking at 300 rpm. Bacterial pellets were harvested by centrifugation at 
6000 rpm for 15 min at 4 °C and processed with a QIAGEN plasmid maxi kit. DNA con-
centration was determined by UV spectroscopy. Analytical digestion of the isolated DNA 
with HindIII and ApaI restriction enzymes and analytical agarose gel electrophoresis was 
performed as described for the Mini-Prep product. The transillumination of the agarose 
gel confirmed the presence of the HindIII-hH2R-ApaI construct in the Maxi-Prep product 
(Fig. 6.2.6). 
 
 
 
Fig. 6.2.6. The digested Maxi-Prep product 
(P) contained the linearized pmKate2-N 
vector (4700 bp) and the HindIII-hH2R-ApaI 
fragment (1100 bp). The 1 kb DNA ladder 
was used as a DNA marker (M). 
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6.2.3.4 Sequencing 
 
Sequencing of the Maxi-Prep product was performed by Entelechon (Regensburg, Ger-
many) using the following primers: 
reverse primer – ML_mKate2_rev1 (annealing at the beginning of the mKate2 gene): 
5’-CCCTCGGATGTGCACTTGAAG-3’ 
reverse primer – ML_mKate2_rev2 (annealing in the middle of the hH2R gene): 
5´-CAAATTAAGACCAGAGAGATGG-3´ 
The alignment of the obtained sequences with the hH2R sequence from the National 
Center for Biotechnology Information data base (available on-line at http://www.ncbi. 
nlm.nih.gov/nuccore/NM_022304.2) was done with the Serial Cloner 2.1 software. It re-
vealed two point mutations (G→A and C→T at the positions 894 and 897 from the ATG 
start codon), which does not change the amino acid sequence of the receptor (Gly298 and 
Tyr299). The isolated plasmid DNA was stored at -20 °C until used for transfection ex-
periments. 
 
6.2.4 Construction and preparation of the hH2R-STOP-pmKate2-N plasmid 
 
In order to obtain the cells, expressing the hH2R and the mKate2 separately as a control 
for further microscopic studies, the hH2R-STOP-pmKate2-N plasmid was constructed. 
For this purpose the hH2R gene (including a stop codon) was subcloned from the 
pcDNA3.1(+)Neo-hH2R plasmid (Fig. 6.2.7) into the pmKate2-N vector via NheI and XhoI 
restriction sites. 
The construction and preparation of the hH2R-STOP-pmKate2-N plasmid were per-
formed as described in the paragraphs 6.2.2 and 6.2.3. Briefly, 10 μg of the 
pcDNA3.1(+)Neo-hH2R plasmid and the pmKate2-N vector were digested, using 2 μL of 
10 U/μL solution of NheI and 8 μL of 10 U/μL solution of XhoI (a 4-fold excess) for each 
sample. After agarose gel electrophoresis, the DNA fragments (the digested H2R DNA 
containing a stop codon and the pmKate2-N vector) were extracted and DNA concentra-
tion was measured by UV spectroscopy. For the subsequent ligation with T4 DNA ligase, 
50 ng of the digested pmKate2-N vector and 59 ng of the NheI-hH2R-STOP-XhoI insert 
were used. After successful transformation with the ligation mixture, 10 bacterial colonies 
were picked from the selective agar plate for the Mini-Prep.  
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However, analytical digestion of the Mini-Prep products with the restriction enzymes (1 
μL of 10 U/μL NheI and 4 μL of 10 U/μL XhoI (a 4-fold excess) for each clone) revealed a 
DNA band corresponding to the hH2R gene only for one clone. This was successfully 
used for the Maxi-Prep, as shown by an analytical agarose gel in Fig. 6.2.8. By the UV 
illumination of the digested insert NheI-hH2R-STOP-XhoI and the undigested hH2R-
STOP-pmKate2-N plasmid, 10 μL of ready-to-use MassRuler DNA ladder mix was used. 
After the estimation of DNA concentration by UV spectroscopy, the plasmid DNA was 
stored at -20 °C until used for transfection experiments. 
 
 
 
 
 
 
Fig. 6.2.7. Schematic representa-
tion of the pcDNA3.1(+)Neo-hH2R 
plasmid (Mosandl, 2009). The 
hH2R cDNA with a stop codon was 
subcloned via NheI and XhoI res-
tiction sites (marked up in red) into 
the multiple cloning site of the 
pmKate2-N vector (cf. Fig. 6.2.2) 
upstream of the sequence of 
mKate2). 
 
 
 
 
 
 
 
 
Fig. 6.2.8. The digested Maxi-Prep 
product (P) contained the 
pmKate2-N vector (4700 bp) and 
the NheI-hH2R-STOP-XhoI frag-
ment (1100 bp). Different forms of 
the uncut hH2R-STOP-pmKate2-N 
plasmid (supercoiled, nicked circle, 
V). The MassRuler DNA ladder mix 
was used as a DNA marker (M). 
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6.2.5 Cell culture and transfection 
 
Wild-type CHO-K1 cells were maintained in Ham’s F12 medium suplemented with 10% 
FCS at 37 °C in the humidified atmosphere containing 5% CO2. Every 4–7 days cells 
were trypsinized and passaged by 1:10 dilution with fresh medium to a 25-cm2 culture 
flask. Prior to transfection with the hH2R-pmKate2-N and the hH2R-STOP-pmKate2-N 
plasmids, cells were seeded in 24-well plates and in μ-slide chambers, respectively. 
Transfection was performed with the FuGENE HD reagent according to the manufac-
turer’s instructions, using 3:2, 5:2 and 8:2 (μL FuGENE HD to μg plasmid DNA) ratios. 
After 2 days, the expression of the mKate2 or the hH2R-mKate2 fusion protein in tran-
siently transfected cells, growing in the μ-slide chambers, was controlled by confocal 
microscopy. For the establishment of a cell line stably expressing the hH2R-mKate2, the 
transfected and the wild-type CHO cells were passaged from the 24-well plate to a 6-well 
plate and grown in the culture medium supplemented with 400 μg/mL geneticin. The 
pmKate2-N vector confers resistance to the aminoglycoside antibiotic geneticin (as well 
as kanamycin and neomycin) to the transfected mammalian cells (cf. Fig. 6.2.2 and the 
plasmid brochure from Evrogen). After the next 2 days the transfected CHO cells sur-
vived and were passaged to a 25-cm2 culture flask, whereas all CHO-K1 cells underwent 
apoptosis. The stably transfected CHO-hH2R-mKate2 cells were further cultivated in the 
selective Ham’s F12 medium, suplemented with 10% FCS and freshly added 400 μg/mL 
geneticin, and passaged 1:10 approx. every 4–7 days. As the clone of the CHO-hH2R-
mKate2 cells with the 5:2 (transfection reagent-to-DNA) ratio showed the highest trans-
fection efficiency (30–50% cells revealed proper membranal expression of the hH2R-
mKate2), it was used for further experiments. However, as determined by confocal mi-
croscopy, the percentage of the CHO cells expressing the hH2R-mKate2 predominantly 
in the cell membrane was dropping with increasing passage number, reaching circa 10% 
in the 15th passage. 
 
6.2.6 Confocal microscopy 
 
6.2.6.1 Preparation of specimens 
 
2 days before microscopy, CHO cells were seeded in a μ-slide chamber and cultivated 
without geneticin at 37 °C in the humidified atmosphere containing 5% CO2 (Gross, 
2006). It is noteworthy that 3 days after seeding the cells would be too old for imaging. 
On the day of the experiment the cells were carefully washed with L-15 medium and 
164 Chapter 6 
200 μL of L-15 medium were placed in each cavity of the μ-slide chamber. At the begin-
ning of each experiment, untreated cells were imaged and the exact position of the 
chamber (without a lid) was stored. If not otherwise stated, 50 μL of the L-15 medium 
were used for total binding, whereas for unspecific binding 50 μL of an antagonist solu-
tion were pipetted with caution before the addition of a ligand tested. The labelled and 
unlabelled compounds were added as 6-fold concentrated feed solutions in the L-15 me-
dium to the final volume of 300 μL per well. In the case of bivalent ligands, 80 µL of 
4-fold feed solutions and the total volume of 320 µL per well were used. Incubation was 
performed at room temperature (20 °C) in the dark. 
For experiments with concanavalin A (Con A), cells were incubated with 180 μL of the 
L-15 medium and 60 μL of 1 mg/mL Con A prior to addition of 60 μL of a feed solution of 
a compound to be tested. 
Staining with the LysoTracker Green was performed according to manufacturer’s instruc-
tions as follows: on the day of the experiment, the culture medium was replaced with the 
serum-free Ham’s F12 medium containing 25 or 50 nM of the LysoTracker Green. After 
15–150 min of incubation at 37 °C in the humidified atmosphere containing 5% CO2, the 
cells were carefully washed with L-15 medium and 200 μL of L-15 medium were placed 
in each cavity of the μ-slide chamber. Thereafter, the cells were processed as described 
above. 
 
6.2.6.2 Microscope settings 
 
Specimens were illuminated using an inverted Carl Zeiss LSM 510 confocal laser scan-
ning microscope. For image collection, a Plan Apochromat ×63 oil immersion objective 
was used. The monomeric far-red fluorescent mKate2 was detected with Texas red filter 
sets as reported elsewhere (Shcherbo et al., 2009). In this work an excitation line of a 
helium-neon (HeNe) ion laser of 543 nm was used (transmission of 87–90%) and fluo-
rescence emission was recorded with a UV/488/543/633 main dichroic beam splitter 
(HauptFarbTeiler, HFT), a 545 nm secondary dichroic beam splitter (NebenFarbTeiler, 
NFT) and a 650 nm long pass (LP) filter (cf. Fig. 6.2.10). If not otherwise stated, for the 
imaging of the LysoTracker Green an excitation line of an argon (Ar) ion laser of 488 nm, 
a 488 nm HFT and a 505–550 nm band pass (BP) filter were used (cf. the excitation and 
emission spectra in Fig. 6.2.9). For image acquisition of double-stained samples, the 
excitation lines of the Ar and HeNe lasers were switched after scanning of each plane. 
This multi-tracking facility of the LSM 510 software enabled the separate collection of 
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fluorescence signals. Fluorescence emission spectra of the transfected and the wild-type 
CHO cells were acquired in the lambda mode with a META detector, collecting the signal 
in series of 10 nm bands. 
 
 
 
Fig. 6.2.9. Fluorescence excitation 
(blue) and emission (red) spectra of 
LysoTracker Green DND-26 in buffer 
at pH 5.2 (redrawn from http:// 
products.invitrogen.com/ivgn/product/ 
L7526). 
 
 
 
 
 
6.2.7 Fluorimetry of the far-red fluorescent protein 
 
Katushka, mKate and mKate2 proteins belong to the family of bright far-red fluorescent 
proteins developed by Evrogen with the same mechanism of chromophore formation and 
very similar spectral properties. Among them, the monomeric mKate2 is specially 
adapted for fusions with cellular proteins allowing the subcellular localization of the tar-
geted protein (Shcherbo et al., 2009). 
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Fig. 6.2.10. Spectral properties of the far-red fluorescent protein Katushka, expressed in human 
glioblastoma U-87 MG cells: The solid lines present the excitation (green) and the emission (red) 
spectra of the U-87 MG Katushka cells suspended in PBS buffer. The excitation and emission 
spectra of PBS were substracted, than the spectra were corrected. The dashed lines indicate the 
confocal microscope settings for the mKate2 channel: a 543 nm excitation line of a HeNe laser 
(green) and fluorescence emission detected beyond 650 nm (red). 
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Since human glioblastoma U-87 MG cell clone 3, expressing the Katushka protein in the 
cytosol, were already used in our research group, they were chosen as a model system 
for later microscopic studies with the mKate2. The cells were cultivated in the EMEM 
medium supplemented with 5% FCS and 750 μg/mL geneticin (G418) for selection as 
described before (Kühnle, 2010). On the day of the experiment, the cells were 
trypsinized, washed and suspended in PBS. The excitation and emission spectra of the 
cell suspension were acquired at room temperature (20-23 ºC) using a Cary Eclipse 
spectrofluorimeter. The excitation and emission spectra of PBS buffer were substracted, 
than the spectra were corrected (Fig. 6.2.10). 
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6.3 Results and discussion 
 
6.3.1 Membranal localization of the hH2R-mKate2 in CHO cells 
 
6.3.1.1 Membranal localization of the mKate2 
 
CHO cells were transiently and stably transfected with the hH2R-pmKate2-N plasmid as 
described under Materials and methods (section 6.2). On the basis of sequencing and 
agarose gel electrophoresis of the plasmid DNA, it was presumed that the hH2R will be 
expressed as a fusion protein with the (C-terminally bound) monomeric mKate2 protein. 
In order to confirm that there was no shift of the open reading frame of mKate2 after the 
insertion of the hH2R into the MCS of the pmKate2-N plasmid, the cells were visualized 
by means of confocal microscopy (Fig. 6.3.1). 
   
Fig. 6.3.1. Membranal localization of the far-red fluorescent protein in CHO cells, transiently (A) 
and stably (B) transfected with the hH2R-mKate2-N plasmid. There was hardly any autofluores-
cence of the non-transfected wild-type CHO-K1 cells (C). Plan Apochromat 63x/1.4 oil, HeNe 543 
(87%), HFT UV/488/543/633, NFT 545, LP 650, pinhole <1.8 μm (2 a.u.). 
   
Fig. 6.3.2. Predominantly cytosolic localization of the mKate2 in the CHO cells, transiently trans-
fected with the hH2R-STOP-mKate2-N plasmid (A and B). Negligible autofluorescence of CHO-K1 
cells (C). Plan Apochromat 63x/1.4 oil, HeNe 543 (87%), HFT UV/488/543/633, NFT 545, LP 650, 
pinhole 3 a.u. 
A hH2R-STOP-mKate2 B hH2R-STOP-mKate2 C   non-transfected 
A   hH2R-mKate2 B    hH2R-mKate2 C   non-transfected 
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6.3.1.2 Binding studies with a fluorescent H2R ligand 
 
In order to confirm the membranal expression of hH2Rs in the transfected CHO cells, 
binding experiments with a fluorescent H2R ligand were performed by means of confocal 
microscopy. As reported before, a series of green fluorescent ligands with the high affin-
ity towards the H2R (pA2 up to 8.0 at the guinea-pig atrium) have been developed in our 
research group (Li et al., 2003). Nevertheless, in this study a new red fluorescent H2R 
ligand (UR-DE74) with a 633 nm laser line excitation was used, as the autofluorescence 
of CHO cells is marginal at this wavelength. 
After 30–60 min of incubation with 200 nM of the fluorescent H2R ligand UR-DE74 
(Kb’ of 162 ± 51 nM in GTPase assay at hH2R-GsαS; Erdmann, 2010), pronounced 
total binding as well as low unspecific binding and autofluorescence were detected 
in the CHO cells expressing hH2R-mKate2 fusion proteins. This enabled a reliable 
estimation of the specific binding of UR-DE74 and confirmed the membranal local-
ization of hH2Rs (Fig. 6.3.3). 
The far-red fluorescence signal of hH2R-mKate2 fusion proteins, detected in the cell 
membranes of the transfected CHO cells, confirmed the proper expression of the 
fluorescently labelled receptors (Fig. 6.3.1). Contrary to that, in the CHO cells tran-
siently transfected with the hH2R-STOP-pmKate2-N plasmid, the fluorescent signal 
came predominantly from the cytosol, suggesting the separate expression of the 
hH2R and the far-red mKate2 fluorescent protein (Fig. 6.3.2). 
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Fig. 6.3.3. Binding of the red fluorescent H2R ligand UR-DE74 to the CHO-hH2R-mKate2 cells. 
The cells were preincubated for 50 min with 100 μM FAM (C and D) or L-15 medium (A, B, E and 
F). Confocal images (rainbow palette) were acquired 30 min after addition of 200 nM UR-DE74 
(A–D) in a multi-track scanning mode. The unlabelled CHO-hH2R-mKate2 cells (E and F) were 
used for reference. Fluorescence emission in the UR-DE74 channel (panels A, C and E: 8% 
HeNe 633, HFT UV/488/543/633, LP 650); fluorescence emission in the mKate2 channel (panels 
B, D and F: 90% HeNe 543, HFT UV/488/543/633, NFT 545, LP 650). Plan Apochromat 63x/1.4 
oil, pinhole <1.5 µm (1.6 a.u.).  
 
  
B    mKate2 channel 
D    mKate2 channel 
F    mKate2 channel E   autofluorescence 
A      total binding 
C    unspec. binding 
170 Chapter 6 
6.3.2 Confocal microscopy imaging of agonist-induced H2R internalization 
 
6.3.2.1 Agonist-independent hH2R-mKate2 internalization 
 
CHO cells stably transfected with the hH2R-pmKate2 plasmid were incubated for up to 
4.5 hours with L-15 Leibovitz medium in the absence of H2R agonists. As the transfected 
CHO cells presented a heterogenic population with respect to the level and the pattern of 
the hH2R-mKate2 expression, only the cells with low cytosolic and high membranal ex-
pression of the fusion proteins were chosen for confocal imaging (the initial amount of 
approx. 30% of all transfected cells was systematically decreasing with the increasing 
number of passages). Otherwise, it would be impossible to estimate the effect of H2R 
ligands in the cellular system, where receptor internalization was considered as the ac-
tual read-out, even though it enabled only a qualitative evaluation of the efficacy of a 
respective ligand. As shown in Fig. 6.3.4, receptor endocytosis did not appear up to 
approx. 90 min of incubation without H2R ligands. However, after longer incubation peri-
ods (up to 270 min) with L-15 medium alone, the hH2R-mKate2 fusion proteins were par-
tially internalized. The internalized receptors formed predominantly diffuse areas. Only in 
a small fraction of the visualized cells, condensed and well defined “spots” were formed 
after receptor endocytosis (Fig. 6.3.4 F). 
  
  
Fig. 6.3.4. Agonist-independent internalization of the hH2R-mKate2 in CHO cells. Images were 
acquired at 0 min (A), 30 min (B), 60 min (C), 90 min (D), 120 min (E) and 270 min (F) of incuba-
tion with medium alone. Arrows indicate the internalized fusion proteins. Plan Apochromat 63x/1.4 
oil, HeNe 543 (90%), HFT UV/488/543/633, NFT 545, LP 650, pinhole <1.5 μm (1.6 a.u.). 
A       0 min B      30 min C      60 min 
D      90 min E     120 min F     270 min 
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In order to check, if H2R antagonists could inhibit this agonist-independent endocytosis, 
the cells were incubated with 100 μM FAM only. The translocation of the receptors did 
not occur during the first 120 min of incubation (Fig. 6.3.5), but later this process of inter-
nalization could not be completely blocked. The reason for that might be increased con-
stitutive activity due to oxidative stress (after removal of culture medium and long incuba-
tion at 20 °C). A certain degree of the constitutive activity was reported before for the 
wild-type hH2R as well as the hH2R-GFP and the hH2R-GsαS fusion proteins expressed in 
recombinant systems (Monczor et al., 2003; Osawa et al., 2005; Preuss et al., 2007). 
Fig. 6.3.5. Ligand-independent internalization of the hH2R-mKate2 in CHO cells. Confocal images 
were acquired before (A) and 30 min (B), 60 min (C), 90 min (D), 120 min (E) and 270 min (F) 
after addition of 100 µM FAM. Arrows indicate the perinuclear localization of internalized hH2R-
mKate2 fusion proteins. Plan Apochromat 63x/1.4 oil, HeNe 543 (90%), HFT UV/488/543/633, 
NFT 545, LP 650, pinhole <1.5 μm (1.6 a.u.). 
 
 
  
No internalization of hH2R-mKate2 fusion proteins could be observed within the first 
90 min of incubation in the absence of agonists. However, after longer incubation 
periods, there was a detectable degree of receptor endocytosis, which could not be 
blocked by 100 µM FAM. Because of the ligand-independent redistribution of recep-
tors, the investigation of H2R internalization in response to agonists should be lim-
ited to an initial time period of 90 min.  
A       untreated B  30 min FAM (100 µM) C  60 min FAM (100 µM) 
D  90 min FAM (100 µM) E 120 min FAM (100 µM) F 270 min FAM (100 µM) 
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6.3.2.2 Effect of histamine on hH2R internalization 
 
Confocal imaging of CHO cells, expressing the hH2R-mKate2, revealed receptor inter-
nalization after 30–60 min of incubation with 10–100 μM HIS. Upon 60-90 min of incuba-
tion, far-red fluorescence was localized in the perinuclear region of each cell as a single 
(clearly distinguishable) round “spot” (Fig. 6.3.6 and 6.3.7 A–B). At the same time the 
cells became slightly rounded. These findings were in agreement with previously pub-
lished results for hH2Rs C-terminally tagged with green fluorescent proteins (Osawa et 
al., 2005). 
The transfected CHO cells showed endocytosis of the hH2R-mKate2 fusion protein 
within 90 min of incubation with 10–100 μM HIS (Fig. 6.3.6 and 6.3.7 A–B), as ex-
pected for a full H2R agonist (Osawa et al., 2005). 
 
 
 
Fig. 6.3.6. HIS-induced internalization of the hH2R-mKate2 in CHO cells. Confocal images were 
acquired before (A) as well as 30 min (B), 60 min (C) and 90 min (D) after addition of 100 μM HIS. 
Arrows indicate the perinuclear localization of internalized hH2R-mKate2 fusion proteins. Plan 
Apochromat 63x/1.4 oil, HeNe 543 (90%), HFT UV/488/543/633, NFT 545, LP 650, pinhole 
<1.8 μm (2 a.u.).  
  
A        untreated B   30 min HIS (100 µM) 
C   60 min HIS (100 µM) D   90 min HIS (100 µM) 
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Fig. 6.3.7. Effect of H2R antagonists on HIS-induced internalization of the hH2R-mKate2. Cells 
were preincubated for 15 min with 100 μM FAM (D) or 300 μM RAN (F). Confocal images were 
acquired before (A, C, E) and 90 min (B, D, F) after addition of 10 μM HIS. Arrows indicate the 
perinuclear localization of internalized hH2R-mKate2 fusion proteins. Plan Apochromat 63x/1.4 oil, 
HeNe 543 (90%), HFT UV/488/543/633, NFT 545, LP 650, pinhole <1.8 μm (2 a.u.).  
A           untreated B         10 µM HIS 
C           untreated D  100 µM FAM + 10 µM HIS 
E           untreated F  300 µM RAN + 10 µM HIS 
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6.3.2.3 Effect of antagonists on the histamine-induced hH2R internalization 
 
In order to prove a receptor-mediated mechanism of internalization, the transfected CHO 
cells expressing hH2R-mKate2 fusion proteins were incubated with H2R antagonists prior 
to the addition of HIS. Similarly to the determination of the unspecific binding in radio-
chemical studies (Kenakin, 2006), the antagonists were used at concentrations providing 
an approx. 200-fold excess relatively to HIS (cf. HIS: EC50 of 830 ± 290 nM, FAM: Kb of 
50 ± 10 nM in calcium assay with fura-2 dye, RAN: Ki of 172 ± 11 nM in radioligand com-
petition binding assay on whole cells; Mosandl, 2009). 
In theory, H2R antagonists (actually inverse agonists in systems with constitutive activity; 
cf. Fig. 1.1.6; Preuss et al., 2007) should be able to up-regulate the spontaneously active 
H2Rs (as shown by an increase in [125I]APT binding; Smit et al., 1996 b). Moreover, ear-
lier studies reported that addition of 100 μM FAM induced the recycling of the H2R-GFP 
fusion proteins internalized upon preincubation with 100 μM HIS to the cell membranes 
within 2 hours (Osawa et al., 2005). However, recycling of the receptor was not observed 
in CHO cells expressing the H2Rs tagged with far-red fluorescent proteins. There was no 
up-regulation of the internalized hH2R-mKate2 fusion protein when cells were treated 
with 100 µM FAM (Fig. 6.3.8). 
 
Fig. 6.3.8. Effect of FAM on the HIS-induced internalization of the hH2R-mKate2 fusion protein. 
Cells were preincubated for 100 min with 100 μM HIS (the same sample as in Fig. 6.3.6). Confo-
cal images were acquired before (A), 30 min (B) and 120 min (C) after addition of 100 μM FAM. 
Plan Apochromat 63x/1.4 oil, HeNe 543 (90%), HFT UV/488/543/633, NFT 545, LP 650, pinhole 
<1.8 μm (2 a.u.). 
 
As shown in Fig. 6.3.7, receptor internalization caused by 10 μM of the endogenous 
ligand could be blocked by H2R antagonists FAM (100 μM) and RAN (300 μM), con-
firming a receptor-mediated mechanism of endocytosis. Remarkably, the CHO-
hH2R-mKate2 cells pretreated with H2R antagonists stayed spindle-shaped.  
A    100 min HIS B    130 min HIS 
      + 30 min FAM 
C    220 min HIS 
      + 120 min FAM 
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6.3.2.4 Effect of other agonists on hH2R internalization 
 
The partial H2R agonist dimaprit (DIM), used at a concentration of 30 μM (cf. EC50 of 
14.00 ± 4.14 µM, efficacy of 0.88 ± 0.03 in calcium assay with fura-2 dye; Mosandl, 
2009; Ki of 25 ± 5 μM in [125I]APT competition binding assay on transfected CHO cells; 
Leurs et al., 1994), induced the translocation of hH2R-mKate2 fusion proteins as shown 
in Fig. 6.3.9. However, the effect was not as pronounced as in case of HIS. The DIM-
induced receptor internalization could be blocked by 100 µM FAM. 
Fig. 6.3.9. DIM-induced internalization of the hH2R-mKate2 in CHO cells. The cells in panels E 
and F were preincubated for 15 min with 100 μM FAM. The images were acquired before (A, D) 
as well as 60 min (B, E) and 90 min (C, F) after addition of 30 μM DIM. Arrows indicate the peri-
nuclear localization of internalized hH2R-mKate2 fusion proteins. Plan Apochromat 63x/ 1.4 oil, 
HeNe 543 (90%), HFT UV/488/543/633, NFT 545, LP 650, pinhole <1.8 μm (2 a.u.). 
 
Similar observations were made for 10 μM arpromidine (ARP), a prototypical H2R partial 
agonist (cf. Ki of 12 ± 2 µM in the flow cytometric and 5.4 ± 1.3 µM in the [3H]TIO compe-
tition binding assay on whole cells; Mosandl, 2009). However, in contrast to DIM, the 
ARP-induced internalization was not completely antagonized by FAM (Fig. 6.3.10). 
 
A      untreated B    60 min DIM 
D      untreated 
C    90 min DIM 
E    75 min FAM 
       + 60 min DIM 
F    105 min FAM 
       + 90 min DIM 
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Fig. 6.3.10. ARP-induced internalization of the hH2R-mKate2 in CHO cells. The cells in panels E 
and F were preincubated for 15 min with 100 μM FAM. The images were acquired before (A, D) 
as well as 60 min (B, E) and 90 min (C, F) after addition of 10 μM ARP. Arrows indicate the peri-
nuclear localization of internalized hH2R-mKate2 fusion proteins. Plan Apochromat 63x/1.4 oil, 
HeNe 543 (90%), HFT UV/488/543/633, NFT 545, LP 650, pinhole <1.8 μm (2 a.u.).  
 
The pattern of H2R internalization in the presence of standard agonists not only confirms 
published imaging results (Osawa et al., 2005), but is also in agreement with radioligand 
binding studies, where H2R agonists reduced the number of receptors in the cell mem-
brane (Fig. 6.3.11; cf. Smit et al., 1996 b). For example, HIS induced 44% down-
regulation of H2Rs in a concentration- (EC50 = 18 nM) and time-dependent (t1/2 = 7 h) 
manner (Smit et al., 1996 a). Also BU-E-75, an ARP-like agonist, caused the internaliza-
tion of the H2R (Legnazzi et al., 2000). However, the present study did not confirm the 
receptor up-regulation in response to antagonists (inverse agonists). 
 
Fig. 6.3.11. Prolonged incubation 
with a H2R antagonist (100 μM CIM) 
leads to an increase in receptor 
number, while 100 μM HIS accounts 
for receptor internalization, meas-
ured as [125I]APT binding on trans-
fected CHO cells expressing rat 
H2Rs (adopted from Smit et al., 1996 
(b) with modifications). 
 
A      untreated B    60 min ARP 
D      untreated 
C    90 min ARP 
E    75 min FAM 
       + 60 min ARP 
F    105 min FAM 
       + 90 min ARP 
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6.3.2.5 Influence of mono- and bivalent acylguanidines on hH2R internalization 
 
Usually, binding of (balanced) H2R agonists leads to receptor internalization, because 
receptor conformation stabilized by agonists activates both G-protein-dependent signal-
ling and recruitment of β-arrestins. However, it is still the mater of debate if the same 
receptor conformations, resulting in β-arrestin-dependent signalling, also lead to desensi-
tization of receptors (Rajagopal et al., 2010). Nevertheless, as mentioned in chapter 4, 
the binding curves of some bivalent acylguanidines revealed no GTPγS-dependent shift 
in competition binding assays at the gpH2R-GsS (compounds 4 and 11 in experiments 
with [3H]TIO and [3H]UR-DE257, respectively). Although this could indicate rather an-
tagonistism, most of the bivalent acylguanidines were found to be agonists in steady-
state GTPase assays both on hH2R-GsS and gpH2R-GsS fusion proteins and spontane-
ously beating guinea-pig right atrium (Kraus, 2007). Only bivalent compounds, containing 
a 20-membered spacer between the carbonyl groups, were neutral antagonists at the 
hH2R-GsS (Birnkammer et al., 2010). 
In light of the aforementioned results, the question of the existence of biased ligands at 
the hH2R was raised. Therefore, influence of the bivalent H2R ligands on receptor inter-
nalization was investigated, in order to compare ligand efficacy with the previous results 
on H2R agonism (from steady-state GTPase assays on hH2R-GsS fusion proteins ex-
pressed in Sf9 cells; cf. Birnkammer et al., 2010). As shown in Fig. 6.3.12, the bivalent 
acylguanidine 4 was found to induce redistribution of the fluorescently labelled H2Rs at a 
concentration of 1 μM. It is noteworthy that the same concentration was sufficient to alter 
the radioligand dissociation rate constant at gpH2R-GsS fusion proteins expressed in Sf9 
cells (cf. Fig. 5.3.2 B and 5.3.3 B). The bivalent agonist 5 also induced the translocation 
of hH2R-mKate2 fusion proteins, as depicted in Fig. 6.3.13. Despite the fact that the in-
ternalization after a 90-min exposure to compound 5 was less pronounced than that in-
duced by HIS (cf. Fig. 6.3.7 B), it was easily distinguishable from that in the untreated 
control (cf. Fig. 6.3.4 D and F). Moreover, the observed endocytosis could not result from 
ligand toxicity, because the used concentration of agonist 5 was 120 nM only (cf. EC50 of 
60 ± 10 nM, efficacy of 0.42 ± 0.01 in calcium assays on intact cells; Mosandl, 2009). 
  
178 Chapter 6 
Confocal microscopy imaging revealed that the incubation with the symmetric biva-
lent ligands 4 and 5, containing octamethylene spacers, led to the internalization of 
the fluorescently labelled H2R (Fig. 6.3.12 and 6.3.13, respectively), thus being in 
line with their agonistic properties with respect to G-protein activation (Kraus, 2007). 
However, it has to be noted that the observation of hH2R-mKate2 internalization 
does not enable the (quantitative) determination of ligand efficacy for β-arrestin-
mediated signalling. 
These microscopic observations confirmed agonistic properties of the bivalent ligands 4 
and 5, being in agreement also with preliminary results obtained in our research group 
from the β-arrestin recruitment assay on the CHO cells expressing hH2Rs as well as the 
cAMP assay on human neutrophils (Mr. Johannes Felixberger and Ms. Irena Brunskole, 
Institute of Pharmacy, University of Regensburg, personal communications). In both 
types of experiments, compounds 4 and 5 were tested up to a concentration of 1 µM, 
showing weak partial agonism (ligand 4 revealed higher efficacy than ligand 5). 
   
Fig. 6.3.12. Internalization of the hH2R-mKate2 in CHO cells induced by the bivalent agonist 4. 
Confocal images were acquired before (A) as well as 30 min (B) and 90 min (C) after addition of 
1 μM of compound 4. Plan Apochromat 63x/1.4 oil, HeNe 543 (90%), HFT UV/488/543/633, NFT 
545, LP 650, pinhole 2 a.u.  
  
Fig. 6.3.13. Internalization of the hH2R-mKate2 in CHO cells induced by the bivalent agonist 5. 
Confocal images were acquired before (A) and 90 min (B) after addition of 120 nM of compound 
5. Arrows indicate the perinuclear localization of internalized hH2R-mKate2 fusion proteins. Plan 
Apochromat 63x/1.4 oil, HeNe 543 (90%), HFT UV/488/543/633, NFT 545, LP 650, pinhole 2 a.u.  
A              untreated B           90 min ligand 5 
B   30 min ligand 4 C   90 min ligand 4 A      untreated 
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In contrast, an experiment with a 140-min exposure to 1 μM of compound 1 revealed 
no significant internalization of the hH2R-mKate2. This was rather unexpected, since the 
monovalent ligand 1 behaved as an agonist in GTPase assays on the hH2R-GsαS (EC50 
of 22 ± 5 nM, efficacy of 0.79 ± 0.02; Kraus et al., 2009) as well as in [3H]TIO competition 
binding assays, showing typical GTPγS-dependent shifts at both hH2R-GsS (Ki of 39 ± 
5 nM; cf. Table 4.3.3; cf. Fig. 4.3.5 E) and gpH2R-GsS fusion proteins (cf. Fig. 4.3.5 F). 
The monovalent H2R agonist 1 did not induce hH2R-mKate2 internalization at a con-
centration up to 300 nM upon 90-min exposure (Fig. 6.3.14 A–B). A prolonged incu-
bation (110 min) with 1 μM of compound 1 led to marginal H2R internalization 
(Fig. 6.3.14 C–D), which was, however, similar to the aforementioned ligand-
independent receptor endocytosis (cf. Fig. 6.3.4 E).  
 
   
   
Fig. 6.3.14. Influence of the monovalent ligand 1 on the internalization of the hH2R-mKate2 in 
CHO cells. Upper panel: confocal images were acquired before (A) and 90 min (B) after addition 
of 300 nM of compound 1; pinhole <1.8 μm (2 a.u.). Lower panel: confocal images were acquired 
before (C) and 110 min (D) after addition of 1 μM of compound 1; pinhole <1.5 μm (1.6 a.u.). Ar-
rows indicate the perinuclear localization of internalized hH2R-mKate2 fusion proteins. Plan 
Apochromat 63x/1.4 oil, HeNe 543 (90%), HFT UV/488/543/633, NFT 545, LP 650. 
Also for the bivalent ligands 12 and 13 containing 20-membered spacers between the 
carbonyl groups no internalization within 90 min was observed. These compounds were 
previously reported to be also neutral antagonists in steady-state GTPase assays on the 
hH2R-GsS (Kb values: compound 12: 1679 nM, compound 13: 770 nM; cf. Birnkammer et 
al., 2010).  
C       untreated D    ligand 1 (1 µM) 
A       untreated B   ligand 1 (300 nM) 
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Fig. 6.3.15. Effect of 12 on the internalization of the hH2R-mKate2 in CHO cells. Confocal images 
were acquired before (A) and 100 min (B) after addition of 10 μM of compound 12. Plan 
Apochromat 63x/1.4 oil, HeNe 543 (90%), HFT UV/488/543/633, NFT 545, LP 650, pinhole 
<1.5 μm (1.6 a.u.).  
  
Fig. 6.3.16. Influence of 13 on the internalization of the hH2R-mKate2 in CHO cells. Confocal 
images were acquired before (A) and 90 min (B) after addition of 10 μM of compound 13. Plan 
Apochromat 63x/1.4 oil, HeNe 543 (90%), HFT UV/488/543/633, NFT 545, LP 650, pinhole 
<1.5 μm (1.6 a.u.).  
Table 6.3.1. Comparison of the effects of the bivalent H2R ligands observed in GTPase assays 
(aKraus, 2007; Birnkammer et al., 2010) and bconfocal microscopy. 
Observed effects Ligands 4 and 5 Ligands 12 and13 
G-protein activation yesa noa 
Receptor internalization yesb nob 
Putative bias no no 
 
In two independent experiments, the incubation with 10 μM of the bivalent ligand 12 
(containing a 20-membered spacer) did not induce the H2R internalization up to 
90 min (Fig. 6.3.15), similar to the negative control (cf. Fig. 6.3.4). Also another biva-
lent compound 13 with a 20-carbon atom linker did not induce the internalization of 
the hH2R-mKate2, when used at a concentration of 10 μM (Fig. 6.3.16). This was in 
line with the previously obtained functional data from GTPase assays, demonstrat-
ing antagonistic properties of these bivalent compounds (Table 6.3.1).  
A      untreated B  ligand 13 (10 µM) 
B  ligand 12 (10 µM) A      untreated 
 Results and discussion 181 
 
 
6.3.2.6 Ligand-specific conformations (functional selectivity) at the hH2R 
 
As described so far, at least in the case of the H2R, binding experiments can be best 
explained by classical pharmacology, allowing a competitive interaction between one 
pharmacophore and a single independent binding site at the receptor (Baker, 2008; Ke-
nakin, 2008). Baker demonstrated namely that affinities of standard H2R antagonists are 
independent of the used agonists, providing a strong argument for the absence of multi-
ple ligand-induced conformations at the hH2R. However, this traditional concept, com-
pleted by the (extended) ternary complex model, cannot explain the aforementioned re-
sults, including the insensitivity of bivalent agonists 4 and 11 to GTPγS at the gpH2R-
GsαS (chapter 4; Fig. 4.3.5 D and 4.3.17; cf. Kelley et al., 2001; Xie et al., 2006) as well 
as the slow changes of the Hill slope and altered kinetics of radioligand dissociation at 
Sf9 membranes, expressing both gpH2R-GsS and hH4R-GAIP + Giα2 + Gβ1γ2 (chapter 5). 
To investigate if bivalent ligands bind to H2Rs in a manner, postulated by classical phar-
macology, additional functional studies (GTPase assays) were performed in our research 
group according to previously described procedures (Wenzel-Seifert et al., 2001). The 
results were not consistent with those obtained previously by Baker (Baker, 2008), as Kb 
values of the tested H2R antagonist depended strongly on the used agonist. Antagonistic 
activities of the monovalent (FAM, RAN, TIO, UR-DE257; Erdmann, 2010) and bivalent 
(11) compounds measured in presence of the bivalent agonist 4 at the hH2R-GsαS were 
significantly different from those assessed in presence of HIS (Table 6.3.2 and Fig. 
6.3.17 A). Additionally, the detrimental effect of agonist 4 on the antagonistic activity was 
found at the gpH2R-GsαS for TIO and UR-DE257 (Table 6.3.2 and Fig. 6.3.17 B). 
Indeed, such behaviour could be expected if each agonist induced/stabilized a unique 
receptor conformation. Ligands stabilizing distinct conformations would be able to bias 
the coupling of receptors to different protein effectors (Kenakin and Miller, 2010). Never-
theless, the action of compound 4 might be only an exception as two other bivalent H2R 
agonists, compound 8 (containing a 2-amino-4-methylthiazole and a 2-aminothiazole ring 
with an octamethylene linker) and compound 11 (symmetric, imidazole-type, with a 
20-membered linker), behaved as predicted by the classical model. 
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Table 6.3.2. Antagonistic activities (pKb ± SEM) of different H2R ligands at hH2R-GsαS and gpH2R-
GsαS fusion proteins as determined in GTPase assays in the presence of HIS and the bivalent 
agonists. The bivalent ligand 11 was an agonist at the gpH2R-GsαS, but it turned out to be an an-
tagonist at the hH2R-GsαS (Birnkammer et al., 2010). Kb values (mean ± SEM of N independent 
experiments preformed in duplicate) were calculated from IC50 values using the Cheng-Prusoff 
equation (Cheng and Prusoff, 1973) and compared using one-way ANOVA analysis – Dunnett’s 
multiple comparison test (for 3 or more unmatched data sets) or unpaired t test (for 2 unmatched 
sets of measurements; Motulsky and Christopoulos, 2004). aThe pKb value for RAN at the hH2R-
GsαS was from previous studies (Preuss et al., 2007). 
pKb at hH2R-GsS 
Antagonist HIS N Agonist 4 N Diff. significant 
FAM 6.83 ± 0.03 3 4.70 ± 0.21 4 yes (P<0.0001) 
RAN 6.08 ± 0.03a 3 3.81 ± 0.22 3 yes (P=0.0006) 
TIO 6.56 ± 0.04 4 4.57 ± 0.13 4 yes (P<0.0001) 
Ligand 11 6.63 ± 0.02 3 6.00 ± 0.08 4 yes (P=0.0012) 
UR-DE257 7.49 ± 0.03 3 4.92 ± 0.47 2 yes (P=0.0052) 
 
pKb at gpH2R-GsS 
Antagonist HIS N Agonist 4 N Agonist 11 N Diff. signific.
FAM 7.22 ± 0.07 3 6.35 ± 0.77 4 6.91 ± 0.10 3 no 
RAN 5.82 ± 0.02 3 5.63 ± 0.53 3 5.44 ± 0.03 3 no 
TIO 6.90 ± 0.09 3 3.43 ± 0.48 2 - - yes  
(P=0.0027) 
UR-DE257 7.34 ± 0.04 3 4.35 1 6.84 1 - 
HISa HIS 4 8
0
2
4
6
8
pK
b 
of
  F
AM
  (
hH
2R
-G
s
S)
HIS 4
0
2
4
6
8
pK
b 
of
  T
IO
  (
gp
H
2R
-G
s
S)
 
Fig. 6.3.17. Antagonistic activities (pKb) of: (A) FAM at hH2R-GsαS and (B) TIO at gpH2R-GsαS fu-
sion proteins as determined in GTPase assays in the presence of different H2R agonists (HIS and 
the bivalent agonists 4 and 8), indicated on the abscissa. Kb values were calculated from IC50 
values using the Cheng-Prusoff equation. The values for FAM (HISa) were from Preuss et al., 
2007. The pKb values obtained in presence of different agonists were compared using (A) one-
way ANOVA analysis – Dunnett’s multiple comparison test (HISa used as control) or (B) unpaired 
t test. Only the differences found for the bivalent agonist 4 (in red) are significant (P<0.05 and 
P=0.0027, respectively). 
A B
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6.3.3 Subcellular localization of the internalized hH2R-mKate2 
 
6.3.3.1 Spectral interference of the LysoTracker Green 
 
In order to identify the subcellular compartment containing the internalized hH2R, the 
CHO-hH2R-mKate2 cells were incubated with the green fluorescent dye LysoTracker 
Green, staining preferably lysosomes. The untransfected CHO-K1 cells were used as 
negative controls. It was assumed that the colocalization of the both used fluorophores 
indicated the lysosomal pathway of the hH2R-mKate2 fusion proteins undergoing ago-
nist-induced internalization (cf. LysoTracker Red; Osawa et al., 2005). However, detect-
able far-red emission was found already for the wild type CHO-K1 cells stained with the 
LysoTracker Green (Fig. 6.3.18 A), although spectral properties of this dye (cf. Fig. 6.2.9) 
should exclude both the excitation with a 543 nm line and the detection with a LP 650 
filter set. Spectral interference (pretending a colocalization) appeared, although the con-
centration of the LysoTracker Green was reduced to 25 nM and the incubation time was 
shortened to 15 min to avoid problems by over-staining (cf. manufacturer’s recommenda-
tion: incubation with 50–75 nM of the dye for 30-120 min).  
The CHO-K1 cells stained with LysoTracker Green revealed a weak but still detect-
able signal in the far-red channel, pretending a colocalization (Fig. 6.3.18 A). This 
resulted from the spectral bleed through of the green dye. As expected, no colocali-
zation was detected by the unstained CHO-K1 (Fig. 6.3.18 B) and CHO-hH2R-
mKate2 (Fig. 6.3.19 C) cells, used as negative controls. 
 
Theoretically, multi-tracking should provide complete separation of signals in case of 
emission cross-talk, where emission signals of fluorescent dyes overlap, but excitation 
spectra differ. Also excitation cross-talk (simultaneous excitation of a few dyes by the 
same laser line without overlapping emission spectra) could be simply avoided by the 
acquisition of signals in separate PMT channels (course materials, Carl Zeiss, 2005). 
Unfortunately, all these precautions taken to avoid spectral interference were not helpful 
in case of the samples stained with the LysoTracker Green. Probably, the reason of this 
phenomenon was a strong excitation (90% transmission of a HeNe laser), used due to a 
very weak fluorescence signal of the membranally expressed hH2R-mKate2 fusion pro-
tein. This could also explain a relatively high level of the autofluorescence of CHO-K1 
cells in the far-red channel (not shown). The found spectral interference would lead to 
false positive results in case of the CHO-hH2R-mKate2 cells stained with the Lyso-
Tracker Green, when analyzing the images with the colocalization facility of the LSM 510 
software. 
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Fig. 6.3.18. Colocalized images of the CHO-K1 wild-type cells: (A) a weak signal pretending colo-
calization in the cells stained with 25 nM of the LysoTracker Green. Arrows indicate the ly-
sosomes. (B) No colocalization could be observed in the unstained cells. Images were acquired in 
the far-red (90% HeNe 543, HFT488/UV/488/543/633, NFT 545, LP 650) and the LysoTracker 
Green channel (5% Ar 488, HFT488, BP 505-530) and colocalized using Zeiss microscope soft-
ware. Plan Apochromat 63x/1.4 oil, pinhole <1.6 μm (1.5 a.u.).  
   
Fig. 6.3.19. CHO-hH2R-mKate2 cells (multi-track, glow scale): (A) fluorescence in the mKate2 
channel (90% HeNe 543, HFT488/UV/488/543/633, NFT 545, LP 650), (B) lacking fluorescence 
emission in the LysoTracker Green channel (5% Ar 488, HFT488, BP 505-530). (C) No colocal-
ization could be observed. Plan Apochromat 63x/1.4 oil, pinhole <1.6 μm (1.5 a.u.). 
In order to solve the problem with the spectral interference of the LysoTracker Green 
(combined excitation and emission cross-talk), prior to the colocalization, confocal im-
ages had to be processed using emission fingerprinting and linear unmixing (cross-talk 
removal by automatic component extraction). As these facilities of the LSM 510 software 
required the acquisition of images in the lambda mode (course materials, Carl Zeiss, 
2005), emission spectra of the stained and unstained CHO-K1 and CHO-hH2R-mKate2 
cells were collected with a META detector (involving a 543 nm excitation line of a HeNe 
laser, exactly as used in the multi-track mode). However, green fluorescence signals 
collected by the META detector had lower intensities than in case of a usual PMT and 
the used excitation wavelength (543 nm) was distant from the excitation maximum of the 
green fluorescent dye (cf. Fig. 6.2.9). These both factors resulted in a merely detectable 
emission spectrum of the CHO-K1 cells stained with the LysoTracker Green (Fig. 6.3.20 
C). For comparison, the spectrum of the same sample collected by the META detector at 
a 488 nm excitation line (as the green channel in the multi-tracking mode) using a 499-
C   no colocalization 
B   no colocalization A     false positive 
          colocalization 
B    green channel A   mKate2 channel 
 Results and discussion 185 
 
 
585 nm band-pass filter for the detection is shown in Fig. 6.3.20 B. Also the mKate2 sig-
nal collected by the META detector was very weak, even when excited with a 100% laser 
transmission (Fig. 6.3.21). 
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Fig. 6.3.21. Far-red emission spectra of the 
CHO-hH2R-mKate2 cells labelled with 25 nM of 
the LysoTracker Green, collected with a META 
detector: (A) 543 nm excitation line (90%) of a 
HeNe laser, pinhole 1.6 a.u. (as used in Fig. 
6.3.20 A); (B) the same cells at 100% transmis-
sion of the HeNe laser, pinhole 3 a.u. Plan 
Apochromat 63x/1.4 oil, HFT UV/488/543/633. 
 
 
 
Low sensitivity of the META detector (excitation at a 543 nm) precluded separation 
of the interfering signal of the LysoTracker Green (Fig. 6.3.20 C and 6.3.21). Thus, 
the analysis of subcellular localization of the internalized H2Rs could not be done by 
the colocalization facility of the LSM 510 software. 
B 2 3
C 
1 
4
A  ROIs 1–4 
Fig. 6.3.20. Images and spectra collected with a 
META detector. (A) Overlaid series of confocal 
images of the CHO-K1 cells stained with 25 nM 
of the LysoTracker Green, acquired by the exci-
tation with a 488 nm line (7%) of an Ar laser. 
The image ROIs: 1 (red), 2 (green) and 4 (yel-
low) included lysosomes, whereas ROI 3 (blue) 
was the background and (B) the corresponding 
emission spectra. (C) Emission spectra (LP 650) 
of the same green-labelled CHO-K1 cells and 
the unlabelled CHO-K1 cells (autofluorescence), 
collected using a 543 nm excitation line (90%) of 
a HeNe laser. Plan Apochromat 63x/1.4 oil, HFT 
UV/488/543/633, pinhole 1.6 a.u. 
C 
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6.3.3.2 Subcellular localization of hH2Rs in the double-staining specimens 
 
The CHO-hH2R-mKate2 cells were stained with 25–50 nM of the LysoTracker Green for 
the visualization of lysosomes and incubated with different agonists. Before addition of 
ligands, hH2Rs tagged with the mKate2 were located mostly in the cell membranes, 
whereas the green labelled lysosomes were in the cytosol (Fig. 6.3.22 as well as Fig. 
6.3.23 A and C). 
 
   
Fig. 6.3.22. Subcellular localization of the fluorescently labelled H2Rs (red) and the lysosomes 
stained with 25 nM LysoTracker Green in the non-stimulated CHO-hH2R-mKate2 cells. Confocal 
images in a multi-track scanning mode: (A) fluorescence emission in the mKate2 channel (90% 
HeNe 543, HFT488/UV/488/543/633, NFT 545, LP 650), (B) fluorescence emission in the Lyso-
Tracker Green channel (5% Ar 488, HFT488, BP 505-530), (C) merged images. Plan Apochromat 
63x/1.4 oil, pinhole <1.6 μm (1.5 a.u.).  
  
Within 90 min of incubation with 100 μM HIS, the fluorescently labelled H2 receptors 
were translocated from the membranes (Fig. 6.3.22) to the perinuclear region of the 
cells (cf. Fig. 6.3.6), but still no overlapping with the lysosomes could be detected 
(Fig. 6.3.23 B). Similar results were obtained for the bivalent agonist 4 as shown in 
Fig. 6.3.25 B (cf. Fig. 6.3.12). This supported the previous findings that upon a short 
exposure to an H2R agonist the receptors undergo the rapid internalization, but not 
the trafficking to lysosomes for enzymatic degradation (Osawa et al., 2005). 
A   mKate2 channel B     lysosomes C      merged 
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Fig. 6.3.23. HIS-induced H2R internalization in the CHO-hH2R-mKate2 cells labelled with 50 nM 
LysoTracker Green. The cells in panel D were preincubated for 15 min with 100 μM FAM. Confo-
cal images were acquired before (A and C) and 90 min (B and D) after addition of 100 μM HIS. 
Arrows indicate the perinuclear localization of the internalized hH2R-mKate2 fusion proteins. 
Merged confocal images acquired in a multi-track scanning mode: the mKate2 channel (90% 
HeNe 543, HFT488/UV/488/543/633, NFT 545, LP 650), the LysoTracker Green channel (5% Ar 
488, HFT488, BP 505-530). Plan Apochromat 63x/1.4 oil, pinhole <1.6 μm (1.5 a.u.).  
 
6.3.3.3 Inhibition of the hH2R endocytosis 
 
Receptor redistribution in the CHO-hH2R-mKate2 cells was shown to be agonist-induced 
(upon 60-90 min of incubation). In order to learn more about this process, the single- and 
double-stained living cells were preincubated with an inhibitor of the receptor internaliza-
tion, the plant lectin concanavalin A (Con A). The lectin is known to block extracellularly 
the clathrin-mediated receptor endocytosis by binding to cell membrane glycoproteins. At 
the same time it does not impede the G-protein-dependent signal transduction, as re-
ported e.g. for the β2-adrenergic (Wang and Liu, 2003) and angiotensin II receptor AT1 
(Tang et al., 2000). 
B          100 µM HIS A        non-stimulated 
C        non-stimulated D  100 µM FAM + 100 µM HIS 
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As shown in Fig. 6.3.24 C–D, the agonist-promoted receptor endocytosis was inhib-
ited by Con A (250 μg/mL), as the hH2R-mKate2 fusion proteins were found in the 
cell membranes still after 2.5 hours of incubation with 10 µM HIS. Similar results 
were obtained also for 2 µM of the bivalent agonist 4 (Fig. 6.3.25 C–D), indicating 
receptor internalization via clathrin-coated pits for both monovalent and bivalent H2R 
agonists.  
 
   
   
Fig. 6.3.24. HIS-induced H2R internalization in the CHO-hH2R-mKate2 cells. The cells in panel D 
were preincubated for 30 min with 250 μg/mL Con A. Confocal images were acquired before 
(A and C) and 100 min (B and D) after addition of 10 μM HIS. Arrows indicate the perinuclear 
localization of internalized hH2R-mKate2 fusion proteins. Plan Apochromat 63x/1.4 oil, 90% HeNe 
543, HFT488/UV/488/543/633, NFT 545, LP 650, pinhole <1.6 μm (1.5 a.u.).  
 
The observed inhibitory effect of Con A on receptor endocytosis confirmed previous find-
ings, suggesting that the H2R belongs to class A GPCRs (in terms of internalization). 
This means that, upon agonist stimulation, receptors are internalized via clathrin-coated 
pits (cf. Fig. 1.1.7) and then, in the absence of agonists, rapidly recycled to the cell 
membrane (Fernandez et al., 2008). Additionally, the endocytosis of the H2R should be 
at least partially dynamin-dependent (Xu et al., 2008). 
 
A        untreated B       10 µM HIS 
C         untreated D   Con A + 10 µM HIS 
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Fig. 6.3.25. Agonist-induced H2R internalization in the CHO-hH2R-mKate2 cells labelled with 
50 nM of LysoTracker Green. The cells in panel D were preincubated for 30 min with 250 μg/mL 
Con A. Confocal images were acquired before (A and C) and 60 min (B and D) after addition of 
2 μM of the bivalent ligand 4. Arrows indicate the perinuclear localization of internalized hH2R-
mKate2 fusion proteins. Merged confocal images acquired in a multi-track scanning mode: fluo-
rescence emission in the mKate2 channel (90% HeNe 543, HFT488/UV/488/543/633, NFT 545, 
LP 650), fluorescence emission in the LysoTracker Green channel (5% Ar 488, HFT488, BP 505-
530). Plan Apochromat 63x/1.4 oil, pinhole <1.6 μm (1.5 a.u.). 
 
 
A      non-stimulated B      ligand 4 (2 µM) 
C      non-stimulated D  Con A + ligand 4 (2 µM) 
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6.4 Summary and conclusion 
 
The H4R antagonist JNJ7777120 (with respect to G-protein stimulation) was reported to 
induce the recruitment of β-arrestins in a G-protein-independent manner (Rosethorne 
and Charlton, 2011; Seifert et al., 2011). As reported by Smit and colleagues, two distinct 
pathways for the down-regulation of the H2R (G-protein-dependent and G-protein-
independent) were found in the transfected CHO cells (Smit et al., 1996 a), indicating a 
second, cAMP-independent mechanism of the agonist-induced H2R translocation. This 
raised the question, if functional selectivity might also occur at H2R. However, such in-
vestigations are not routine for the H2R so far due to the lack of both appropriated assays 
and reference ligands. This prompted us to explore the H2R internalization in the pres-
ence of structurally diverse agonists using genetically engineered fluorescent hH2R fu-
sion protein expressing CHO cells. The results of the confocal microscopy were consis-
tent with the following conclusions: 
 
1) The hH2R was successfully subcloned into the pmKate2-N vector, encoding the 
monomeric far-red fluorescent protein mKate2 (Shcherbo et al., 2009), and stably 
expressed in CHO cells. In contrast to the CHO cells expressing both the hH2R 
and the mKate2 separately (Fig. 6.3.2), the far-red fluorescence signal of the 
hH2R-mKate2 fusion protein was detected in the cell membranes (Fig. 6.3.1). Ad-
ditionally, the membranal localisation of the H2R was confirmed by using a selec-
tive fluorescent H2R antagonist (Erdmann, 2010) as shown in Fig. 6.3.3. 
2) The incubation with monovalent H2R agonists (HIS, DIM and ARP, but not the 
monovalent ligand 1) led to the fast internalization of the hH2R-mKate2 (Fig. 
6.3.6–10), as expected (Osawa et al., 2005). For the first time, it was possible to 
visualize the intracellular fate of receptors after exposure to the bivalent H2R 
ligands. As listed in Table 6.3.1, the bivalent H2R agonists 4 and 5 with 
8-membered linkers induced endocytosis (Fig. 6.3.12–13), whereas the bivalent 
H2R antagonists 12 and 13 with 20-membered linkers had no influence on the re-
ceptor internalization (Fig. 6.3.15–16), hence being in line with the previous re-
sults on H2R agonism, e.g. from steady-state GTPase assays on hH2R-GsS fu-
sion proteins expressed in Sf9 cells (Birnkammer et al., 2010). However, it should 
be noted that microscopic imaging of the CHO cells expressing mKate-tagged 
H2Rs could be carried out only within the first 90 min of incubation, because of 
the subsequent ligand-independent redistribution of receptors (Fig. 6.3.4–5). 
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3) Due to the weak spectral bleed through between the lysosomal fluorescent dye 
LysoTracker Green and the far-red florescence emission channel (Fig. 6.3.18 A), 
colocalization studies on the CHO-hH2R-mKate2 cells were discontinued. None-
theless, confocal imaging of the agonist-induced H2R internalization (Fig. 6.3.23–
25) supported previous finding that these receptors do not undergo the lysosomal 
degradation pathway after short exposure to an agonist (Osawa et al., 2005). In 
doing so, the receptor internalization pattern in the presence of the bivalent H2R 
agonists was very similar to that in the presence of HIS. The preincubation with 
an inhibitor of the clathrin-mediated receptor internalization, concanavalin A re-
sulted in the complete blockage of the agonist-induced endocytosis of the hH2R-
mKate2 fusion protein (Fig. 6.3.24–25). This finding confirmed that mono- and bi-
valent H2R agonists release the receptor internalization via clathrin-coated pits. 
 
Confocal microscopy studies on the living CHO cells, expressing the hH2R fused to 
the monomeric far-red fluorescent protein mKate2 (Shcherbo et al., 2009), re-
vealed that both mono- and bivalent H2R agonists (with respect to G-protein activa-
tion) induced clathrin-mediated receptor internalization (Fig. 6.3.6–10 and 6.3.12–
13). Moreover, bivalent ligands known to be neutral antagonists in steady-state 
GTPase assays on hH2R-GsS fusion proteins (Birnkammer et al., 2010) did not in-
fluence the endocytosis of hH2Rs (Fig. 6.3. 15–16). It is important to emphasize 
that the observation of hH2R-mKate2 internalization does not enable the (quantita-
tive) determination of ligand efficacy for β-arrestin-mediated signalling. Additionally, 
it is still the mater of debate if the same receptor conformations, resulting in 
β-arrestin-dependent signalling, also lead to desensitization of receptors (Ra-
jagopal et al., 2010). Nevertheless, in consideration of the results from systems 
with different read-outs (Table 6.3.1; receptor internalization requires β-arrestin, 
whereas the measurement of GTPase activity is limited to the receptor-dependent 
G protein activation), there is no hint to unconventional (biased) signalling of the 
hH2R in the presence of the investigated ligands. Future work in this field should be 
focused on the development of assays for direct quantification of β-arrestin-
mediated signalling at the H2R and the H2R. Additionally, a Schild plot analysis 
should be performed to examine if the bivalent ligands bind competitively and to 
uncover possible non-equilibrium steady states (Kenakin, 2006). 
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7 Summary 
 
In the last three decades, a large amount of experimental data (for example Förster 
resonance energy transfer (FRET) at fluorescently labelled receptors) supported the hy-
pothesis of the dimerization of G-protein-coupled receptors (GPCR), including neuropep-
tide Y (NPY YxR) and histamine (HxR) receptors. Targeting GPCR dimers could be help-
ful to understand (patho)physiological processes and may be applied therapeutically. 
This work aimed at the exploration of the applicability of FRET-based and ligand-based 
approaches to the investigation of NPY Y1R and histamine H2R dimers. Special attention 
was paid to bivalent NG-acylated hetarylpropylguanidines, the most potent H2R agonists, 
known so far, which were initially designed to bind to the orthosteric recognition sites of 
dimerized H2R protomers. Surprisingly, agonists having octamethylene linkers, insuffi-
cient in length to bridge two adjacent receptor molecules, proved to be most active. 
Thus, the intent of this thesis was to investigate the assumed mode of binding of such 
“twin compounds”, e.g. with respect to the ternary complex model, allosterism and func-
tional selectivity. 
 
Fluorescently labelled NPY Y1 receptors 
Human Y1Rs, tagged either with enhanced cyan (ECFP) or with yellow fluorescent pro-
teins (EYFP), were stably expressed in human U-373 MG glioblastoma cells (plasmids 
from Prof. Dr. A. Beck-Sickinger, University of Leipzig). Membranal localization of the 
labelled receptors was confirmed by radioligand and flow cytometric binding assays. 
However, imaging of the transfected U-373 MG and CHO cells by means of confocal 
microscopy (CLSM) revealed primarily intracellular distribution of the fusion proteins, 
precluding prospective FRET-based investigations of receptor dimerization. Additionally, 
bivalent argininamide-type Y1R antagonists, developed in our group, did not support the 
hypothesis of receptor dimerization. Thus, all further work was focused on bivalent 
H2R/H4R ligands. 
 
Hill slopes of bivalent H2R/H4R ligands 
Radioligand binding assays were performed on Sf9 membranes, expressing either the 
human (h) or guinea-pig (gp) H2R-GsαS fusion protein or the hH4R, because the imidazo-
lylpropylguanidine moiety turned out to be a privileged structure with respect to histamine 
receptors (cooperation with Prof. Dr. Roland Seifert, Medical School of Hannover). Satu-
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ration binding experiments confirmed that tiotidine is an inverse agonist of H2R, and that 
fusing of the H2Rs and GsαS proteins did not alter ligand-receptor interactions. GTPγS-
dependent shifts of the competition binding curves, predicted by the ternary complex 
model, were found for monovalent H2R agonists, but not for the bivalent ligands, tested 
at the gpH2R-GsαS, suggesting antagonism rather than agonism. Additionally, Hill coeffi-
cients (nH) < 1 (negative cooperativity) observed for short bivalent compounds (gpH2R-
GsαS), as well as nH > 1 (positive cooperativity) for the bivalent compound with a 20-mem-
bered linker, approximated unity after very long periods of incubation (gpH2R-GsS and 
hH4R), disclosing the failure of having reached equilibrium. 
 
Radioligand off-rate (k2) 
Radioligand dissociation kinetics at the gpH2R-GsS and the hH4R (k2 of [3H]histamine at 
hH4R: 0.0108 ± 0.0007 min-1, reported for the first time) revealed a concentration-
dependent increase in k2 in the presence of bivalent ligands. This could result from am-
phiphilic properties (for the “longer” bivalent compounds) or from an existence of the al-
losteric binding site either at the same protomer or at a neighboring receptor. 
 
H2R internalization 
Clathrin-mediated receptor endocytosis was visualized in transfected CHO cells by con-
focal microscopy (CLSM). Both mono- and bivalent H2R agonists, but not bivalent an-
tagonists (with respect to G-protein activation), induced the internalization of human 
H2Rs fused to the monomeric far-red fluorescent protein mKate2. These observations 
were in line with previously obtained functional data from GTPase assays, and there is 
no evidence for unconventional (biased) signalling of the hH2R. By contrast, agonist-
dependent activities of standard antagonists were found in GTPase assays at the hH2R-
GsαS in presence of a bivalent agonist with an 8-membered linker. 
In conclusion, the obtained results cannot be solely explained by the competitive binding 
model. Considering the size of the bivalent H2R/H4R ligands, additional temporary inter-
actions with the extracellular domains of the receptors seem to be inevitable. Provided 
that the ortho- and the allosteric binding sites were occupied by two pharmacophoric 
moieties simultaneously, these bivalent compounds might act as true dualsteric ligands. 
Future work at the H2R and the H4R should be focused on the differentiation between 
G-protein-dependent and β-arrestin-mediated signalling. Additionally, the preparation of 
a bivalent radioligand is suggested to determine the ligand-receptor stoichiometry. 
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